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Developed in the late 20th century, the conceptual descriptive framework for this 
thesis was inspired by Walt and Gilson’s health policy triangle (HPT). The HPT model 
is a policy analysis framework universally used and applied in the literature to analyse 
various health-related issues, mainly at national or international level. Robust 
research is required to seek a greater understanding of the application and utilisation 
of the HPT framework to describe smaller-scale health policy decisions under 
investigation at local and regional level. Such local and regional decisions may then 
inform both national and international decisions. The author’s directive was to 
retrospectively analyse local, regional and national health policy change within 
different Irish healthcare settings over the last decade with regard to (i) development 
processes, (ii) evidence generation, (iii) implementation, and (iv) outcomes using the 
HPT framework within the context of the current Irish Sláintecare reforms. 
Methods 
Using diverse local, regional and national Irish healthcare settings, this thesis 
examined the generalisable nature of the HPT framework when applied to variety of 
health-related policy decisions at different stages in their life cycle. Methodologies 
such as literature reviews, economic evaluations (cost-effectiveness analysis and cost 
minimisation analysis), and qualitative analysis (using the Framework Approach) 




The narrative literature review in Chapter 2 identified that the types of health policies 
analysed by the HPT framework were mainly positioned at national or international 
level in lower to upper-middle-income countries and were primarily focused upon 
public health topics. This research concluded that given its generalisable nature, 
future research that utilises the HPT framework in smaller scale health policy 
decisions investigated at local and regional levels, could also be beneficial.  
A subsequent literature review in Chapter 3 applied Walt and Gilson’s health policy 
triangle model, as a scaffolding framework, to help describe how emerging evidence 
was used by a large acute Irish teaching hospital to permit the introduction of 
biosimilar infliximab CT-P13, for the treatment of IBD, into routine care in a safe and 
timely manner. The review of this local policy decision found that there was a 
significant time lag of over three years between regulatory approval and clinical 
acceptance for biosimilar infliximab CT-P13 in this large local hospital’s switching 
process. The actors concluded that with the existential concern and uncertainty still 
surrounding biosimilar medicines, a distinct and individualised approach for 
biosimilar medicine implementation is required. 
The cost-effectiveness analysis in Chapter 4 demonstrated that on average, the 
intervention arm of a physician-led medication review programme was more costly 
but was also more effective. Compared with usual care, the intervention was 
associated with a non-statistically significant increase of €877 (95% CI −€1,807, 
€3,561) in mean healthcare cost, and a statistically significant decrease of −0.164 
(95% CI −0.257, −0.070) in the mean number of adverse drug reaction events per 
3 
 
inpatient. The HPT framework was used to describe how this local level policy 
decision concerning the physician-led STOPP/START intervention was not 
implemented but that the generated economic evidence contributed to the evolving 
STOPP/START criteria policy formation, growth and future evaluation. 
The cost minimisation analysis in Chapter 5 assessed which formulation of 
trastuzumab (injected via different administration routes) was more cost-effective 
and time saving in relation to active healthcare professional (HCP) time. Over a full 
treatment course of 17 cycles, average HCP time saved accumulated to 16.78 hours 
with an estimated direct cost saving of €1,609.99 in favour of the trastuzumab 
subcutaneous formulation. The HPT framework elaborated on various contributing 
components concerning this contemporary regional policy which ultimately led to the 
replacement of the trastuzumab intravenous formulation by the trastuzumab 
subcutaneous formulation in clinical practice. 
The qualitative interview study in Chapter 6 revealed that both community 
pharmacists and general practitioners (GPs) accepted the theoretical concept of a co-
payment attached to the Irish public health insurance scheme as it prevents moral 
hazard. GPs independently suggested that a co-payment system introduced in their 
field of practice may inhibit moral hazard by publicly insured patients in the utilisation 
of GP services. The HPT framework was used to depict the interrelated factors which 
underpin this national pharmaceutical policy where going forward, both GP and 
pharmacy unions have expressed interest to be more involved in the policy formation 





This research has illustrated how generalisable and adaptable the HPT framework is 
when applied to health-related policy decisions in various Irish healthcare settings. 
Given this advantage, it is proposed that the HPT framework should be used in 
Sláintecare reform policy. Using a common descriptive framework and standardising 
the approach to health policy analysis during this ten-year reform has the potential 




1 Chapter 1 Introduction 
1.1 Chapter description 
This chapter provided an overview of the literature which informed the research 
detailed within this thesis. The chapter began by discussing Sláintecare: Ireland’s ten-
year plan for health reform, first published in May 2017. Its political history and 
overarching aim and objectives were explored. Secondly, the topic of health policy 
analysis was discussed. Some of the more commonly applied health policy analysis 
frameworks that are frequently used in the field were identified and defined. 
Additional attention was given to one health policy analysis framework in particular: 
the health policy triangle model. Following this, evidence generation in terms of 
health economic evaluations and qualitative research studies and how evidence of 
this nature supports the health-related policy decisions under investigation in this 
thesis was discussed. Thereafter, how the health policy triangle model can be 
retrospectively applied as an overarching framework to a variety of health-related 
policy decisions at local, regional and national level, using various case studies from 
the Irish healthcare system was described.  The case for why this model could be 
incorporated and used as a common descriptive health policy framework in the 
analysis of all upcoming Sláintecare-related health policy decisions was outlined. 
Finally, the hypothesis underpinning this research and an outline of the overall aim 





1.2.1 Sláintecare history 
The Irish health system is frequently described as ‘two-tier’, where the national 
health service is funded predominantly through general taxation (1). There is no 
universal entitlement to public health care in Ireland, with eligibility varying according 
to residency, age and socioeconomic status (2). All residents are entitled to receive 
care in public hospitals free of charge or at a reduced cost. However, individuals with 
an income below a defined threshold or with certain medical conditions receive 
access to health services on the General Medical Services (GMS) scheme. The GMS 
scheme is a tax-funded, means-tested, public health insurance scheme (3). It provides 
many health benefits including access to primary care and hospital services free of 
charge and medicines with limited co-payments (4). Currently, 1.6 million (32%) of 
the Irish population receive healthcare on this scheme (5). Patients who avail of 
health coverage on the GMS scheme are known as medical card holders. Some other 
population groups (10 % of the population) have access to a general practitioner (GP) 
visit card that covers GP charges but does not cover the costs of medicines or hospital 
fees (6). The remaining population (58 %), who neither hold a medical card nor a GP 
visit card, must cover the costs of accessing GP services themselves (2).  
In Ireland, more than two in five people purchase voluntary (private) health insurance 
which plays a supplementary role (2). In comparison to publicly insured patients, 
subscribers to private health insurance plans avoid long waiting times for specialist 
appointments and elective surgery in hospitals, but experience high premium costs 
(4). People are encouraged to buy private health insurance through substantial tax 
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subsidies, and since 2015, the Irish Government introduced lifetime community 
rating regulations which modified existing community rating regulations so that 
premiums individuals pay would increase with the age at which market entry took 
place. Subject to some exemptions, late entry loadings, set at 2% per year, apply to 
individuals 35 years of age and over who postpone market entry (7). Private health 
insurance does not fill all gaps in coverage e.g. It offers limited coverage of primary 
care and dental care; private health insurance subscriptions are heavily concentrated 
among richer people (4). 
Overall, health spending per capita in Ireland is higher than other Organisation for 
Economic Co-operation and Development (OECD) countries notwithstanding that 
Ireland remains the only western European Union (EU) health system without 
universal healthcare coverage (UHC) for primary care (2). In 2019 for example, Ireland 
spent $5,276 per capita on health, compared to the OCED average of $4,224 (8). It 
has been long argued that the two-tier Irish healthcare system does not achieve 
sufficient ‘bang for the buck’ (9, 10). Aware of this concern in 2011, the Irish 
Government decided to commit to the provision of UHC for the first time in the 
State’s history. At the time, the Fine Gael [A right-leaning Irish political party] and 
Labour [A left-leaning Irish political party] majority coalition Government (2011-
2016) stated their intention to establish ‘a universal, single-tier health service, which 
guarantees access to medical care based on need, not income’ in their programme 
for Government on March 6th, 2011. This would be paid for by the introduction of a 
compulsory Universal Health Insurance (UHI) (11). In April 2014, a white paper on the 
topic of UHI entitled ‘The Path to Universal Healthcare: White Paper on Universal 
Health Insurance’ published by then Minister for Health Dr. James Reilly, outlined 
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how UHC might be achieved. Under the proposed plans for UHI in Ireland, which 
closely resembled the Dutch model of social health insurance (12), all citizens would 
be insured for a standard package of primary and hospital care services, including 
mental health services; insurance would be provided under a multi-payer insurer 
model with no distinction between ‘public’ and ‘private’ patients (13). While health 
insurance would be mandatory, a system of financial support would ensure 
affordability by paying or subsidising the cost of insurance premia for all those who 
qualify (14). General taxation would remain the core financing mechanism (12). 
However, a review conducted by the Economic and Social Research Institute shortly 
after concluded that the UHI initiative would be too costly to implement and would 
increase health care expenditure in Ireland by between 3.5% and 10.7% per annum 
(15). Ultimately, succeeding Minister for Health Dr. Leo Varadkar effectively ended 
the Government’s pursuit of UHI, stating that a decision on funding would be taken 
‘in the  latter  part  of  the  next  Government  term  and  implemented  in  the  term  
thereafter’ (16). When the Fine Gael-Labour Government coalition disbanded on 
February 3rd, 2016, no real progress had been made on this front. In fact, there was 
a shift in focus to UHC without any specifics as to how to achieve universalism in 2015 
where the Irish health system was considered less universal in 2015 than in 2011 (17).  
The election campaign that followed the launch of Fine Gael’s 2016 election 
manifesto reinstated its commitment to UHC and referred to the party’s attempts to 
implement UHI during its time in Government. However, the manifesto did not 
proclaim a commitment to UHI implementation and instead stated that research into 
‘various models’ should be conducted (18). While Fine Gael had previously failed to 
9 
 
introduce UHC while in Government, the concept now appeared to be back on the 
policy agenda. At the same time, other Irish major political parties like Labour and 
Sinn Féin [A left-leaning Irish political party] discussed the concept of UHC on their 
political manifestos; Fianna Fáil [A right-leaning Irish political party] did not. 
Fine Gael returned to power in 2016, but in a less powerful minority coalition with 
independent Teachtaí Dála [Members of Parliament]. On May 11th, 2016, the 
Programme for Partnership Government was published, and the new Fine Gael-
Independent coalition stated its commitment to UHC. While this promise aligned with 
the previous Government’s health policy, a parliamentary committee was established 
to oversee UHC execution ‘to develop a single long term vision plan for healthcare 
over a ten-year period’ (19). Significantly, it was remarked that the plan ‘should have 
cross-party consensus on healthcare planning and a shared vision’ (19). The idea of 
the cross-party committee had emerged on May 10th, 2016 when opposition Deputy 
Róisín Shortall, Social Democrats [A left-leaning Irish political party] co-leader 
launched a cross-party motion for a ‘ten-year plan to deliver single-tier health 
service’, supported by 89 (56.3%) opposition Members of Parliament (out of a total 
of 158) (20). 
On May 24th, 2016, Minister for Health Simon Harris proposed a motion to establish 
the cross-party committee. The Committee’s membership would be balanced based 
on seats in Government: four members from the Fine Gael-Independent coalition, 
three from Fianna Fáil, two from Sinn Féin and one each from five smaller parties and 
parliamentary groups. The motion was welcomed by opposition parties. From June 
2016 to May 2017, the Committee regularly met while also holding public hearings 
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and requesting written submissions from stakeholders. On May 30th, 2017, its work 
culminated in the publication of a report entitled ‘Sláintecare’ (21). Given that multi-
party agreement was now in place, a commitment to and action plan on how to 
implement and fund UHC began to emerge. The health system would be 
fundamentally reoriented: from two-tier to single tier; from hospital towards primary 
and social care settings e.g. by increasing access to diagnostics in the community. 
Moreover, access would be expanded by the provision of universal primary and GP 
care and by the removal of inpatient and emergency care charges. It was proposed 
that a national health fund, primarily financed by general taxation, would be 
established to fund the plan (21). Projected costings would necessitate investment of 
€2.844 billion over ten years and approximately €3 billion in transitional funding (21). 
Implementation timelines were outlined, and a Sláintecare Programme 
Implementation Office was established to bring effect to the plan. 
Since the publication of the seminal Sláintecare report in May 2017, the Programme 
Implementation Office has refined the implementation strategy (which contained 
106 sub-actions) into the 2019 programmatic action plan (22). Although progress to 
date has been slow, with early milestones missed and altered (23), health reform is 
being observed. On June 27th, 2020, a new Government comprising of a Fianna Fáil-
Fine Gael-Green Party coalition was announced by the newly elected Taoiseach [Irish 
Prime Minister], Micheál Martin (24). Given that Sláintecare implementation is still in 
its early stages, this newly formed Government will have a pivotal role to enforce the 




1.2.2 Sláintecare content and goals 
Sláintecare is a 187-page document which outlines a ten-year plan to reform the Irish 
health system (21). The Committee’s work plan included a commitment, ‘to establish 
what healthcare entitlements should be covered under an agreed definition of 
universal healthcare’ (25). The Committee decided to adopt the following definition 
of universal healthcare based upon the World Health Organisation’s (WHO) concept 
of UHC ‘A universal healthcare system will provide population, promotive, 
preventative, primary, curative, rehabilitative and palliative health and social care 
services to the entire population of Ireland, ensuring timely access to quality, 
effective, integrated services on the basis of clinical need’ (21). The Sláintecare report 
comprises five main sections: 
i. Population health profile 
ii. Entitlements and access to healthcare 
iii. Integrated Care 
iv. Funding 
v. Implementation 
(i) Population health profile 
This section begins by examining the current demographics and health status of the 
Irish population. It then explores the social determinants of health and the ways in 
which they affect health outcomes and impact the health service. It concludes by 
discussing the various interventions that can be made in response, both at public 
health and health service levels e.g. the ‘Healthy Ireland’ strategy (26). The 
Committee also recommend that the role of Minister of State for Health Promotion 
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should be retained in future Governments. This section of the report is informed by 
international evidence, submissions made to the Committee through consultations 
processes and current Irish policy and research. 
(ii) Entitlements and access to healthcare 
This segment of the report outlines the complexity of entitlements and access to 
services as experienced by the Irish population. In line with its commitment to the 
provision of UHC, the Committee proposes the introduction of a Cárta Sláinte [health 
card] which all residents in Ireland will have within five years of the reform plan being 
initiated. The Cárta Sláinte will entitle all those ordinarily resident to access care 
based on need. This part of the report also describes a remarkable expansion of care 
to meet population health needs, as well as the removal of private care from public 
hospitals (27). Interestingly, the policy agenda in the UK is moving towards increasing 
the amount of private practice in public hospitals, albeit from a much lower base than 
that in Ireland or Australia (28). 
(iii) Integrated care 
This section outlines the case and initial directions for the delivery of integrated care 
throughout the Irish health system. It builds on this by presenting the international 
evidence in favour of integrated care. It is centred on reorienting the system towards 
primary and community care; delivering care at the lowest level of complexity and 
empowering people to play a pivotal role in managing their own health. It reviews 
the critical challenges involved in developing integrated care throughout the Irish 
health system. It evaluates the required leadership and governance, funding 
mechanisms, information communications technology, workforce planning, and 
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analysis required to deliver integrated care by utilising the WHO health system 
building blocks ‘The Committee’s vision requires a system that is integrated in terms 
of all stages of an individual’s life, from cradle to the grave, and also in terms of a 
comprehensive continuum of care from health promotion and disease prevention to 
diagnosis, treatment, disease management, rehabilitation and palliative care’ (21). It 
also addresses the obstacles posed by the current capacity constraints across the 
health system, including long waiting lists and emergency department overcrowding. 
(iv) Funding 
This part of the report explores the current financing of the Irish health budget and 
sets it in context internationally. It also explores the costs of funding a package of 
health service entitlements. The Committee recommends the establishment of a 
single national health fund which would include a mixture of general taxation and 
specific earmarked funds. They state that there should be a guaranteed expansion of 
health funding by between €380 and €465 million per year, for expanded 
entitlements and capacity to delivery UHC. The funding section also details the 
necessity for a €3 billion transitional fund to make up for a historical under 
investment in health, and to fund both physical and programme infrastructure to 
deliver a quality, integrated care in a timely manner.  
(v) Implementation 
One of the strongest concerns of the Committee on the Future of Healthcare is to 
ensure that this is not just another report on the health sector which is not 
implemented. The implementation section of the report clearly sets out the steps 
that must be taken to ensure effective implementation. Drawing on international and 
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national lessons on successful policy processes, this component outlines the ‘how’ it 
should be done, and awareness that the nature of the policy cycle means that the 
policies should be continually designed, refined and reviewed as they are delivered. 
It also emphasises the importance of a whole system and process response to the 
report, how each section is interdependent on other sections and should not be 
handpicked for implementation. 
In summary,  Sláintecare details a ten-year plan for health reform with the aim of 
establishing a universal, single-tier health service where patients are treated solely 
on the basis of health need; reorienting of the health system ‘towards integrated 
primary and community care, consistent with the highest quality of patient safety in 
as short a time-frame as possible’ (23). Its main objective is to provide universal 
access to timely, quality integrated care for all citizens in Ireland. As mentioned, a 
newly elected Government which comprises of a Fianna Fáil-Fine Gael-Green Party 
coalition was formed in late June 2020 (24). In line with the Sláintecare Programme 
Implementation Office, it is envisaged that this Government will provide the required 
continued political leadership and investment to support the delivery of sustained 
and progressive reform across the Irish health system. 
 
1.3 Health policy 
1.3.1 Health policy analysis 
The WHO defines health policy as ‘the decisions, plans, and actions (and inactions) 
undertaken to achieve specific health care goals within a society or undertaken by a 
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set of institutions and organisations, at national, state and local level, to advance the 
public’s health’ (29). Health policy informs decisions like which health technologies 
to develop and utilise, how to structure and fund health services, and which 
pharmaceuticals will be freely available (30). Appreciating the intrinsic relationship 
between health policy and health, and the impact that other policies have on health, 
is crucial as it can help to address some of the major health problems that exist (31). 
However, health policy decisions are not always the result of a rational process of 
discussion and evaluation of how a particular objective should be met. The context 
in which the decisions are made can often be highly political and concern the degree 
of public provision of healthcare and who pays for it (32). Health policy decisions can 
also be conditional on the value judgements implicit in society. As a result, health 
policies do not always achieve their aims and implementation targets (33, 34). 
Consequently, health policy analysis is regularly undertaken to understand past policy 
failures and successes and to plan for future policy implementation (31). 
Just as there are various definitions of what policy is, there are many ideas about the 
analysis of health policy, and its focus (30, 31). However, what a lot of health policy 
analysis studies have in common, whether that be analysis of policy or analysis for 
policy (35), is the use of a policy framework. A myriad of policy frameworks and 
theories exist (31). The burgeoning literature of health policy analysis sees novel 
policy frameworks being developed quite frequently with the ‘policy cube’ approach 
being the latest addition (36). Some of the more commonly applied frameworks 
include stages heuristic model (37), the advocacy coalition framework (ACF) (38), 
Kingdon’s multiple streams theory (39), the punctuated equilibrium framework (40) 
and the institutional analysis and development framework (40).  
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The stages heuristic is the ‘idealistic’ to the policy process (37). It divides the policy 
process into a series of five stages:  
i. agenda setting 
ii. policy formulation 
iii. policy adoption 
iv. policy implementation 
v. policy assessment 
This model has been widely criticised given that its linear, systematic approach to 
solving policy problems is rarely found. Nonetheless, it is helpful to think of 
policymaking occurring in these different stages (30). 
The ACF was designed as an alternative to the stages heuristic; it intentionally avoids 
a linear description of the policy process (38). It addresses highly challenging issues 
in which there are substantial goal conflicts, important technical disputes and 
multiple actors from several levels of Government (40). The ACF examines the 
interaction within a policy subsystem of a small number of advocacy coalitions 
composed of actors from different institutions sharing similar policy beliefs (40). The 
ACF describes three tiers of beliefs: 
i. deep core beliefs 
ii. policy core beliefs 
iii. secondary beliefs 
Kingdon’s multiple streams theory within the policy process focuses on the role of 
policy ‘entrepreneurs’ inside and outside Government who take advantage of agenda 
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setting opportunities ‘policy windows’ and move items onto the Government’s formal 
agenda (30). The model postulates that policy choices are made when the three 
streams (problem stream, policy stream and politics stream) intersect at pivotal time 
points ‘policy windows’ where opportunities can occur spontaneously (39). When a 
policy window opens, the policy entrepreneur must immediately seize the 
opportunity to initiate action. 
Punctuated equilibrium model theorises that the policymaking process is 
characterised by periods of stability with minimal or incremental policy change, 
disrupted by bursts of rapid transformation (31). The concept was initially developed 
in paleontology to explain sudden bursts of change in the fossil record scattered 
among longer-term minor changes (41). Central to the theory are the concepts of 
the ‘policy image’ and the ‘policy venue’. The model has been used to explain the 
tendency for policy inactivity and sudden change in health policy issues like drug 
abuse and pesticide control in the USA (42). 
The institutional analysis and development framework provides a language, and way 
of thinking about the means in which different institutions foster collective action. It 
highlights key insights on institutional, technical, and participatory aspects of 
collective interventions, or the commons problem, and their resulting effects (43). At 
the framework’s core is the ‘action arena’. The action arena is composed of an action 
situation and actors and is used as the unit of analysis and investigation (44). The 
action situation refers to a social space where the actors interact, solve the commons 
problem, and exchange goods and services; the actors are those who participate in 
the situation (40). A major advantage of the framework is bringing an institutional 
18 
 
perspective to policy analysis, which does not appear to be as present in other 
frameworks. 
Interest in conducting a policy analysis will presumably be driven by the knowledge 
of a particular health issue, existing evidence, and a particular policy area for further 
exploration. The aforementioned frameworks, models and theories have firmly 
carved out a position for themselves in the health policy process literature. Their use 
extends beyond the health sector where health policy analysts are researching means 
to improve their applicability and generalisability (45). All except the stages heuristic 
can be used to provide a comprehensive and explicit explanatory analysis. However, 
before this step can be achieved, it is often necessary to procure the ‘raw materials’ 
by conducting an initial descriptive analysis of the health policy in question. In this 
regard, the health policy triangle (HPT) framework claims dominance over the health 
policy analysis literature (30). 
1.3.2 Health policy triangle 
The HPT framework was designed in 1994 by Walt and Gilson for the analysis of 
health sector policies, although its relevance extends beyond this field (46). The 
triangle model is a simplified framework grounded in a political economy perspective, 
and can be used to assess the feasibility of  policy change by considering how four 
components  (context, actors, content and process) interact (30). The framework 
helps investigate the power and politics of policymaking for a particular health policy. 
It explores the interrelationships of the four components in each stage of policy 
process in a systematic manner. The model originated when Walt and Gilson noted 
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that health policy research focused largely on the content of policy, neglecting actors, 











Figure 1.1 Walt and Gilson policy triangle framework 
Policy context refers to systematic factors that have the potential to influence the 
policy process but are not part of the process. Such factors could be categorised as 
political, social, economic, cultural and other environmental conditions (30). Context 
can often be influenced by temporal and geospatial factors and thus is subject to 
change. To understand how health policies change, or do not, requires an ability to 
examine the context in which they are formed, and if possible, an assessment on how 
the contextual factors may influence policy outcomes. 
Content forms the substance of a particular policy which details the subjects and 
topics covered (e.g. its specific objective and methods of implementation). It can be 
composed of policy objectives, operational policies, legislation, regulations, 
guidelines, and so much more. Traditionally, it was argued that many health policy 









dimensions of process, actors and context which can make the difference between 
effective and ineffective policy choice and implementation (46). Content questions 
are concerned with the particular focus of a policy, its stated intentions and strategies 
to achieve its policy goal but are no longer the sole focus in health policy analysis (47). 
The ‘actors’ component of the HPT framework is placed in the centre of the model 
signifying its key role in relation to its interactions with context, content and process. 
Actors denote any influential participant in a policy process that has leverage on 
policymaking. Actors may be used to represent individuals, members of groups or 
organisations, or the State or Government. When classifying actors involvement in a 
particular health policy, it is important to recognise that individuals cannot be 
separated from the organisations within which they work where certain individuals 
may share different beliefs and values on the health policy in question (30). The 
extent of an actor’s impact on the policy process is commensurate with their power 
level.  
Power is defined as the ability to influence people and control resources to achieve a 
desired outcome by whatever means required (48). It is a key factor in the health 
policy process and an important element in determining the political feasibility of 
policy change from a political science perspective (49). Contextual factors may act as 
a source of power to instigate policy actors’ action, inaction, and choice where actors 
can gain ascendancy within a specific environment to impact policy agenda setting 
and formulation processes (50). As noted by Mintzberg, to be an influencer, one 
requires some source of power – defined by control of a resource, a technical skill 
and body of knowledge, or stemming from a legal prerogative – or authority, coupled 
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with active involvement in ongoing processes in a politically skilful way (51). A 
stakeholder analysis can be conducted to elucidate the power levels that different 
actors obtain (52). 
Process refers to the way in which policies are initiated, developed or formulated, 
negotiated, communicated, implemented and evaluated (30). While the policy 
process may seem or be presented in a linear fashion, analysts have criticised models 
like the stages heuristic for presuming a linearity to the public policy process that 
does not exist in reality, for postulating neat demarcations between stages that are 
blurred in practice, and for offering no propositions on causality (31, 40). 
Policymaking is an iterative process and is influenced by policy content, actors and 
context. 
The HPT framework, which can be used retrospectively and prospectively, has 
influenced health policy research in many countries with diverse systems and has 
been used to analyse a large number of health issues (47). A review of literature has 
previously reported on the wide-ranging use of the HPT framework to understand 
many policy experiences in multiple lower-middle-income country (LMIC) settings 
(47). By investigating the application of the HPT framework to health policies in this 
context, such analysis can inform action to strengthen future global policy growth 
and implementation, and provide a basis for the development of policy analysis work. 
Given its broadly applicable nature, the policy triangle is a useful way to organise and 
think systematically about the various factors that might affect many different types 




1.4 Evidence generation for use in health policy analysis 
1.4.1 Research policy relationship 
The relationship between research and policy is one that appears straightforward, 
yet when explored, is a highly complex one. There are different approaches to 
theorising the relationship between knowledge and policy (53); these include: 
i. knowledge shapes policy 
ii. politics shapes knowledge 
iii. co-production 
iv. autonomous spheres 
The research generated form this thesis  broadly  aligns with the ‘knowledge shapes 
policy’ theory or also known as the ‘engineering’ model (30). This evidence-based 
policy approach focuses on how research can be used (instrumentally) to adjust, 
improve, or refine policy. On this account, policymakers draw on research and 
evidence to produce more effective policies. Notwithstanding criticism for being a 
rather simplistic, linear, rationalist model of the policy process, it permits 
policymakers to seek out the best evidence to adjust policy in a way that will improve 
policy outputs (53). The evidence generated in this thesis, which fed into the content 
component of the HPT framework for the particular health policy in question, 
comprises of both quantitative research (in the form of health economic evaluations) 




1.4.2 Health economic evaluations 
Economic evaluation is defined as ‘the systematic appraisal of costs and benefits of 
projects, normally undertaken to determine the relative economic efficiency of 
programs’ (54).  Although its origins can be traced back to the 17th century (56), it 
has really only risen to prominence in the past 35 years and remains a relatively 
contemporary field of study. Improvements in the methodologies applied and 
increased confidence in outcomes associated with research in the field has helped 
health economics become more acceptable to all stakeholders especially health 
policy decision-makers (57). Two factors have mainly led to an increased use of 
economic evaluations by health policymakers. First, increasing pressures on health 
care budgets have led to a shift in focus from merely assessing clinical effectiveness, 
to one on assessing both clinical effectiveness and cost-effectiveness (54). Secondly, 
decision-making processes have emerged in several jurisdictions that enable the 
results of economic evaluations to be used as an integral part of funding, 
reimbursement, or coverage in health-related policy decisions (54). Full economic 
evaluations such as cost-effectiveness analyses are highly preferential sources of 
evidence for use by decision-makers as are economic analyses which adopt more 
than one perspective (58, 59), and budget impact analyses (BIAs) (60). Indeed, 
economic evaluations contribute to evidence-based decision-making in the health 
arena by helping policymakers and the community identify, measure, and compare 




1.4.3 Qualitative research 
While heated discourse between qualitative and quantitative methodologists 
continues (62), it is now generally accepted that qualitative research methods can 
inform health-related policy decisions (63). One of the more commonly used analysis 
methods which originated in large-scale social policy research, but is becoming an 
increasingly popular approach in medical and health research, is the Framework 
Approach (64). The Framework Approach was developed during the 1980s at the 
National Centre for Social Research in the UK and is now widely used by qualitative 
researchers. The Framework Approach is a matrix-based method for analysing 
qualitative data. It facilitates data management such that all the stages involved in 
the analytic hierarchy can be conducted (64). This method is used by multidisciplinary 
health research teams which can be composed of nurses, doctors, pharmacists, 
sociologists, psychologists epidemiologists, health economists, management 
scientists and others (55). Furthermore, as well as clinical representation, applied 
health research increasingly has patient and public involvement (65) where this 
analysis method is also accessible to them. Given its uncomplicated nature and origin 
in the policy arena, qualitative studies using the Framework Approach can shed 
explanatory and predictive light on important phenomena and contribute to the 






1.5 Health policy analysis and Sláintecare 
1.5.1 Contemporary Irish health policy environment 
Before the introduction of Sláintecare, the Irish health system had been particularly 
dominated by incremental change and a lack of reform/non-execution of reform 
implementation (17, 23). Despite the rhetoric of UHC circulating at the time, the Irish 
people endured years of austerity from the collapse of the Irish economy which 
began in 2007 (66). It led to poorer access to essential healthcare and little extension 
of population coverage (67). In 2015, the Irish health system was at a critical juncture, 
veering between a potential path to UHC and a system, overwhelmed by years of 
austerity, which maintained the status quo (17). Fortunately, the cross-party political 
consensus of the Committee on the Future of Healthcare ensured that Ireland has 
taken its first step in the direction of change and reform, veering away from the status 
quo (21).  
Health policy processes are usually driven by the Department of Health (DoH), the 
Health Service Executive (HSE) or an expert group appointed by the Minister, the DoH 
or HSE. The policy process surrounding the initiation of Sláintecare is atypical due to 
the cross-party nature of the Committee and their consensual way of working (23). 
The process removes the governing party’s politics from the policymaking process, 
but still situates health policymaking in the political domain (21). For whole system 
health reform on the scale of that proposed by the Committee, a clear and strategic 
implementation plan is recommended for health policies and strategies (68, 69). 
Thus, the Sláintecare Programme Implementation Office has refined the 
implementation strategy (which contained 106 sub-actions) into the 2019 
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programmatic action plan (22). However, what this ten-year health reform plan 
seems to be lacking is the use of conceptual health policy framework.  
1.5.2 Health policy frameworks and Sláintecare implementation 
Recent heath policy analyses carried out on national health-related policy decisions 
such as palliative care, diabetes and chronic disease management in the Irish context 
used frameworks like the policy triangle model (33, 34, 70) and the Kingdon’s multiple 
streams theory (34). However, there is little information available on local and 
regional health-related policy decisions in the Irish setting; HSE national divisions, 
hospitals and community health facilities around the country hold their own policies 
and procedures, many of which are not made publicly available (71). In 2008, Walt 
and colleagues commented on the paucity of theoretical frameworks in health policy 
analysis, ‘the absence of explicit conceptual frameworks, little detail on research 
design and methodology, and a preponderance of single case studies on particular 
issues’ (31). They subsequently argued that ‘To advance health policy analysis, 
researchers will need to use existing frameworks and theories of the public policy 
process more extensively’ (31). Thus, while health policy frameworks are being 
applied to some national policy decisions in Ireland, it is unknown if they’re being 
used when analysing local and regional health-related policy decisions. 
Burke et al. claim more research is needed to assess whether the political consensus 
achieved in Sláintecare’s development will lead to the implementation of major 
health system reform to deliver UHC in Ireland (23). Throughout this thesis, it is 
professed that upcoming Sláíntecare health policy decisions at local, regional and 
national level should apply a common descriptive health policy framework, in 
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particular, the Walt and Gilson policy triangle model (46). According to a suggestion 
made by Walt, theoretical models do not imply an approach to analysis but rather 
provide consistency and potential avenues for linking themes and concepts (31). The 
utilisation of a common descriptive framework means that all stakeholders can ‘sing 
from the same hymn sheet’ in terms of health policy or funding decisions that must 
be made under Sláintecare reform. The work in this thesis retrospectively applies the 
policy triangle model to local, regional and national health-related policy decisions as 
an overarching descriptive framework given it is a policy analysis framework 
specifically for health, and has been used to analyse many health-related policy 
issues, all diverse in nature (47). Walt and Gilson have already demonstrated that 
retrospectively applying health policy frameworks to health-related issues can 
benefit future applications of frameworks when used prospectively (72). While the 
Sláintecare Programme Implementation Office has recently launched an 
implementation strategy in the 2019 programmatic action plan (22), its progress 
could potentially be ameliorated with the successful application of a health policy 
framework like the policy triangle model to its health-related policy decisions at local, 
regional and national level (31). 
 
1.6 Hypothesis, aim, and objectives 
1.6.1 Hypothesis 
The Walt and Gilson policy triangle model is a policy analysis framework used 
ubiquitously in the literature to analyse a large number of health-related policy 
issues, almost all of which are positioned at national or international level (47). 
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Robust research is required to seek a greater understanding of the application and 
utilisation of the HPT framework to describe smaller-scale health policy decisions 
under investigation at local and regional level. 
1.6.2 Thesis aim and objectives 
The overarching aim of this thesis was to retrospectively analyse local, regional and 
national health policy change within different Irish healthcare settings over the last 
decade with regard to (i) development processes, (ii) evidence generation, (iii) 
implementation, and (iv) outcomes using the HPT framework. 
Individual thesis objectives included: 
i. Conduct a review of the literature to explore and summarise the application 
of the HPT framework in health-related (public) policy decisions (Chapter 2). 
ii. Review and generate appropriate formal evidence, in the form of economic 
evaluations, for various health policy changes made at both local and regional 
level in the Irish secondary healthcare context (Chapters 3, 4 and 5). 
iii. Investigate an ongoing national pharmaceutical policy change, and key 
stakeholder involvement in that change, by means of qualitative analysis in 
the Irish primary care setting (Chapter 6). 
iv. Demonstrate the generalisable nature and novel application of the HPT 
framework to local, regional and national healthcare decisions in the Irish 
context with reference to its potential usefulness to decision-makers involved 




Chapter specific objectives included: 
Chapter 2 - Health policy triangle framework: narrative review of the recent literature 
i. Review and summarise the literature concerning the application of the 
HPT framework in health-related (public) policy decisions from 2015 to 
2020. 
ii. Identify which countries, classified by income, use the HPT framework as 
a means of policy analysis. 
iii. Reveal which genres of health policy fields commonly use the HPT 
framework. 
Chapter 3 - Biosimilar infliximab introduction into the gastroenterology care pathway 
in a large acute teaching hospital: a review of policy change at local level 
i. Review how the first Irish hospital switched their inflammatory bowel 
disease patient cohort from originator infliximab to biosimilar infliximab 
CT-P13. 
ii. Explore evidence supporting the effective introduction and switching to 
biosimilar infliximab by means of a literature review. 
iii. Serve as a position paper by suggesting multiple evidence-based 
approaches to biosimilar medicine introduction in the absence of a 
national biosimilar policy in Ireland. 
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Chapter 4 - Cost-effectiveness analysis of a physician-implemented medication 
screening tool in older hospitalised patients: evidence against policy change at local 
level 
i. Perform an economic evaluation comparing the impact of the novel 
structured physician-led pharmaceutical regimen review compared with 
usual hospital care. 
ii. Use a multi-level mixed effect regression model to control for variables 
and construct a cost-effectiveness acceptability curve based on several 
hypothetical thresholds. 
iii. Use consolidated health economic evaluation reporting standards to 
ensure that the quality of the economic evaluation was of the highest 
international standard.  
Chapter 5 - Cost minimisation analysis of intravenous or subcutaneous trastuzumab 
treatment in patients with HER2-positive breast cancer: evidence for policy change 
at regional level 
i. Compare trastuzumab treatment routes of administration in HER-2 
positive breast cancer patients in the hospital setting and assess which 
route is more cost-effective and results in greater time savings for the 
healthcare professionals involved. 
ii. Perform sensitivity analyses to test the robustness of the results and 
various assumptions made in the economic evaluation. 
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iii. Use consolidated health economic evaluation reporting standards to 
ensure that the quality of the economic evaluation was of the highest 
international standard.  
Chapter 6 - Out of pocket or out of control: a qualitative analysis of healthcare 
professional stakeholder involvement in pharmaceutical policy change at national 
level 
i. Explore the involvement and perceptions of community pharmacists and 
general practitioners on a national pharmaceutical policy change. 
ii. Conduct semi-structured, face-to-face interviews and use the Framework 
Approach to analyse the data. 
iii. Use consolidated criteria for reporting qualitative research to ensure that 
the quality of the qualitative analysis was of the highest international 
standard. 
Chapter 7 - Discussion 
i. Critically examine findings of previous chapters in terms of known 
information and consideration of new evidence generated by this 
research. 
ii. Examine the strengths and limitations of the major research findings. 
iii. State how research results were communicated to relevant policymakers. 
iv. Advocate for the use of the policy triangle model in assisting with health 
policy analysis under Sláintecare reform plans. 
32 
 
1.6.3 Thesis outline 
Each of the individual thesis objectives outlined above are associated with a specific 
study chapter (Chapters 2 - 6), which are then followed by an overarching discussion 
chapter (Chapter 7). The author of this thesis was the primary investigator for all 
research presented within the thesis. The author was responsible for devising 
research strategies and implementing methodologies. The chapters described 
throughout provide the main evidence for this thesis. The conclusions and 
recommendations forthcoming from this thesis are based on the findings of Chapters 
(2 - 6) inclusive, where Chapters (2 - 6) are all published in academic peer reviewed 
journals. The author of this thesis is listed as the lead author on all external 
publications generated from work presented in this thesis.  
This body of research illustrates how generalisable and adaptable the HPT framework 
is when applied to health-related policy decisions in various Irish healthcare settings. 
Given this advantage, it is proposed that the HPT framework should be used in 
Sláintecare reform policy. Using a common descriptive framework and standardising 
the approach to health policy analysis during this ten-year reform has the potential 
to increase the successful fruition of Sláintecare policy goals. Figure 1.2 summarises 
how the individual studies undertaken as part of this doctoral research address the 
overarching aim and objectives of this thesis, and when combined, these chapters 
provide a comprehensive investigation into the analysis of local, regional and national 




Background and Hypothesis (Chapter 1): 
The HPT framework is widely used to analyse health-related issues commonly positioned at (inter)national level. Further research was required to seek a greater 
understanding of the application of the HPT framework to health-related issues to inform its use in smaller scale health policy decisions at local and regional levels 
 
Discussion (Chapter 7): 
Synthesise the findings from each chapter to show the generalisable nature and novel application of the HPT framework to local, regional and national 




Explore the involvement 
and perceptions of 
community pharmacists 
and general practitioners 











To analyse local, regional and national health policy change within different Irish healthcare settings over the last decade using the HPT framework 
Objective 2: 
Review and generate appropriate formal evidence, in the form of 
economic evaluations, for various health policy changes made at both 
local and regional level in the Irish secondary healthcare context 
 
Objective 3: 
Investigate an ongoing national 
pharmaceutical policy change impacting 
key stakeholders in the Irish primary care 
setting by means of qualitative analysis 
 
Objective 1: 
Conduct a narrative review of the 
recent literature to explore and 
summarise the application of the HPT 
framework to health-related policies 
Chapter 3: 
 
Review how the first Irish 
hospital switched their 
inflammatory bowel 
disease patient cohort 
from originator infliximab 




Perform an economic 
evaluation comparing the 
impact of a novel 
structured physician-led 
pharmaceutical regimen 
review compared with 







2 Chapter 2 Health policy triangle framework: narrative 
review of the recent literature 
2.1 Chapter description 
This chapter collated the recent literature on health-related policy articles that use 
the policy triangle model as part of their policy analysis. The primary aim was to 
explore and summarise the application of the health policy triangle framework to 
health-related (public) policy decisions over the last demi-decade. This review helped 
inform the research questions and the health policy triangle framework applications 
seen in subsequent chapters. A literature search was conducted, and the retrieved 
literature was screened for eligibility. The study findings were summarised in a 
narrative format. The other authors of this chapter and publication reviewed the 
chapter and gave their input and advice during the study. 
2.2 Publication 
The work of this chapter has been published as O’Brien GL, Sinnott SJ, Walshe V, 
Mulcahy M, Byrne S, Health Policy Triangle Framework: Narrative Review of the 
Recent Literature, Health Policy OPEN, 2020, 1(1), 





Developed in the late 20th century, the health policy triangle (HPT) is a policy analysis 
framework used and applied ubiquitously in the literature to analyse a large number 
of health-related issues. 
2.3.2 Objective 
To explore and summarise the application of the HPT framework to health-related 
(public) policy decisions in the recent literature. 
2.3.3 Methods 
This narrative review consisted of a systematic search and summary of included 
articles from January 2015 January 2020. Six electronic databases were searched. 
Included studies were required to use the HPT framework as part of their policy 
analysis. Data were analysed using principles of thematic analysis. 
2.3.4 Results  
Of the 2,217 studies which were screened for inclusion, the final review comprised of 
54 studies, mostly qualitative in nature. Five descriptive categorised themes emerged 
(i) health human resources, services and systems, (ii) communicable and non-
communicable diseases, (iii) physical and mental health, (iv) antenatal and postnatal 





This review identified that the types of health policies analysed were almost all 
positioned at national or international level and primarily concerned public health 
issues. Given its generalisable nature, future research that applies the HPT 
framework to smaller scale health policy decisions investigated at local and regional 





The WHO defines health policy as ‘the decisions, plans, and actions (and inactions) 
undertaken to achieve specific health care goals within a society or undertaken by a 
set of institutions and organisations, at national, state and local level, to advance the 
public’s health’ (29). Health policy informs decisions like which health technologies 
to develop and utilise, how to structure and fund health services, and which 
pharmaceuticals will be freely available (30). Appreciating the intrinsic relationship 
between health policy and health, and the impact that other policies have on health, 
is crucial as it can help to address some of the major health problems that exist. 
However, health policy decisions are not always the result of a rational process of 
discussion and evaluation of how a particular objective should be met. The context 
in which the decisions are made can often be highly political and concern the degree 
of public provision of healthcare and who pays for it (32). Health policy decisions can 
also be conditional on the value judgements implicit in society. As a result, health 
policies do not always achieve their aims and implementation targets (33, 34). 
Consequently, health policy analysis is regularly undertaken to understand past policy 
failures and successes and to plan for future policy implementation (31). 
Just as there are various definitions of what policy is, there too are many ideas about 
the analysis of health policy, and its focus (30, 31). However, what a lot of health 
policy analysis studies have in common, whether that be analysis of policy or analysis 
for policy (35), is the use of a policy framework. A myriad of policy frameworks and 
theories exist (31). The burgeoning literature of health policy analysis sees novel 
policy frameworks being developed quite frequently with the ‘policy cube’ approach 
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being the latest addition (36). A recent literature review investigated the application 
of some of the more commonly applied frameworks (44): the ACF (38), the stages 
heuristic model (37), the Kingdon’s multiple streams theory (39), the punctuated 
equilibrium framework (40) and the institutional analysis and development 
framework (40). See Appendix V for brief descriptions of policy frameworks. While 
the review did mention the HPT framework as a means to help organise and think 
about the descriptive analysis of key variable types and to facilitate use of said 
information in one of the aforementioned political science theories/models, it did 
not investigate its application to public health policies.  
The HPT framework was designed in 1994 by Walt and Gilson for the analysis of 
health sector policies, although its relevance extends beyond this sector (46). They 
noted that health policy research focused largely on the content of policy, neglecting 
actors, context and processes (Figure 1.1). Content includes policy objectives, 
operational policies, legislation, regulations, guidelines, etc. Actors refer to influential 
individuals, groups and organisations. Context refers to systemic factors: social, 
economic, political, cultural, and other environmental conditions. Process refers to 
the way in which policies are initiated, developed or formulated, negotiated, 
communicated, implemented and evaluated (30). The framework, which can be used 
retrospectively and prospectively, has influenced health policy research in many 
countries with diverse systems and has been used to analyse a large number of health 
issues (47). 
In 2015, a historic new sustainable development agenda was unanimously adopted 
by 193 United Nations (UN) members (73). World leaders agreed to 17 sustainable 
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development goals (SDGs). These goals have the power to create a better world by 
2030; they strive to end poverty, fight inequality and address the urgency of climate 
change. The SDGs call on all sectors of society to mobilise for action at a global, local 
and people level. Given that an estimated 40·5 million of the 56·9 million worldwide 
deaths were from non-communicable diseases in 2016 (74); approximately 810 
women died every day from preventable causes related to pregnancy and childbirth 
in 2017 (73); an estimated 6.2 million children and adolescents under 15 years of age 
died mostly from preventable causes in 2018 (73); and approximately 38 million 
people globally were living with HIV in 2019 (73), SDG no. 3 aims to address these 
issues by ensuring healthy lives and promoting wellbeing for all (73). This goal has 
many sub-targets: to reduce maternal mortality; fight communicable diseases; end 
all preventable deaths under five years of age; promote mental health; achieve UHC; 
increase universal access to sexual and reproductive care, family planning and 
education; and many more. Fortunately, these health topics are regularly examined 
in the health policy literature and frequently analysed with policy frameworks like the 
policy triangle model (75-78).  
Having established prominence in its field, the aim of this review is to explore and 
summarise the application of the HPT framework to health-related (public) policy 
decisions in the recent literature i.e. from January 2015 (corresponding with the year 
that the SDGs were launched) to January 2020. By investigating the application of the 
HPT framework to health policies during this time period, such analysis can inform 
action to strengthen future global policy growth and implementation in line with SDG 
no.3, and provide a basis for the development of policy analysis work. A review of 
past literature has previously reported on the wide-ranging use of the HPT framework 
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to understand many policy experiences in multiple LMIC settings only (47). This piece 
is the first literature review to include a compilation of health policy analysis studies 
using the HPT framework in both LMIC and high-income country (HIC) settings. 
 
2.5 Methods 
2.5.1 Literature search 
The Medline, CINAHL Plus with Full Text, Web of Science (Core Collection), APA 
PsycInfo, PubMed and Embase databases were searched for primary, original 
literature in English published between 1st January 2015 and 31st January 2020. No 
Geofilter was applied to the searches. Given the subtle differences which exist 
between Medline and PubMed databases, it was deemed prudent to search both. 
A search strategy was developed based on the use of index and free-text terms 
related to (i) Health Policy Triangle OR (ii) Policy Triangle Framework OR (iii) Policy 
Triangle Model. The lack of index terms to describe the HPT framework complicated 
the development of the search strategy. After much debate and perusal of the 
literature (44, 79), a qualified medical librarian reviewed and approved a search 
strategy prior to undertaking the literature searches. The search strategy was pre-
tested prior to use to maximise sensitivity and specificity and to optimise the 
difference between both. See Appendix VI for the complete search strategy which 
attempted to include medical subject headings (MeSH) and Emtree terms and the 
use of Boolean operators. 
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Search results from multiple databases were transferred to a reference manager, End 
Note X9 (80). Due to the broad remit of the search strategy, a ‘title review’ stage was 
conducted to remove non-pertinent studies. Studies were removed in a cautious 
manner. An abstract review was then performed whereupon studies which clearly 
did not meet the inclusion criteria were excluded. The remaining studies underwent 
full-text review. To ensure consistency, one reviewer performed all stages of the 
review. Experts in academia were contacted to provide several suggestions for 
potentially pertinent studies. A ‘snowballing’ approach was used to identify 
additional literature through manual screening of the reference lists of the retrieved 
literature as well as the reference lists of such articles eligible for inclusion. 
2.5.2 Study selection 
The retrieved literature was screened for eligibility according to pre-specified 
inclusion and exclusion criteria (Table 2.1). 
Table 2.1 Inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
(i) Original primary research articles 
published in English between January 
1st, 2015 and January 31st, 2020 
(i) Articles not specifically related to 
health-related/public health policy issues 
(ii) Articles interested in the application 
of the HPT framework to health-
related/public health policy issues from 
countries of all income levels 
(ii) Commentaries, conference abstracts, 
editorials, posters, (research/study) 
protocols, reports, and white papers 
(iii) Articles addressing all four 
components of the HPT framework i.e. 
content of the policy; actors involved; 
process of policy development and 
implementation; context within which 
policy is developed 
(iii) Book (chapters), (thesis) dissertations 




2.5.3 Study appraisal and data synthesis 
The findings of each study included could not be pooled or combined as in systematic 
reviews or meta-analyses, and it was not deemed necessary to formally assess the 
study quality (81). Indeed, due to the nature of this review, not all of the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were 
relevant, however, insofar as was practical; the PRISMA guidelines were followed 
(82).  Instead, data from each study included in the review were extracted following 
guidance from similar studies (44, 83-85), the National  Institute  for  Health  and  Care 
Excellence (NICE) (85) and from the Centre for Reviews and Dissemination’s guidance 
for undertaking reviews in healthcare (86). Data were extracted and categorised 
according to country, country classification by income in 2020 (87), study design, data 
collection method, type and number of participants, type of analysis and health policy 
field i.e. non-communicable diseases, mental health, tobacco control, etc. The health 
policy field of the included studies were grouped according to similarity by applying 
the principles of thematic analysis (88, 89). Occasionally, ambiguity arose as to 
whether some of the included articles’ content concerned health-related/public 
health policy issues, particularly in relation to the studies which investigated road 
traffic injury prevention (90) and domestic violence prevention and control (91). In 







2.6 Results  
2.6.1 Search results 
From the literature searches conducted in the six databases, a total of 2,217 citations 
were retrieved after the removal of duplicates. Based upon the title and abstract 
screening of the citations, 2,142 articles were excluded. Another 35 articles were 
excluded after reading the full texts. Considering the additional records identified 
through consultation with experts in the field and by handsearching bibliographies, a 
total of 54 studies were eligible for inclusion in the review. The process of study 
selection and reasons for exclusions are outlined in Figure 2.1. Corresponding 
authors of all conference abstracts (n=9) excluded were emailed to inquire whether 
a full-length manuscript of their work was published. The response rate was 100%. 





























Figure 2.1 Flow chart of study selection process
Records identified through 
database searching 
(n = 4,199) 
Duplicates 
removed             
(n = 1,982) 
Records screened at title 
(n = 2,217) Records excluded 
based on title 
(n = 1,930) 
Full-text articles assessed 
for eligibility 
(n = 75 + 3 = 78) 
Full-text articles 
excluded 
(n = 35);  
Articles did not 
utilise HPT 
framework in their 
analysis (n = 23) 
Conference 
abstracts (n = 9) 
Commentary (n = 1) 
Thesis dissertation 
(n = 1) 
Articles claiming to 
utilise HPT 
framework but did 
not (n = 1) 
 
Articles included in 
narrative review 
(n = 43 + 11 = 54) 
Records screened at abstract 
(n = 287) 
Records excluded 
based on abstract 








experts in the field 




2.6.2 Study characteristics 
The characteristics of the 54 studies included in the review are summarised in Table 
2.2. Forty-two of these studies describe themselves as having primarily used a 
qualitative study design. Data collection via various interview formats seemed to be 
the most common means of information retrieval. Eight of these studies would 
consider themselves to have a document analysis study design where one of the eight 
studies also included field work in its methodology. The remaining four studies can 
be described respectively as having a scoping review, mixed methods approach, 
literature review and theoretical analysis study design. According to country 
classification by income in 2020 (87), four of the included studies investigated low-
income countries (LICs), 20 LMICs, 16 upper-middle-income countries (UMICs), and 
six HICs. Eight studies were classed as ‘varied’ due to multiple countries of different 
classifications of income being simultaneously examined. All the included studies can 
be described as some variant of policy analysis. Certain articles highlighted whether 
the policy analysis was retrospective, prospective or comparative in nature; 
approximately 20% of the studies incorporated additional conceptual frameworks. 
Such additional details are outlined in the ‘Type of analysis’ column in Table 2.2. Six 
studies conducted a supplementary stakeholder analysis/mapping (92). 
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Table 2.2 Characteristics of included studies (listed alphabetically according to first author) 
Study, year Country Country classification 
by income in 2020 (87) 
Study design Data collection Participants, (n) Type of analysis Health policy field 












Policy analysis Alcohol-related 
policies 
Abolhassani et al. (94), 
2017 










policy to restrict 
look-alike 
medication names 






Key actors, (n=?) Retrospective 
policy analysis 
Illegal drug policies 
Alostad et al. (96), 2019 Bahrain and 
Kuwait 







Policy analysis Herbal medicine 
registration and 
regulation 








Study, year Country Country classification 
by income in 2020 (87) 
Study design Data collection Participants, (n) Type of analysis Health policy field 












Azami-Aghdash et al. 
(90), 2017 









Policy analysis Road traffic injury 
prevention 
Chen et al. (99), 2019 China UMIC Qualitative Semi-structured 
interviews and 
document searches 






Doshmangir et al. (79), 
2019 





















Study, year Country Country classification 
by income in 2020 (87) 
Study design Data collection Participants, (n) Type of analysis Health policy field 





















announced at the 
third global forum 
on HRH 











Oral health policy 
Faraji et al. (102), 2015 Iran UMIC Document 
analysis 







Guo et al. (103), 2019 China UMIC Qualitative  Semi-structured 
interviews and 
document analysis 










LMIC, UMIC and UMIC Scoping 
review 
Journal, article, 
report and book 
searches 






Study, year Country Country classification 
by income in 2020 (87) 
Study design Data collection Participants, (n) Type of analysis Health policy field 
Hansen et al. (105), 
2017 
















payments to GPs 





Policy analysis Contracting-out 
urban primary 
health care 
Joarder et al. (107), 
2018 














Doctor retention in 
rural settings 



































Study, year Country Country classification 
by income in 2020 (87) 










Kaldor et al. (111), 
2018 




Policy analysis Regulation to limit 














Policy analysis Contracting of 
health services 
policy 













Policy analysis Domestic violence 
prevention and 
control 











Study, year Country Country classification 
by income in 2020 (87) 








et al. (114),  2018 











Policy analysis Role of community 
health workers in 
malnutrition 
management 
Mapa-Tassou et al. 
(115), 2018 











Policy analysis Tobacco 
prevention and 
control policies 
Mbachu et al. (116), 
2016 














and child health 


















Study, year Country Country classification 
by income in 2020 (87) 
Study design Data collection Participants, (n) Type of analysis Health policy field 




Misfeldt et al. (118), 
2017 
















Mohamed et al. (119), 
2018 















Mohseni et al. (120), 
2019 


















under five years of 
age 
Mokitimi et al. (121), 
2018 
South Africa UMIC Document 
analysis 
Document searches Documents, 
(n=10) 





Study, year Country Country classification 
by income in 2020 (87) 
Study design Data collection Participants, (n) Type of analysis Health policy field 
Moshiri et al. (122), 
2015 













addition to HPT) 
Formation of 
primary health 
care in rural Iran in 
the 1980s 
Mukanu et al. (123), 
2017 















al. (124), 2019 










Policy analysis Skilled birth 
attendance policy 
implementation 
Mureithi et al. (125), 
2018 





















Mwagomba et al. (126), 
2018 









Policy analysis Multi-sectoral 





Study, year Country Country classification 
by income in 2020 (87) 
Study design Data collection Participants, (n) Type of analysis Health policy field 
Documents, 
(n=12) 














Policy analysise Implementation of 
national programs 
for the prevention 











All HIC countries Document 
analysis 





support for chronic 
diseases 
Odoch et al. (128), 
2015 
Uganda LIC Document 
analysis 





in addition to 
HPT)f 
Male circumcision 
for HIV prevention 
policy process 
Ohannessian et al. 
(129), 2018 












coverage in the pay 
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Study, year Country Country classification 
by income in 2020 (87) 
Study design Data collection Participants, (n) Type of analysis Health policy field 
for performance 
scheme 
Oladepo et al. (130), 
2018 



















action of tobacco 
control policies 















addition to HPT) 
School food policy 
development and 
implementation 
































Study, year Country Country classification 
by income in 2020 (87) 
Study design Data collection Participants, (n) Type of analysis Health policy field 
Shiroya et al. (134), 
2019 












Policy analysis Translation of the 





Srivastava et al. (135), 
2018 































in addition to 
HPT)h 
HIV testing policies 
among female sex 
workers 



















Study, year Country Country classification 
by income in 2020 (87) 
Study design Data collection Participants, (n) Type of analysis Health policy field 
Van de Pas et al. (138), 
2017 
57 countries 














Policy analysis Implementation of 
the HRH 
commitments 
announced at the 
third global forum 
on HRH 



































Policy analysisi Influence of the 
WHO framework 
convention on 
tobacco control on 
tobacco legislation 
and policies 






























Study, year Country Country classification 
by income in 2020 (87) 
Study design Data collection Participants, (n) Type of analysis Health policy field 










Policy analysisj Progress of 
midwifery-related 
policies  
Zupanets et al. (143), 
2018 









and health system 
integration 
Abbreviations: ACF - Advocacy Coalition Framework; AIDS - Acquired Immune Deficiency Syndrome; EMCONET - Employment and Working Conditions Knowledge Network; GP - General 
Practitioner/Physician; HIC - High-Income Country; HIV - Human Immunodeficiency Virus; HPT – Health Policy Triangle (Framework); HPV – Human Papillomavirus; HRH - Human Resources for Health; LIC - 
Low-Income Country; LMIC - Lower-Middle-Income Country; UHC – Universal Health Coverage; UMIC - Upper-Middle-Income Country; UN – United Nations; WHO – World Health Organisation; ? – Not 
specifically mentioned in related text 
(a) Hansen et al. (105), 2017 - Content and process factors omitted in HPT analysis but justified elsewhere in manuscript 
(b) Juma et al. (109, 110), 2018 - Juma et al. have published two study papers on a related topic from the same project using the same retrieved data sources. Thus, given the similarity, one data entry was 
deemed sufficient to encompass these two related study papers 
(c) McNamara et al. (117), 2017 - A framework by the EMCONET of the WHO’s Commission on the Social Determinants of Health that comprehensively outlines pathways to health via labour markets (144) 
(d) Mureithi et al. (125), 2018 - A conceptual framework by Liu et al. (145) on the impact of ‘contracting-out’ on health system performance  
(e) Nogueira-Jr et al. (127), 2018 – Actor factor omitted in HPT analysis but justified elsewhere in manuscript 
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Study, year Country Country classification 
by income in 2020 (87) 
Study design Data collection Participants, (n) Type of analysis Health policy field 
(f) Odoch et al. (128), 2015 – Bespoke frameworks used that were conceived from Walt and Gilson’s concepts for analysing the interrelationships between actors, process, and contexts (46). Odoch et al. 
also cited Kingdon’s multiple streams theory model (39), Foucault’s concept of power (146) and the Glassman et al. (147) concept of position mapping of actors, in their bespoke frameworks 
(g) Oladepo et al. (130), 2018 - Interview guides were informed by the Walt and Gilson policy analysis framework (46) and the McQueen analytical framework for intersectoral action (148) 
(h) Tokar et al. (136), 2019 - A framework analysis initially developed by Goffman et al. (149) and adapted by Caldwell et al. (150) was used in order to examine how the HIV/AIDS programme was 
conceptualised 
(i) Wisdom et al. (140), 2018 – Wisdom et al. use the same key informant interviews data source that was utilised by Juma et al. (109, 110) 
(j) Zhu et al. (142), 2018 – Authors purport to use a policy triangle framework proposed by Hawkes et al. (151). Upon further inspection and email contact with Hawkes, the framework used was in fact the 
HPT model originally proposed by Walt and Gilson (46) thus this study was included in the review. It is assumed that the authors accidentally miscited the policy triangle framework in their study 






2.6.3 Study findings 
From the content analysis approach to the health policy fields of the included studies, 
five broad descriptive categorised themes were identified demonstrating how the 
HPT framework was applied to health-related (public) policy decisions in the recent 
literature: (i) health human resources, services and systems, (ii) communicable and 
non-communicable diseases, (iii) physical and mental health, (iv) antenatal and 
postnatal care and (v) miscellaneous. Unsurprisingly, many of the health policy fields 
explored in the included studies aimed to address sub-targets of SDG no. 3 (73). 
2.6.3.1 Health human resources, services and systems 
The implementation of the human resources for health (HRH) commitments 
announced at the third global forum on HRH (152), with particular attention given to 
health workforce commitments, were analysed by two separate studies for different 
countries (100, 138). Another study by Witter et al. focused on the patterns and 
drivers of HRH policymaking in post-conflict and post-crisis health systems: namely 
those of Cambodia, Sierra Leone Uganda and Zimbabwe, all low to lower-middle-
income countries. Similarly, Van de Pas et al. conducted a policy analysis study which 
sought to inform capacity development that aimed to strengthen public health 
systems, and health workforce development and retention, in a post-Ebola LIC setting 
(137). Indeed, a policy analysis on health workforce retention was also carried out by 
Joarder et al. where retaining doctors in rural areas of Bangladesh was a challenge 
(107). 
Two studies looked at potential issues and policies surrounding UHC facilitation in the 
primary healthcare setting (79, 98). The somewhat related concept of contracting 
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health services arose in three studies where it was explored in relation to contracting 
for public healthcare delivery in rural Cambodia (112), contracting-out urban primary 
healthcare in Bangladesh (106), and the emergence of three GP contracting-in 
models in South Africa (125). 
At primary and community healthcare level, a variety of policy analysis studies 
scrutinised topics like the formation of primary healthcare in rural Iran in the 1980s 
(122), contextual factors and actors that influenced policies on team-based primary 
healthcare in Canada (118), the potential implementation of out-of-pocket payments 
to GPs in Denmark (105), and policy resistance surrounding integrated community 
case management for childhood illness in Kenya (108). 
There were three policy analysis studies which focused on medicines and 
pharmaceutical safety within the health system. Abolhassani et al. reviewed 
medication safety policy that saw the establishment of the drug naming committee 
to restrict look-alike medication names (94). Alostad et al. investigated herbal 
medicine registration systems policy (96) while Zupanets et al. sought to formulate 
theoretical approaches to the improvement of pharmaceutical care and health 
system integration (143). 
2.6.3.2 Communicable and non-communicable diseases 
The policy response to non-communicable diseases by the Ministry of Health in 
Zambia was explored by Mukanu et al. (123), where similarly, Juma et al. investigated 
non-communicable disease prevention policy development and processes, and how 
multi-sectoral action is involved (109, 110). Kaldor et al. analysed policy which used 
regulation to limit salt intake and prevent non-communicable diseases (111). 
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O’Connell et al. compared frameworks from different countries that aimed to 
improve self-management support for chronic (non-communicable) diseases (70). 
Two studies focused on diabetes, one of the leading non-communicable diseases 
worldwide, where prevention and control policies for the disease state were 
reviewed (102, 134). 
Communicable disease policy analysis studies concentrated on two main viruses; 
human immunodeficiency virus (HIV) and human papillomavirus (HPV). Analyses in 
relation to HPV looked at the feasibility of implementation and non-implementation 
of a HPV vaccination programme in upper-middle to high-income countries (99, 129). 
HIV-related studies varied from policies like task shifting of HIV/AIDS case 
management to community health service centres (113), and male circumcision for 
HIV prevention (128), to HIV testing policies among female sex workers (136). 
Nogueira-Jr et al. investigated the implementation of national programs for the 
prevention and control of healthcare associated infections in three upper-middle to 
high-income countries (127). 
2.6.3.3 Physical and mental health 
Alcohol consumption, illegal drug ingestion, nutritional habits and tobacco inhalation 
are all potential determinants of the quality of physical health status. Four studies 
investigated varying factors surrounding tobacco control policies (115, 119, 130, 
140). Two studies examined alcohol-related policies (93, 126) and one study 
scrutinised illegal drug policies (95). Three studies explored nutrition: two focusing 
on malnutrition management and prevention in UMICs (114, 120) and one reviewing 
school food policy development and implementation in the Philippines (131). 
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Interestingly, all three mental health policy analysis studies included in this review 
focused on the topic of child, and more frequently, adolescent mental health policy 
(103, 121, 132). 
2.6.3.4 Antenatal and postnatal care 
Policy analysis studies regarding pregnancy and mother and child wellbeing featured 
strongly. Zhu et al. outlined the progress of midwifery-related policies in 
contemporary and modern China (142) while Munabi-Babigumira et al. analysed the 
strategies implemented and bottlenecks experienced as Uganda’s skilled birth 
attendance policy was launched (124). Other studies looked at the various factors 
which promoted or impeded agenda setting and the formulation of policy regarding 
perinatal healthcare reform (139), person-centered care in maternal and newborn 
health, family planning and abortion policies (135), and the integrated maternal 
newborn and child health strategy (116). 
2.6.3.5 Miscellaneous 
There were some other policy analysis studies that can be treated as standalone 
articles within the context of this review: palliative care system design (97); national 
law on domestic violence prevention and control within the health system (91); oral 
health policy development (101); road traffic injury prevention (90); national school 
health policy implementation (133); and medical tourism policy (104). Interestingly, 
given that the impact of the Trans-Pacific partnership agreement on employment and 
working conditions is a major point of contention in broader public debates 
worldwide (153), one prospective policy analysis study examined the potential health 
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impacts of the Trans-Pacific partnership agreement (154) by investigating labour 
market pathways (117). 
 
2.7 Discussion 
From the findings of this review, the most common method of data collection was by 
means of some form of interview with participants involved in the relevant policy 
area. The same finding was found in a similar review (47). Talking to actors can 
provide rich information for policy analysis. These collection methods may be the 
only way to gather valid information on the political interests and resources of 
relevant actors and to gather historical and contextual information. Indeed, 
interviews are generally more useful in eliciting information of a more sensitive 
nature where the goal of the interview is to obtain useful and valid data on 
stakeholders’ perceptions of a given policy issue (30). However, interview data can 
be ambiguous in the sense that what interviewees say and the manner in which they 
say it, may contrast what one actually thinks or does. Many of the studies included in 
this review overcome this potential limitation by triangulating the responses with 
additional responses from other informants, or with data collected via alternative 
channels, particularly documentary sources. 
Many different types of policy fields were unearthed throughout the data extraction 
process. Quite a lot of the studies reviewed large-scale health policies at national 
level whether that policy be UHC implementation, infectious disease vaccination 
programmes, or malnutrition management. Some studies conducted policy analysis 
at international level investigating areas such as the health impact of the Trans-Pacific 
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partnership agreement, and the implementation of the HRH commitments 
announced at the third global forum on HRH that involved over fifty countries. Cross-
country comparative policy analysis was also common and examined topics like 
medical tourism, factors of HRH policymaking in post-crisis health systems, and 
frameworks to improve self-management support for chronic diseases. Indeed, 
health policy fields explored within the descriptive categorised theme ‘miscellaneous’ 
demonstrated how wide-ranging the applicability of the HPT framework is to a variety 
of health-related (public) policy decisions. None of the included published literature 
explored policy analysis of local or regional health-related policy decisions using the 
HPT framework. Given its generalisable nature, further and perhaps more novel uses 
of the descriptive policy triangle model could be trialed in a diverse range of health 
policy decisions made at local and regional level. 
Of the policy analysis study countries reviewed, approximately 40% were classified 
as LMIC settings. In recent years, such work has been incorporated into analysis of 
LMIC public sector reform experiences (47) thus possibly explaining this relatively 
high percentage. In addition, a reader recently published by WHO to encourage and 
deepen health policy analysis work in LMIC settings, which considers how to use 
health policy analysis prospectively to support health policy change, could explain 
this high percentage (155). Interestingly, notwithstanding that work conducted 
within the field of policy analysis is fairly well-established in the United States and 
Europe (156, 157), only approximately 12% of the policy analysis studies yielded from 
this review were conducted in HIC settings. This finding is open to many 
interpretations with one crude deduction being that perhaps policy analysis is 
currently more common in LMIC settings than in HIC settings. Another possibility is 
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that commissioned policy analysis studies in HIC settings are seldom published in 
peer reviewed academic journals. Also, it may be the case that LMIC settings rely on 
external academics to carry out and publish their health policy analysis studies as a 
recently published evidence assessment reports that LMICs often have an incomplete 
and fragmented policy framework for research (158). Further research is required. 
All the included studies in this review can be described as some variant of policy 
analysis where certain articles specifically stated whether the policy analysis was 
retrospective, prospective or comparative in nature. In fact, the vast majority of 
studies can be categorised as analyses of policy rather than for policy (35). Most of 
the studies still seek to assist future policymaking, but are largely descriptive in 
nature, limiting understanding of policy change processes. Similar findings are found 
in the literature (47). 
The comparative policy analysis studies included often involved more than one 
country with exception of the analysis by Misfeldt et al. who explored the context 
and factors shaping team-based primary healthcare policies in three Canadian 
provinces (118). Although such comparative studies may introduce further challenges 
(such as working across multiple languages and cultures, and procuring additional 
funding), the comparisons between similar (and different) country contexts can help 
disentangle generalisable effects from country context-specific effects in policy 
adaptation, evolution and implementation (31). 
Six studies conducted a supplementary stakeholder analysis/mapping. Stakeholder 
analysis can be used to help understand about relevant actors, their intentions, 
interrelations, agendas, interests, and the influence or resources they have brought 
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or could bring on decision-making processes during policy development (52). The use 
of stakeholder analysis in this review was complemented by other policy analysis 
approaches as is corroborated by the literature (92). 
Interestingly, approximately 20% of the studies in this review applied an additional 
analytical/theoretical framework. McNamara et al. used a framework by the 
Employment and Working Conditions Knowledge Network (EMCONET) of the WHO’s 
Commission on the Social Determinants of Health (117) which comprehensively 
outlines pathways to health via labour markets (144). Mureithi et al. applied a 
conceptual framework by Liu et al. on the impact of contracting-out on health system 
performance (125, 145). Odoch et al. decided to implement many bespoke 
frameworks (128) that were conceived from Walt and Gilson’s concepts for analysing 
the interrelationships between actors, process, and context (46) as well as citing the 
Kingdon’s multiple streams theory model (39), Foucault’s concept of power (146) and 
the Glassman et al. concept of position mapping of actors (147). Oladepo et al. 
utilised the McQueen analytical framework for intersectoral action (130, 148) while 
Tokar et al. incorporated a framework analysis that was initially developed by 
Goffman et al. and subsequently adapted by Caldwell et al. in order to examine how 
the HIV/AIDS programme in question was conceptualised (136, 149, 150) . Given that 
there is a paucity of theoretical and conceptual approaches to analysis of the 
processes of health policy in LMIC settings (31, 72), the need to use multiple bespoke 
frameworks in the aforementioned recent policy analyses may be a plausible finding. 
In addition, other research has shown that the Walt and Gilson triangle model ‘needs 
to be operationalised and transformed’ in practice which may suggest that it is not fit 
68 
 
for purpose in its primitive state (159). This could explain why auxiliary frameworks 
are applied alongside the HPT model in these studies.  
Other studies applied the Kingdon model in addition to the HPT framework (105, 120, 
122) where Reeve et al. used components of the ACF, Kingdon model and HPT 
framework (131). The policy triangle model is often regarded as being descriptive in 
nature (40, 44) thus supplementation with additional frameworks such as the ACF 
and Kingdon model can enrich the analysis by making it more explanatory (44). 
Doshmangir et al. used a tailored version of the HPT framework incorporating the 
stages heuristic model to guide data analysis (79). Like the policy triangle model, the 
stages heuristic are often characterised as being descriptive in nature (44), thus the 
aforementioned study provided a highly descriptive policy analysis of UHC facilitation 
in the primary healthcare setting in Iran. Unfortunately, no single policy framework 
offers a fully comprehensive description or understanding of the policy process as 
each model answers somewhat different questions (72, 160). Existing policy 
frameworks have complementary strengths since policy dynamics are driven by a 
multiplicity of causal paths (161). Thus, multiple frameworks can be applied as ‘tools’ 
in order to assess and plan action. However, it is important to discern which 
frameworks may be better suited for particular scenarios and policy issues (160). 
Some of the 23 articles (see Figure 2.1) that were excluded from this review for not 
utilising the policy triangle model used other bespoke and well-known health policy 
frameworks, with the Kingdon’s multiple streams theory being the most common 
(39). As previously mentioned, a ‘snowballing’ approach was used to identify 
additional literature through manual screening of the reference lists of the retrieved 
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literature as well as the reference lists of such articles eligible for inclusion. Eleven 
additional studies were identified from this strategy (Figure 2.1) meaning many more 
were excluded for not meeting the inclusion criteria (Table 2.1). Such studies were 
too many to document. However, two articles identified from this process appeared 
to be quite misleading and thus noteworthy. Onwujekwe et al. described a 
conceptual model that they used in their policy analysis which was almost identical 
to the HPT framework (162). However, as the authors did not characterise or 
reference their framework to the policy triangle model or to the work of Walt and 
Gilson, it was omitted from the review. Similarly, Doshmangir et al. portrayed their 
results in such a way that correlated to the four components of the HPT framework 
(163). While the authors did mention the policy triangle framework as a talking point 
in their discussion section, they failed to explicitly reference it in their methodology 
and results paragraphs. This led to the exclusion of their study from the review. It is 
not known why these studies did not appropriately reference the utilisation of the 
HPT framework when its application was apparent. It is possible that more policy 
analysis studies which exist in the recent literature could be presented in a similarly 
ambiguous manner. 
2.7.1 Limitations 
The included articles were mostly qualitative in nature albeit other study designs 
were also utilised. Limitations inherent to such study designs may present a bias in 
the quality of the included articles. Grey literature including reports may have 
provided important sources of information regarding the application of the HPT 
framework to health-related (public) policy decisions. However, given the difficulty 
70 
 
associated with designing internet search strategies, the heterogenous nature of grey 
literature documents and the additional time required, it was excluded from the 
review (164). It was decided to only include primary English-language published 
literature on this topic from January 2015 to January 2020. It is recommended that 
additional reviews of other language literature be conducted in association with a 
wider time frame. This review does not claim to be a fully comprehensive summary 
of all policy analysis studies which utilised the HPT framework between 2015 and 
2020. Further consultation with additional experts, citation searching methods, and 
handsearching of key journals may produce more relevant articles for inclusion. 
However, given that the majority of studies analysed thematically in this review are 
qualitative in nature, it can be argued that it is not necessary to locate every available 
study for such purposes (89, 165). In addition, it is known that some of the doctoral 
theses and unpublished material in the field are already represented within the 
published literature included here. Sometimes, the components of the HPT 
framework i.e. actors, content, context, process are described as such in the 
literature without exclusively referring to the HPT framework itself. Thus, these 
studies would not have been detected using the search strategy chosen for this 
review (Appendix VI). Finally, when compared to other research designs (e.g. 
systematic reviews), narrative reviews of the literature are more susceptible to bias 







This narrative review of the recent literature sought, retrieved and summarised the 
application of the HPT framework to health-related (public) policy decisions. Based 
on the findings of the review, it appears that the use of this framework appears to be 
ubiquitous in the health policy literature where many researchers supplement with 
additional health policy frameworks to further enhance their analysis. 
Notwithstanding a previous debate which disputes that there is a dearth of 
theoretical and conceptual approaches to analysis of the processes of health policy 
in low and middle-income countries (31, 72), this review demonstrates that the 
shortage of health policy analysis studies now appears to come from high-income 
countries. The finding suggests the need for additional health policy analyses to be 
conducted in such settings, or if this is already happening, the demand to publish 
more. In relation to the types of health policies being scrutinised, almost all were 
positioned at national or international level and primarily concerned public health 
issues. However, given its universal presence in the literature, and its unique 
adaptability and generalisability to many varied health policy topics, future research 
applying the HPT framework to smaller scale health policy decisions being 






3 Chapter 3 Biosimilar infliximab introduction into the 
gastroenterology care pathway in a large acute 
teaching hospital: a review of policy change at local 
level 
3.1 Chapter description 
In this chapter, a health-related policy decision in a large acute Irish teaching hospital 
was investigated. The policy decision concerned the initiation and switching of 
patients to biosimilar infliximab CT-P13 from the originator medicinal product. It was 
decided to conduct a literature review on the supporting evidence behind such a 
policy decision. The HPT framework was applied as a scaffolding framework to 
describe the various contributing components which ultimately led to the successful 
implementation of the biosimilar policy. This study applied the policy triangle model 
to a health-related policy decision made at a local level; this has not been observed 
in the literature. The other authors of this chapter and publication reviewed the 
chapter and gave their input and advice during the review. On October 18th, 2018, 
the following published paper was submitted to the HSE-Medicines Management 
Programme in response to their national ‘best-value biological medicines’ 
consultation; parts of the published paper helped inform version 2.0 of the ‘MMP 
roadmap for the prescribing of best-value biological medicines in the Irish healthcare 





The work of this chapter has been modified and published as O’Brien GL, Carroll D, 
Mulcahy M, Walshe V, Courtney G, Byrne S, Biosimilar Infliximab Introduction into 
the Gastroenterology Care Pathway in a Large Acute Irish Teaching Hospital: A Story 
behind the Evidence, Generics and Biosimilars Initiative Journal (GaBI Journal), 2018, 






Biosimilar medicines are not considered exact replicas of originator biologic 
medicines. As a result, prescribers can be hesitant to introduce such medicines into 
the clinical setting until evidence surfaces confirming their safety and effectiveness. 
In Ireland, a national biosimilar medicines policy is currently in development but the 
decision to prescribe biosimilar medicines remains at the discretion of the physician.  
3.3.2 Objective 
To describe how emerging evidence was used by a large acute Irish teaching hospital 
to permit the introduction of biosimilar infliximab CT-P13, for the treatment of 
inflammatory bowel disease (IBD), into routine care in a safe and timely manner. 
3.3.3 Methods 
The Walt and Gilson health policy triangle was applied as a scaffolding framework to 
help describe how the supporting evidence was used to effectively introduce 
biosimilar infliximab in a large acute Irish teaching hospital. A literature review was 
conducted which consisted of published studies, reviews, reports, position 
statements, articles, clinical guidelines and recommendations from national bodies, 




3.3.4 Results  
In September 2014, the accumulated evidence base provided physicians with 
reassurance to prescribe biosimilar infliximab CT-P13 for new patients suffering from 
IBD in this large acute Irish teaching hospital. In September 2016, as the evidence 
base grew, physicians began to safely and confidently switch patients from the 
originator infliximab product to the biosimilar medicinal product. 
3.3.5 Conclusion 
There was a significant time lag between regulatory approval and clinical acceptance 
given that the European Medicines Agency (EMA) had granted market authorisation 
for biosimilar infliximab CT-P13 three years prior to the initiation of this hospital’s 
switching process. Although conservative in their execution, the actors conclude that 
with the existential concern and uncertainty still surrounding biosimilar medicines, a 
distinct and individualised approach for biosimilar medicine implementation is 
required. It is hoped that the Irish biosimilar medicines policy will improve upon 





In 2014, six of the top 10 blockbuster medicines were monoclonal antibodies (167). 
In recent times, small molecule chemical entity (SMCE) blockbuster drugs like Viagra® 
and Lipitor®, have been superseded by blockbuster biologics such as Humira® and 
Enbrel®, demonstrating the newly acquired prominence of biological medicines (168, 
169). However, these large complex proteins (comprised of or derived from living 
cells or organisms) are more complicated than traditional SMCEs due to their unique 
manufacturing process (170). Unlike generic drugs of SMCEs, biosimilar medicinal 
products (biosimilars) which aim to replicate originator biologic products, have given 
rise to concerns related to their pharmaceutical quality, safety (especially 
immunogenicity) and efficacy (particularly in extrapolated indications) (171, 172). 
This can create confusion around the practice of interchangeability which is not as 
lucid for biosimilars as it is for generic drugs of SMCEs (173). 
Substitution, switching and interchangeability are terms often used when discussing 
biosimilars. Pharmacists can substitute generic drugs of SMCEs in Ireland and the UK 
on the proviso these medicines are deemed interchangeable (173-175). The 
European Medicines Agency (EMA) defines substitution as ‘the practice of dispensing 
one medicine instead of another equivalent and interchangeable medicine at 
pharmacy level without consulting the prescriber’ whilst interchangeability refers to 
‘the possibility of exchanging one medicine for another medicine that is expected to 
have the same clinical effect’ (176). However, pharmacist substitution of biosimilars 
is not currently permitted in most countries (170, 177), although pharmacists 
practising in Australia can substitute some biological medicines (178). In the majority 
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of cases, it appears that pharmacists are bound by legislative constraints at the point 
of dispensing (179). As a result, physicians are the key stakeholders to switch patients 
to and from different brands of the same or similar biologic medicines, where 
switching is defined as ‘when the prescriber decides to exchange one medicine for 
another medicine with the same therapeutic intent’ (176).  
There is no longer a dearth of evidence when it comes to the science and 
interchangeability status of biosimilar medicines. However, knowing when it is most 
appropriate and timely to implement these medicines into routine clinical practice 
can be difficult. In a large acute Irish teaching hospital, biosimilar infliximab CT-P13 
was introduced in place of originator brand infliximab (Remicade®), to treat 
inflammatory bowel disease (IBD). As well as Crohn’s disease (CD) and ulcerative 
colitis (UC), Remicade® is licensed to treat a range of other autoimmune diseases 
such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and psoriasis 
(180). In the absence of a national Irish biosimilar medicines policy and with 
perceived uncertainty surrounding biosimilar medicines, the aim of this descriptive 
review is to illustrate how emerging evidence was used by a large acute Irish teaching 
hospital to permit the introduction of biosimilar infliximab CT-P13, for the treatment 
of IBD, into routine care in a safe and timely manner.  
 
3.5 Methods 
The scaffolding framework for this review follows Walt and Gilson’s HPT model which 
indicates how different actors interact to influence formulation, planning, 
implementation, and evaluation of health policies. This framework also helps to 
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assess perceptions, processes, and complexities of established strategies (46). In this 
review, components of the policy triangle have been applied retrospectively to 
describe the implementation of biosimilar infliximab CT-P13 in one large Irish acute 
hospital. It provides for understanding the processes through which influence is 
played out and how the actors and contemporary contextual factors shape and 
formulate the new biosimilar medicine policy for this healthcare setting (46). Recent 
evidence consisting of published studies, reviews, reports, position statements, 
articles, clinical guidelines and recommendations from national bodies, regulatory 
authorities and professional organisations were gathered and used by actors.  
3.5.1 Content and Process 
In June 2013, biosimilar infliximab was licenced by the EMA (181). The agency’s 
committee for medicinal products for human use (CHMP) recommended the granting 
of marketing authorisations for the first two monoclonal antibody biosimilars, 
Remsima® and Inflectra®, both of which contain the same known active substance 
infliximab CT-P13. The decision to provide marketing authorisation for both these 
infliximab biosimilar medicines was based on the same documentation. Their 
application dossiers demonstrated parallel similarity to the biological medicine 
Remicade®, which has been authorised in the EU since 1999 (181). Remsima® and 
Inflectra® are recommended for authorisation in the same indications as Remicade®.   
A few weeks after biosimilar infliximab CT-P13 was licensed, the European Crohn’s 
and Colitis Organisation (ECCO) released a position statement. They articulated 
within that post-marketing pharmacovigilance and unequivocal identification of 
infliximab CT-P13 as a biosimilar was in place. However, their overall stance on the 
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issue was that the use of most biosimilars in patients with IBD should require testing 
in this particular patient population with comparison to the appropriate innovator 
product (Remicade®) before approval (182). The ECCO also considered the benefits 
of wider access with appropriate use of biological therapy in IBD and potential direct 
cost savings important, but its primary concern was that rigorous testing was 
necessary in patients with IBD to ensure that appropriate efficacy and safety 
standards were met. The organisation was of the opinion that final clinical decisions 
should always be made on an individual basis, taking into account both the 
circumstances of the individual patient and the prescribing physician. The ECCO 
defied the practice of extrapolation for biosimilar infliximab at this time. In addition 
to stance taken by the ECCO, several national physician societies initially questioned 
marketing authorisations of biosimilars, including the extrapolation to IBD. It became 
obvious that there was a lack of understanding of the biosimilar development 
concept at this time (183).                                
Contrary to the guidance from the ECCO, the influencing actors of a large acute Irish 
teaching hospital i.e the chief pharmacist and consultant gastroenterologist, decided 
to introduce biosimilar infliximab CT-P13 for use in new patients in September 2014. 
Both parties had been documenting the evidence trail since the licencing of the 
biosimilar medicine in June 2013 and believed there was enough accumulated 
evidence from various sources to support their decision (181, 184). This information 
was relayed to all prescribing physicians during an internal staff meeting where the 
chief pharmacist and consultant gastroenterologist explained the science behind 
their evidence-based decision. All physicians accepted this decision and agreed to 
prescribe biosimilar infliximab CT-P13 for new patients in this setting. Physicians 
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agreed to report any adverse drug reactions (ADRs) to the Health Products Regulatory 
Authority (HPRA) in Ireland and to the EMA. Hospital budget co-ordinators were 
pleased given that the biosimilar product was cheaper than the originator brand. 
With verbal reassurance to patients on the safety and efficacy at the point of 
prescribing, physicians faced no opposition from new patients.  
Although this new prescribing practice could have been deemed hasty, the British 
Society of Gastroenterology (BSG) released a position statement with updated 
guidance two months later where they justified the introduction of biosimilar 
infliximab CT-P13 in the clinical setting. The BSG recommended that infliximab should 
be prescribed by brand name (185). This prescribing practice contradicts the trend 
for SMCE medicines where prescribing generically is encouraged (173). This 
statement also proposed the use of a prospective registry of all biological use in IBD 
patients to capture safety data and side effects. For patients already on therapy, it 
was recommended to avoid switching from the originator product to the biosimilar, 
or vice versa, at least until safety data was made available (185).  
During the summer of 2015, the National Institute for Health and Care Excellence 
(NICE) remarked positively on the topic of biosimilar prescribing. Their report 
concluded that the EMA was content that the pharmacokinetics, efficacy, safety and 
immunogenicity profiles of  biosimilars were similar to those of the originator product 
and concluded that the recommendations for infliximab could apply both to the 
originator product and its biosimilars (186). In addition, the HPRA released a guide to 
biosimilars for healthcare professionals (HCPs) and patients in December 2015. This 
guide discussed the concept of extrapolation in the context of biosimilars where a 
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clinical study is carried out in one of the approved indications of the biological 
medicine and the efficacy data are then extrapolated to all authorised indications 
(177). As stated in this guide, extrapolation is not unique to the authorisation of 
biosimilars; a similar approach may also be used to deal with post-authorisation 
changes for reference biological medicines.  
In February 2016, both the NICE and the BSG updated their previous guidance on the 
subject. The NICE reinforced that all HCPs should ensure biological medicines, 
including biosimilar medicines, are prescribed by brand name so that products cannot 
be automatically substituted at the point of dispensing. The choice of whether a 
patient receives a biosimilar or originator biological medicine should rest with the 
clinician in consultation with the patient (170). The BSG however decided to go one-
step further, releasing a position statement on infliximab brand switching. Their 
guidance stated that there was sufficient evidence to recommend that patients who 
were in stable clinical response or remission on Remicade® therapy can be switched 
on the same dose and dose interval to biosimilar infliximab CT-P13. This switch should 
be carried out after discussion with individual patients and an accompanying 
explanation for switching (which is usually on the grounds of benefit to the overall 
service by reduction in costs of the drug and its administration) (185). Despite the 
position statement from the BSG, this large acute Irish teaching hospital judged that 
it was premature to switch all its patients from Remicade® to biosimilar infliximab CT-
P13 at this time.  
Two months later, a review entitled ’Switching to biosimilar infliximab (CT-P13): 
Evidence of clinical safety, effectiveness and impact on public health’ published in 
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Biologicals journal concluded that whilst prudent switching practices should be 
employed, growing safety experience accumulated thus far with infliximab CT-P13 
and other biosimilars was favourable and did not raise any specific concerns (187). 
Similar evidence that was in favour of switching had also started to surface (185, 188). 
In June 2016, ScienceDaily published a research article on their website entitled 
’Biosimilar switching not suitable for all patients’ (189). At first, it appeared to the 
consultant gastroenterologist and chief pharmacist that this article, based on a study 
conducted in Spain (190), would counteract previous evidence in favour of switching. 
However, when examined closely, the results of the study showed that when antidrug 
antibodies develop in response to Remicade®, these antibodies also cross-react with 
biosimilar infliximab CT-P13 as both biologics share structural properties, including 
antigenic epitopes. These findings suggested that antibody-positive patients being 
treated with Remicade® should not be switched to biosimilar infliximab CT-P13 since 
these antibodies would also interact with the biosimilar and potentially lead to a loss 
of response. Despite its misleading title, the results of this research article actually 
emphasised the similarities between the originator and biosimilar brands of 
infliximab and strengthened the science behind the safety of switching. In fact, it 
should be reinforced that antidrug antibodies prevent a switch only if the exposure 
or clinical effect of the reference product is fading.  
July 2016 saw the European Commission (EC) release guidance stating that 
biosimilars, despite small differences, were expected to be as safe and effective as 
the reference medicine (191). This publication followed previous documentation 
issued by the EC in 2014 explaining the concept of biosimilars to HCPs and the 
pharmaceutical industry (192). Therefore, based on all the continually emerging 
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evidence in favour of switching, the chief pharmacist and consultant 
gastroenterologist of the large acute Irish teaching hospital decided to switch all its 
patients from originator brand infliximab to biosimilar infliximab CT-P13 commencing 
in September 2016. This decision was relayed to all prescribing physicians during an 
internal staff meeting where the chief pharmacist and consultant gastroenterologist 
explained the science behind their evidence-based decision. All physicians accepted 
this and agreed to switch patients given the vast amount of evidence presented. 
Physicians agreed to report any ADRs to the HPRA and to the EMA. Hospital budget 
co-ordinators were once again pleased. Although physicians found it more 
challenging to reassure patients of the switch at first, they reported that after 
informing and addressing all patient concerns at the point of prescribing, no 
opposition to switching arose. 
In October 2016, explorative subgroup analyses of patients with CD and UC in the 
NOR-SWITCH study showed similarity between patients treated with originator 
infliximab and biosimilar infliximab CT-P13 with regard to efficacy, safety and 
immunogenicity (193). Although this was one of the more large-scale controlled 
studies where biosimilar infliximab CT-P13 was tested in IBD patients, the small 
sample size of the IBD subgroup was too small to demonstrate any difference in ADR 
identification or minor differences in effect (193). However, it was still an 
advancement on previous evidence for switching which was justified on the concept 
of extrapolation. The ECCO released an updated statement in December 2016 that 
revised its previous guidelines. One of the prominent recommendations was that 
switching IBD patients from the originator brand to a biosimilar product was now 
deemed acceptable. It also stated that studies of switching can provide valuable 
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evidence for safety and efficacy and that scientific and clinical evidence is lacking 
regarding reverse switching, multiple switching, and cross-switching among 
biosimilars in IBD patients (194). In this rapidly moving field, the evidence is 
continuing to grow supporting the case that biosimilar infliximab CT-P13 is just as safe 
and effective as the originator biologic. Figure 3.1 illustrates in diagrammatic form, 
the systematic trail of evidence behind the decision-making process to introduce and 
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Figure 3.1 Independent systematic evidence base behind the decision-making 
process to implement biosimilar infliximab CT-P13 in a large acute Irish teaching 
hospital for the treatment of IBD 
 
3.6 Results and discussion 
3.6.1 Context 
The decision to treat new and switch existing patients to biosimilar infliximab CT-P13 
in this large acute Irish teaching hospital was a multifactorial one underpinned by a 
robust and extensive evidence-based trail that ultimately convinced prescribing 
physicians. From September 2014, all new patients requiring infliximab therapy for 
the treatment of IBD were prescribed biosimilar infliximab CT-P13. In September 
2016, all IBD patients receiving Remicade® were switched to biosimilar infliximab CT-
P13. Switching from originator infliximab to biosimilar infliximab CT-P13 in IBD 
patients occurred in this hospital before any other Irish hospital and before the 
release of the NOR-SWITCH study data. Biosimilar infliximab CT-P13 was first licensed 
in June 2013 (181) but it was not until approximately three years later that prescribers 
in this large acute Irish teaching hospital decided to switch patients. It is evident that 
there was a significant time lag between regulatory approval and clinical acceptance. 
In fact, Ireland has the second lowest record of biosimilar use due to Irish HCPs being 
slow to accept biosimilars (195, 196). This is possibly owing to a lack of confidence, 
unwillingness or knowledge to prescribe biosimilars which is also seen in other 
European countries (197). Work which aims to enhance the understanding of 
biosimilar medicines amongst stakeholders and to encourage best practice of 
biosimilar use is currently being conducted by a collaborative organisation of various 
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interested parties (198, 199). However, it could be argued that Ireland has 
exceptionally low biosimilar uptake because biosimilar prescribing is not mandated 
unlike in other countries (200). In addition, the Irish biosimilar market does not 
appear very appealing to pharmaceutical companies. Despite the potentially huge 
cost savings to be made from switching, only 54 packets of the biosimilar product 
Benepali® were sold since its introduction to Ireland in August 2016 compared to 
almost 46,856 of the established originator brand Enbrel® (as of May 2017) (201). 
Furthermore, various funding systems of different countries can too have an impact 
where, for example in the UK, a major motivation for switching was reinvestment of 
some of the cost savings in improvements to patients’ care (186).  
The decision by this Irish teaching hospital to switch patients to biosimilar infliximab 
could have been regarded as over cautious, delayed and conservative given that the 
EMA had already licensed the biosimilar medicine three years earlier (181) and thus, 
one wonders why prescribers had not switched patients sooner. With regard to the 
current biosimilar medicine landscape, it is possible that prescribers may feel more 
comfortable issuing biosimilars if national authorities would actively enforce and 
implement individual EMA biosimilar-related decisions as they are published. The 
EMA has the best knowledge of biosimilars amongst regulators but cannot influence 
interchangeability that is within the mandate of individual national regulatory 
agencies (176). These authorities have different capacities to produce information on 
biosimilars and as a result, this predicament contributes to the differential rate of 
acceptance of biosimilars within EU member states. With continually emerging 
positive evidence, it is clear that a three-year time lag for the next biosimilar 
medicine, from market authorisation to the patient switching process, should not 
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occur. Flixabi®, biosimilar infliximab SB2 (202), received market authorisation 
approximately three years after biosimilar infliximab CT-P13 (203). Given its late 
entry in the field relative to biosimilar infliximab CT-P13, it has been unsuccessful in 
penetrating the Irish market so far. Both the chief pharmacist and consultant 
gastroenterologist of this teaching hospital note that they would not be comfortable 
in switching patients from biosimilar infliximab CT-P13 to biosimilar infliximab SB2 
without conducting a comprehensive review of the available evidence, (especially 
evidence from a switching study), even if the national regulator did declare all 
licensed biosimilars completely interchangeable (177). Interestingly however, this 
large acute Irish teaching hospital were content to switch patients to Tevagrastim®, 
a biosimilar of filgrastim (204), from the originator brand without performing such a 
robust evidence review. Due to the difference between these medicines and their 
respective disease states, the onset of response on neutrophil count from filgrastrim 
therapy occurs very quickly after administration and thus is routinely measured to 
ascertain treatment effectiveness. In contrast, there is no such clear-cut marker for 
assessing the onset of response from infliximab therapy at these very early stages. 
Hence why an extensive evidence review was conducted prior to switching patients. 
The comparison between the implementation of these two biosimilars demonstrates 
that each biosimilar medicine requires a distinct and individualised approach when 
considering its introduction into the clinical setting; one approach does not suit all.  
In the field of gastroenterology, biosimilar adalimumab, which is licensed to treat IBD, 
was recently granted market authorisation (205). In the Irish context to date, there 
has been efforts made to introduce or switch patients to this biosimilar (206). In 
contrast to infliximab, which is commonly dispensed in the secondary care 
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environment, adalimumab is predominantly dispensed by pharmacists in the primary 
care setting. This difference is quite interesting as it raises the issue that perhaps 
primary care pharmacists should be targeted by regulatory agencies to encourage 
patients to switch to biosimilar adalimumab in an effort to increase biosimilar 
medicine market penetration. However, as previously noted, this switch would have 
to be initiated by the prescribing physician (175) and be based upon appropriate 
evidence. Indeed, there are already many interesting and established approaches to 
biosimilar medicine implementation which demonstrate that just because a 
biosimilar medicine is licensed, does not mean that its use will be accepted by 
prescribers nor that all patients receiving the originator brand should be 
automatically switched. One such approach is whereby the American National Kidney 
Foundation sponsored a symposium entitled ‘Introduction of Biosimilar Therapeutics 
Into Nephrology Practice in the United States’ (207). With an anticipated increase in 
biosimilar products in the field of nephrology, mutually accepted lack of knowledge 
regarding the biosimilar approval process and development, and lack of trust with 
respect to biosimilar medicines’ safety and efficacy, this community of experts 
decided to meet at a nationwide level to discuss the introduction of biosimilars into 
their area of medicine. The colloquium highlighted several controversies but also 
made recommendations related to public policy, professional and patient education, 
and research needs (207). With the introduction of new biosimilars set to increase on 
the market in coming years (208), this example of individual fields of medicine taking 
responsibility for biosimilar usage pertaining to their area may be a safe, feasible and 
effective approach to introduce biosimilars into the clinical setting. This strategy 
might be particularly suitable for fields like oncology and other inflammatory diseases 
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where biosimilar usage is set to substantially increase (209, 210). Another possible 
approach is that original biologic and biosimilar medicines can be prescribed on the 
proviso that patients will be entered in disease-specific registries. These registries 
may be used as surveillance systems for monitoring ADRs, as well as to quantify and 
evaluate the risk-benefit ratio throughout a medicinal product’s life. Registries may 
be particularly effective for the evaluation of rare ADRs occurring in the real world 
population of treated patients, as opposed to the highly selected populations in 
registration studies (211).   
Following on from information released by the medicine management programme 
(MMP) on biosimilars in the Irish healthcare setting in 2016 (212), and guidance 
issued by the national cancer control programme (NCCP) on the use of biosimilar 
medicines in oncology in August 2017 (213), the DoH disseminated a consultation 
paper in mid-August 2017 (195). This paper indicates that the DoH is developing a 
national biosimilar medicines policy which aims to increase biosimilar use in Ireland 
by creating a robust framework where biologicals and biosimilars can be safely, cost-
effectively and confidently used in the health service (179). Table 3.1 reveals which 
topics of interest are being scrutinised. It is hoped this policy will address the 
interhospital variation to biosimilar medicine implementation in Ireland and shorten 
the acceptance process of using biosimilars in the clinical setting. An interesting issue 
raised by the consultation paper is that of inappropriate business practices (179). 
Although this was not of concern for this large acute Irish teaching hospital, the 
impact of the source of information and collaboration of prescribers with the 
pharmaceutical industry can in principle, have an influence on originator product and 
biosimilar product prescribing patterns. The consultation paper highlights that France 
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and Germany have laws banning physicians from receiving gifts from pharmaceutical 
companies. For biosimilar medicine uptake to increase and be maintained, the 
information and evidence used by prescribers must not be tainted with commercial 
interests. 
Table 3.1 Topics under investigation in the Irish biosimilar consultation paper 
Topic Description 
Prescribing and Interchangeability By focusing on the remit of biological 
medicine prescribing, it is hoped that the 
low uptake of biosimilars in Ireland can 
be increased 
International Biosimilar Medicines 
Policies  
International policies are being 
examined to decide which policy, if any, 
could be implemented in the Irish 
context 
Education and Supports Educational programs and supports are 
being researched from the perspectives 
of the patient, healthcare professionals 
and pharmaceutical suppliers 
Incentives and Disincentives Incentives such as gain-sharing 
agreements and disincentives like 
patient co-payment systems are being 
analysed 
Tendering and Pricing Policies Internal and/or external referencing 
pricing arrangements as well as the 
various types of tendering processes 
used in different countries are being 
probed for their suitability in the Irish 
setting 
Prevention of Inappropriate Business 
Practices 
In addition to inappropriate business 
practices previously highlighted, 
exploration of such professional 
misconduct is being carried out 
 
One of the consultation paper’s recurring themes is that there is too much money 
being spent on originator biologics when there are cheaper, equally effective 
alternatives available. It highlights that only 11 biosimilars are currently reimbursable 
by the Irish healthcare system, while over €200 million is spent each year on biologic 
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drugs that already have approved biosimilars or that will have available biosimilars 
throughout 2018 (179). The potential cost savings to be accrued from switching to 
biosimilars can increase patient access to other new medicinal products. The Irish 
Pharmaceutical Healthcare Association (IPHA) framework agreement plans to save 
money on biological medicines (196, 214) where most of these medicines are 
reimbursed on Ireland’s high-tech medicine scheme. This scheme has seen an 
increase in expenditure from €177.49 million in 2005 to €562.29 million in 2015 (215, 
216). This prodigious level of pharmaceutical expenditure cannot be maintained. 
Research from the Irish National Centre for Pharmacoeconomics (NCPE) has shown 
that when pharmaceutical companies submit BIAs for new high-cost medicines such 
as biologics, the majority of these high-cost medicines have a greater cost burden on 
the budget than what is forecasted in their BIAs (217, 218). This results in taxpayers 
spending more than anticipated. Thus, an increase in the uptake of biosimilar 
medicines would be a more sustainable approach to lower the Irish drug bill.  
Ireland is currently in the process of attempting to deliver whole system health 
reform and UHC, known as Sláintecare, for all its citizens over a ten-year period (23). 
The Sláintecare committee recognises that there is a significant focus on reducing the 
cost of medicines through the IPHA framework agreement, commercial negotiation 
with manufacturers supported by health technology assessment from the NCPE, and 
the development of the national biosimilars policy in draft (21). Through the 
establishment of a national drugs management portfolio, the Sláintecare committee 
intend to promote increased use of generic and biosimilar medicines (21). Figure 3.2 
briefly summarises this hospital’s biosimilar policy decision using the four 
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Figure 3.2 HPT framework describing biosimilar infliximab CT-P13 policy formation 
and implementation 
 
At present, one approach the DoH could take would be to establish gainsharing 
agreements at hospital level. Hospitals could be financially awarded for using 
biosimilars (186) or fiscally penalised for lack of utilisation. Gainsharing agreements 
have already proven to be a powerful incentive in increasing biosimilar use at EU level 
(219). With respect to the Danish biosimilar landscape, their initial passive approach 
to switching actually led to an administrative order (200). Thus, another approach the 
DoH could adopt would be to introduce reference pricing of biologic products which 
would accelerate the path to increased biosimilar usage (179). Reference pricing of 
SMCE medicines has already resulted in savings of millions of euro in the Irish primary 
care setting (196). Success of the use of biosimilar infliximab CT-P13 at University 
Context: Irish biosimilar landscape influenced 
by national biosimilar policy; DoH; EMA; 
HPRA; IPHA; MMP; Sláintecare reform 
Actors: Consultant 
Gastroenterologist 
& Chief Pharmacist 
 Content: Independent 
systematic evidence trail 
outlined in Figure 3.1 
 
Process: Three-year 
procedure; new patients 
initiated; all patients 
subsequently switched; 
continuous post-switch 
monitoring by actors 
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Hospital Southampton (220, 221) and in Norway and Denmark was observed, where 
biosimilar infliximab reached market penetration levels in excess of 90% (as of April 
2016) (222). Such uptake resulted in substantial drug acquisition cost savings and 
subsequently increased patient access to the biosimilar medicine (188, 220). A recent 
report by QuintilesIMSTM has shown that the entrance of biosimilars into the market 
increases price competition while also generating price reductions for both biosimilar 
and reference products (223). However, this report stresses that if the problem of 
low biosimilar uptake is not appropriately managed in the long term, this could lead 
to fewer new biosimilars being developed, reducing overall competitive pressure. 
 
3.7 Conclusion 
This review examined the evidence considered by a large acute Irish teaching hospital 
to safely and effectively introduce biosimilar infliximab CT-P13 into the 
gastroenterology care pathway using components of the HPT framework. There was 
a significant time lag between regulatory approval and clinical acceptance 
notwithstanding that the EMA had granted market authorisation for biosimilar 
infliximab CT-P13 three years prior to the initiation of this hospital’s switching 
process. However, the conservative approach to biosimilar infliximab 
implementation discussed in the review is justified given the conflicting and changing 
evidence disseminated from various sources over this three-year period. Alternative 
approaches that could be used to increase biosimilar medicine adoption into 
healthcare environments have been suggested. Undisputedly, this review 
demonstrates that increased biosimilar medicine usage is of benefit to all 
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stakeholders: increased access for patients, more treatment options for prescribers, 





4 Chapter 4 Cost-effectiveness analysis of a physician-
implemented medication screening tool in older 
hospitalised patients: evidence against policy change at 
local level 
4.1 Chapter description 
Similar to chapter 3, a health-related policy decision in a large acute Irish teaching 
hospital was investigated. However, in this chapter, evidence in the form of an 
economic evaluation to inform policy process development was synthesised. The 
policy decision concerned whether a physician would be the most cost-effective 
healthcare professional to implement a medication screening tool based upon the 
STOPP/START criteria from the perspective of the Irish health service. A cost-
effectiveness analysis alongside conventional outcome analysis in a cluster 
randomised controlled trial (RCT) was used to generate compelling evidence. The HPT 
framework was used to describe the different relevant components which show how 
this topical policy is still maturing. The study applied the policy triangle model to a 
health-related policy decision made at a local level; this has not been observed in the 
literature. The other authors of this chapter and publication reviewed the chapter 
and gave their input and advice during the study. On July 13th, 2018, the following 
published paper was submitted to the creators of the STOPP/START criteria to help 
inform future policymaking regarding the most appropriate means of application and 




The work of this chapter has been modified and published as O’Brien GL, O’Mahony 
D, Gillespie P, Mulcahy M, Walshe V, O’Connor MN, O’Sullivan D, Gallagher J, Byrne 
S, Cost-Effectiveness Analysis of a Physician-Implemented Medication Screening Tool 
in Older Hospitalised Patients in Ireland, Drugs & Aging, 2018, 35(8):751-762, 






A recent randomised controlled trial (RCT) conducted in an Irish University teaching 
hospital that evaluated a physician-implemented medication screening tool 
demonstrated positive outcomes in terms of reduction of incident adverse drug 
reactions (ADRs). 
4.3.2 Objective 
To evaluate the cost-effectiveness of physicians applying this screening tool to older 
hospitalised patients compared with usual hospital care in the context of the earlier 
RCT. 
4.3.3 Methods 
Cost-effectiveness analysis alongside conventional outcome analysis in a cluster RCT. 
Patients in the intervention arm (n=360) received a multifactorial intervention 
consisting of medicines reconciliation, communication with patients’ senior medical 
team and generation of a pharmaceutical care plan in addition to usual medical and 
pharmaceutical care. Control arm patients (n=372) received usual medical and 
pharmaceutical care only. Incremental cost-effectiveness was examined in terms of 
costs to the healthcare system and an outcome measure of ADRs during inpatient 
hospital stay. Uncertainty in the analysis was explored using a cost-effectiveness 
acceptability curve (CEAC). 
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4.3.4 Results  
On average, the intervention arm was more costly but was also more effective. 
Compared with usual care (control), the intervention was associated with a non-
statistically significant increase of €877 (95% CI −€1,807, €3,561) in mean healthcare 
cost, and a statistically significant decrease of −0.164 (95% CI −0.257, −0.070) in the 
mean number of ADR events per patient. The associated incremental cost-
effectiveness ratio (ICER) per ADR averted was €5,358. The probability of the 
intervention being cost-effective at threshold values of €0, €5,000 and €10,000 was 
0.236, 0.455 and 0.680 respectively.   
4.3.5 Conclusion 
Based on the evidence presented, this physician-led intervention is not likely to be 
cost-effective compared with usual hospital care. More economic analyses of 
structured medication reviews by other healthcare professionals (HCPs) and by 
computerised clinical decision support software (CDSS) need to be explored to inform 





Within the 37 member countries of the OECD, people born today have an average 
life expectancy of 80.6 years (224). Given this ten-year increase in life expectancy 
from just 45 years ago, the greatly expanded older person population is one of the 
most resource-consuming patient groups interfacing with healthcare systems in all 
OECD countries (225). This cohort is often exposed to inappropriate prescribing and 
polypharmacy (226, 227) which can frequently lead to ADRs (228, 229). The 
increasing incidence of ADRs within the older population is a growing health problem 
(230). It is estimated that approximately 2,000 bed days are due to an ADR at any one 
time and where the total costs are likely to exceed £171 million annually for ADRs 
occurring during admission in the UK (231). This cost rises to approximately £1 billion 
when all ADRs are taken into account (232). Initiatives which enhance medication 
management in the older people can ameliorate patient outcomes and attenuate 
unnecessary expenditure (233, 234). Given that an estimated 57% of all ADRs are 
considered avoidable, it makes sense to invest in interventions to prevent ADRs, 
particularly in older people who are at highest risk (235). 
Structured and unstructured medication reviews in the hospital environment can be 
an effective means to optimise pharmacotherapy. However, there can be variability 
in the ways these reviews are implemented (236). They are generally carried out on 
an ad hoc basis and can differ depending on which HCP performs the review (237). 
The published literature has numerous examples of RCTs testing different 
interventions that have the common overarching aim of improving prescribing in the 
older adult (238-240). One trial in particular demonstrated a statistically significant 
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reduction in serious ADRs (241). However there are only two published clinical trials 
that have used potentially inappropriate medication (PIM) or potential prescribing 
omission (PPO) criteria as a structured medication review intervention for the 
purpose of ADR prevention in high-risk hospitalised older adults (242, 243).  
Both of these RCTs have employed the widely used STOPP/START (Screening Tool of 
Older Persons’ Prescriptions / Screening Tool to Alert doctors to Right Treatment) 
criteria (version 1.0) (244). The fundamental aim of the STOPP criteria is to minimise 
medication-related adversity by highlighting and avoiding PIMs. The complementary 
aim of the START criteria is to minimise preventable therapeutic failures by 
highlighting PPOs and encouraging appropriate prescriptions if they are absent for no 
justified clinical reason (245). One of these cluster RCTs applied a structured 
pharmacist review of medication (SPRM) which was supported by a computerised 
clinical decision support system (CDSS). It resulted in significant reductions of ADRs 
(243) and proved cost-effective (246).  
The other cluster RCT involved a single time-point intervention in which patients had 
their medications screened according to the STOPP/START criteria by a physician. 
Instances in which STOPP and START criteria had been contravened were highlighted 
to the attending medical team with advice to adjust the patients’ prescriptions 
accordingly. This once-off application of STOPP/START criteria alongside usual 
pharmaceutical care resulted in a significant reduction in incident ADRs compared to 
similar older patients receiving usual pharmaceutical care only (242). However, 
before adopting any medication optimisation technology, appraisal of its economic 
and budgetary impact is important. Notwithstanding the significant ADR attenuation 
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that arose from the application of the STOPP/START criteria (242), an economic 
evaluation of this intervention has not yet been undertaken. The aim of this study 
was to conduct a cost-effectiveness analysis of the physician-implemented structured 
medication review based on its application in a RCT in an older population that aimed 
to reduce incident hospital-acquired ADRs. This is the first economic evaluation of a 
physician-led intervention that is based on the application of the STOPP/START 
criteria.   
The execution of this economic evaluation comes at a time when the Irish healthcare 
system is undergoing major political, economic and health policy reform under the 
Sláintecare policy (23). Through political concord, the Irish Government is aiming to 
establish a universal, single-tier health service where patients are treated solely on 
the basis of health need but it also plans to reorient the health system ‘towards 
integrated primary and community care, consistent with the highest quality of patient 
safety in as short a time-frame as possible’ (21). The Sláintecare report states that ‘in 
acute care where hospital assessment is needed, the principal of ambulatory care 
should apply in order to return older patients to their homes when possible and 
medically appropriate. The emphasis for these patients should be on ambulatory 
emergency care, with rapid clinical assessment, investigation and treatment, leading 
to same day discharge and return to community as the default position’ (21). If 
demonstrated to be cost-effective, the physician-implemented STOPP/START criteria 
medication screening tool could prove instrumental in the implementation of certain 





4.5.1 The prevention of ADRs in older hospitalised patients RCT 
Full details of the particular RCT methods are published elsewhere (242, 247). In brief, 
the single-blinded RCT was conducted in an 810-bed University teaching hospital in 
the south of Ireland over a 13-month period between May 2011 and May 2012. This 
trial was cluster-randomised with consultants from each speciality represented in 
each trial arm. Patients were randomised into either intervention or control groups 
based on the consultant with primary responsibility for their care during their 
hospital stay. The intervention arm consisted of 360 patients. The control arm 
included 372 patients. All in this study received usual medical and pharmacist 
inpatient care, which consisted of full medication reconciliation, surveillance of 
prescription order sheets (independent of medical prescribers) with specific written 
advice attached to the prescription order sheets. The baseline characteristics and 
trial-related outcomes of the study population are presented (see Table 4.1). No 
significant differences existed between the groups in terms of age, functional status, 
cognitive function or number of medications at entry to the study (242). Although 
there was a statistically significant sex imbalance between the groups, it is unlikely 






Table 4.1 Baseline characteristics and trial-related outcomes of study population in 
the RCT 
Variable  Measure  Intervention (n = 360)  Control (n = 372)  P-value 
Age   Median (IQR)  80 (73-85)  78 (72-84)  0.100 
Male  n (%)  130 (36.1%)  187 (50.3%)  0.001 
Female   n (%)   230 (63.9%)   185 (49.7%)   0.001 
Nursing home 
residents 
n (%)   51 (14.1%) 36 (9.6%) 0.080 
Total number of 
daily drugs 
N 3,147 3,212 0.520 
Distribution of 
drugs 
Median (IQR) 9 (6-11) 8 (6-11) 0.710 
Length of 
hospital stay    
Median (IQR)   8 (4 – 14)  8 (4 – 14)  0.961 
Hospital 
mortality rate  
n (%)  11 (3.1%)  9 (2.4%)  0.535 
Key: IQR: Interquartile range; NS: Non-significant (Type 1 error rate of 0.05 used)  
 
A research physician applied the STOPP/START intervention to patients’ medication 
lists within 48 hours of admission. The intervention consisted of three elements. The 
first of these involved the research physician applying the STOPP/START criteria once 
only in each intervention group participant on the basis of the diagnoses documented 
in their case records and the list of prescribed drugs and doses at the time of study 
enrolment. The second element involved the research physician discussing the 
presence of any STOPP/START-defined PIMs and/or PPOs with a senior member of 
the patient’s attending team (i.e. senior residents or in most cases, consultants). 
Thirdly, within 24 hours of applying STOPP/START criteria, the research physician 
placed a printed report in the participant’s case record, reinforcing the oral 
recommendations based on the specific criteria that applied in each case. The final 
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decision regarding acceptance or rejection of STOPP and START criteria 
recommendations lay with the participant’s attending senior medical staff. All 
patients aged ≥ 65 years admitted under the care of the medical or surgical services 
through the emergency department were considered eligible for inclusion. However, 
exclusion criteria were: (i) aged < 65 years, (ii) admission directly to psychiatric 
services, intensive care unit, palliative care unit, specialist geriatric or clinical 
pharmacology services, (iii) anticipated length of stay (LOS) <48 hours, (iv) elective 
admission, (v) terminal illness, (vi) refusal to participate. 
4.5.2 Economic evaluation 
The economic evaluation consisted of a trial-based analysis conducted alongside the 
cluster RCT. The perspective of the Irish public healthcare provider, the HSE, was 
adopted with respect to trial-related costs and outcomes. Evidence on resource use 
and patient health outcomes were collected by the research physician during the 
course of the trial and a retrospective review of patient medical records was carried 
out. The time horizon for ADR evaluation was confined to patient discharge or ten-
day follow-up, whichever was sooner; this was informed by average LOS for an elderly 
patient in the Irish hospital system at the time (249). The average LOS for patients 
aged 65 - 74 years is 7.9 days and is 10.4 days for patients aged 75 - 84 years. The 
study was not designed to measure the medium/long term impact of this 
intervention and discounting of costs or outcomes was not required due to the 
limited follow-up period. Moreover, missing/censored data were not an issue in this 
evaluation, as follow-up was facilitated by a unique hospital number identifier and 
confined to a single centre over a short time period. Statistical analysis was 
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conducted on an intention to treat basis, and in accordance with guidelines for 
conducting economic evaluations alongside cluster RCTs (250), which require that 
both the correlation and clustering of the cost and effect data be explicitly 
considered.  
4.5.2.1 Cost analysis 
Multiple cost components were included in the analysis and are described (see Table 
4.2). Costs are expressed in Euros (€) using 2012 prices (unless otherwise stated). The 
primary component was the cost of employing the research physician, who then held 
the post of specialist registrar (i.e. senior resident) physician in geriatric medicine, to 
implement the required intervention steps. The mid-point of the HSE specialist 
registrar physician pay scale was used and adjusted according to guidelines for 
conducting economic evaluation in Ireland (60, 251). Salary was adjusted for 
employers’ insurance cost, pension payments and general overheads. Based on 
experience-based opinion from the primary research team and estimates from the 
literature (252), it was assumed for the analysis that 40 minutes was an appropriate 
duration to assign for the trained research physician to apply the intervention.   
The second component consisted of the associated follow-up time for senior 
members of patients’ attending teams to discuss and decide upon the suggested 
STOPP/START recommendations. Based on experience-based opinion from the 
primary research team, it was assumed for the analysis that this took seven minutes. 
The mid-point on the HSE consultant physician pay scale was used in the cost analysis. 
The third major component was the cost of hospital inpatient stay; this cost was 
obtained from aggregated national data (253). In general, micro-costing estimates for 
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patients are preferable. However, in the context of this piece of research, the 24-hour 
national Irish hospital stay average cost per patient was more pragmatic to use 
despite patients being admitted with a diverse range of primary indications. The 
fourth component consisted of the specialist registrar’s training in the use of 
STOPP/START criteria. Interactive training courses given by the creators of the 
STOPP/START criteria generally last for approximately four hours and were costed 
accordingly. 
All resource use was valued using a vector of unit cost data presented in 2012 Euro 
(€) prices and summed to calculate a total cost variable for the statistical analysis 
given that the trial was completed in 2012. However, at the time of study execution 
(December 2017), the contemporaneously available healthcare costs (CAHC) in the 
Irish context were re-applied to the intervention steps. These costs are expressed in 
2015 Euros (€) prices unless otherwise stated (see Appendix IX). The incremental 
cost-effectiveness analysis was re-run with the CAHC and original trial effectiveness 
data (see Appendix X). This supplementary analysis was undertaken as a point of 
interest to examine the stability of medical inflation in Ireland during the post 
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4.5.2.2 Effectiveness analysis 
The primary outcome measure of this cluster RCT was the difference in the 
proportion of participants in the two arms experiencing one or more ADRs during 
index hospitalisation. ADRs were identified by the research physician and a blinded 
second researcher. A comprehensive description of ADR identification and outcomes 
is provided elsewhere (242).  
4.5.2.3 Cost-effectiveness analysis 
In an economic evaluation, one health technology (treatment/intervention) is 
considered more cost-effective than its comparator if it meets one of the following 
criteria (54);  
a) Less costly and more effective;  
b) More costly but more effective, with an incremental cost-effectiveness ratio 
(ICER) which is considered acceptable by decision-makers;   
c) Less costly and less effective, but the additional cost per unit of effect of its 
comparator is not considered worth paying by decision-makers.  
In the context of the current study, a cost-effectiveness analysis was conducted to 
identify which of the three conditions applies here. Notably, the ICER represents the 
additional cost per unit effect, which in this case, is the additional cost of preventing 
an additional non-trivial ADR in secondary care. This raises the concern of what 
healthcare policymakers and decision-makers in Ireland would be willing to pay to 
prevent an ADR. While threshold values exist for some generic measures such as 
quality-adjusted life years (QALYs), no such value per ADR prevented currently exists. 
In this analysis, we present our results in the context of a number of hypothetical 
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thresholds, as previously proposed in the literature (246). Recent work that compares 
methods for estimating direct costs of ADRs may inform a threshold value for ADR 
prevention in the future (254). 
Statistical techniques were adopted to account for the effect of both clustering and 
correlation of cost and effect data collected alongside cluster RCTs (255). The 
incremental analysis was undertaken using multilevel regression models for both the 
cost and effect data. Both models were estimated to control for treatment arm, age, 
sex, number of medications at admission and consultant (cluster group). The 
regression for total cost variable was estimated using a multilevel mixed-effects 
linear regression model and the regression for the ADR event variable was estimated 
using a mixed-effects logistic regression model. The estimated treatment arm effects 
represent the incremental costs and incremental effects for the intervention relative 
to the control. The 95% confidence intervals report the statistical significance of these 
co-efficients based on standard errors estimated using the ‘mixed’ command in 
STATA® version 13 (StataCorp, College Station, TX, USA).  
Uncertainty in the analysis was addressed by estimating confidence intervals and a 
cost-effectiveness acceptability curve (CEAC), which links the probability of a 
treatment being cost-effective to a range of potential threshold values (λ) that the 
healthcare system may be willing to pay for an additional unit of effect (256). 
Commonly, non-parametric bootstrapping can be conducted on the difference in 
mean costs and mean ADRs to generate ICER replicates with which to construct a 
CEAC (257). However, the CEAC in this analysis was estimated parametrically using 
the net benefit regression framework following the method proposed by Hoch et al. 
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(258). The CEAC explicitly presents the uncertainty relating to the threshold value 
coupled with the statistical variability inherent in trial data.  
Finally, a series of scenario analyses was performed which varied the time required 
by all HCPs to complete the intervention by +/- 50%. The scenario analysis was re-run 
using CAHC and the original trial effectiveness data (see Appendix XI). The aim was 
to assess the cost-effectiveness of this intervention if it was to be implemented in 
usual clinical care by hospitals in more recent times. Analysis was performed using 
STATA® version 13 and Microsoft Excel® 2010 (Microsoft Corporation, Redmond, WA, 
USA).  
4.5.3 Guidelines and ethical considerations 
This analysis followed the Consolidated Health Economic Evaluation Reporting 
Standards (CHEERS) guidelines for reporting health economic evaluations (259) (see 
Appendix XII) with joint reference to the published good research practices for cost-
effectiveness analysis alongside clinical trials, i.e. the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) Task Force on Good Research 
Practices: Randomized Clinical Trials-Cost-Effectiveness Analysis (ISPOR RCT-CEA) 
report (260). The original clinical cluster randomised trial conformed to Consolidated 
Standards of Reporting Trials (CONSORT) guidelines (261). The research ethics 
committee (institutional review board) of the local teaching hospitals network 
approved the trial protocol and the trial was registered with the United States 
National Institutes of Health (NCT01467050- 
http://clinicaltrials.gov/show/NCT01467050). Written consent was sought and 
obtained from all participating patients, prior to enrolment in the original cluster RCT 
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study. Ethical approval was not required for this secondary analysis of anonymised 
data. 
 
4.6 Results  
The physician-led STOPP/START intervention resulted in a marked absolute risk and 
relative risk reduction for incident ADRs i.e. 11.4% and 47.7% respectively (242). 
However, this was accompanied by an increased cost relative to usual medical and 
pharmaceutical care (Table 4.3). The mean (standard deviation (SD)) cost of caring 
for an intervention patient during a single admission was €12,102 (€13,490). In the 
control group, the mean (SD) cost of care was €11,160 (€12,506). Median costs were 
higher for the intervention group (€7,430) compared to the control group (€7,380). 
Following application of a multi-level mixed effects model in STATA® version 13 and 
accounting for baseline differences across both arms, the adjusted incremental 
difference in cost of €877 was statistically non-significant.   
In contrast, the effectiveness measures favoured the intervention strategy and were 
statistically significant. The odds ratio for a patient experiencing an ADR was 0.391 
when comparing the intervention (STOPP/START criteria) group to the control (usual 
hospital care) group. This related to an adjusted difference in the mean number of 
ADRs of −0.164. Although the physician-implemented STOPP/START intervention was 
more costly, it too was more effective than usual clinical care. The calculated ICER 
was €5,358 for the prevention of an ADR. However, as with all attempts to calculate 
the cost-effectiveness of an intervention, there is a degree of uncertainty 
surrounding the ICER. Even if the healthcare payer was willing to pay the €5,358 for 
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the prevention of an ADR, the probability of the intervention being cost-effective was 
50%. There was a 92.6% probability that the intervention would be cost-effective if 
the healthcare payer was willing to pay €20,000 for the prevention of an ADR (Table 
4.3 and Figure 4.1). When the cost-effectiveness analysis was rerun using CAHC and 
the original trial effectiveness data, the ICER underwent a slight increase to €5,469 
(see Appendix X). Scenario analyses demonstrated that if HCP times associated with 
the intervention were altered by +/- 50%, this had a minimal effect on the original 
ICER estimate (Table 4.4). This was also true of the scenario analyses that used CAHC 
and original trial effectiveness data (see Appendix XI). 
The overall cost of applying the STOPP/START intervention to a group of 360 patients 
was estimated to be approximately €18,000 or €50 per patient. The majority of the 
intervention costs were associated with the expense of the research physician’s time 
conducting the intervention (~€33 per patient). Length of hospital stay was 




Table 4.3 Incremental cost-effectiveness analysis using 2012 data 
 Intervention group (n = 360)  Control group (n = 372)  
Cost analysis   
Total healthcare cost (€)      
    Mean (SD)  12,102 (13,490)  11,160 (12,506)  
Effectiveness analysis   
Participants experiencing ≥ 1 
ADRs [n (%)]  
42 (11.67)  78 (20.97)  
ADRs experienced per patient 
[n (%)]  
    
    0  318 (88.33)  294 (79.03)  
    1  39 (10.83)  67 (18.01)  
    2  3 (0.83)  11 (2.96)  
ADRs per patient [mean (SD)]  0.125 (0.356)  0.239 (0.492)  
  
Incremental cost-
effectiveness analysis  
Intervention vs Control  
Incremental cost  
Difference in mean 
healthcare cost (€) (a,b) 
877 (95% CI −1807, 3561) 
Incremental effect  
Difference in odds ratio for 
ADR events (a,c) 
0.391 (95% CI 0.233, 0.657)  
Difference in mean ADR 
events (a,c)    
−0.164 (95% CI −0.257, −0.070)  
ICER per ADR averted (€) 5,358 
Threshold value (λ) per  
ADR averted (€) 
Probability that intervention is cost-effective (d) 
             0  0.236 
         500  0.255 
      1,000  0.275  
      5,000  0.455 
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Threshold value (λ) per  
ADR averted (€) 
Probability that intervention is cost-effective (d) 
    10,000  0.680 
    20,000  0.926  
Key: SD: standard deviation; ADR: adverse drug reaction; CI: confidence interval; ICER: 
incremental cost-effectiveness ratio 
a) Reported estimates for incremental differences in costs and effects adjusted to 
account for baseline differences between arms.  
b) Regression for total costs estimated using multilevel mixed-effects linear 
regression models and controlling for treatment arm, age, sex, number of 
medications at admission and clustering. 
c) Regression for ADR event estimated using mixed effect logistic regression 
models and controlling for treatment arm, age, sex, number of medications at 
admission and clustering. 
d) Probabilities for cost-effectiveness estimated parametrically using net benefit 







Figure 4.1 Cost-effectiveness acceptability curve (controlling for treatment arm, age, sex, number of medications at admission and 





























Value of threshold value per ADR averted
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Table 4.4 Scenario analysis using 2012 data 
50% increase in healthcare professional 
time  
Incremental Analysis - Intervention vs Control 
Incremental Cost: Total Cost (€) 
Difference in Mean  
900 (95% CI −1783, 3584) 
  
Incremental Effect: No. of ADR Events (n)     
Difference in Mean  
−0.164 (95% CI −0.257, −0.070) 
Incremental cost-effectiveness ratio (€) 5,500 
50% decrease in healthcare professional 
time 
Incremental Analysis - Intervention vs Control 
Incremental Cost: Total Cost (€) 
Difference in Mean 
854 (95% CI −1831, 3539) 
Incremental Effect: No. of ADR Events (n)     
Difference in Mean 
−0.164 (95% CI −0.257, −0.070) 
Incremental cost-effectiveness ratio (€) 5,216 




It is unlikely that the physician-led STOPP/START intervention is cost-effective. For 
instance, at a willingness-to-pay threshold of €10,000 per ADR averted; the 
probability of the intervention being cost-effective is only 68%. The probability of the 
intervention being cost-effective increases to 92.6% if a significantly higher threshold 
of €20,000 is applied. The willingness-to-pay thresholds used in this analysis were 
arbitrary but when one considers that the mean cost associated with a single ADR 
event in secondary care has been estimated at €2,250 (262), the threshold values 
presented in Table 4.3 and Figure 4.1 are a reasonable measure of what could be 
considered value for money. This cited mean cost of a single ADR also suggests that 
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it is unlikely decision-makers would be willing to pay the quoted threshold values 
because a high probability of cost-effectiveness is only reached at high threshold 
values. Similar increases in the cost of care could be imputed from this study, as 
patients who experienced an ADR had their median LOS increased by three days 
(242).  
The principal barrier to the application of this intervention by a trained physician at 
a wider level is physician working hours’ capacity. The senior resident research 
physician screened no more than four new patients each day for trial enrolment 
during the cluster RCT. It should be noted that the research physician was not 
employed on a full-time basis to apply the intervention to patients. If all older 
hospitalised patients were to receive this level of pharmaceutical care, increased staff 
numbers would likely be required. However, given the results from the analysis, it 
could be argued that the role of the specialist physician is to conduct all relevant 
medical duties in the secondary care environment. Although there are some 
published data in the primary care setting literature (263), we could find no reputable 
references dealing with economic analyses of physician-led medication-related 
interventions in the secondary care setting literature. Thus, it is difficult to align the 
results of this analysis with similar studies. One similar trial involving a research 
pharmacist conducting a similar medication review-based intervention supported by 
computerised CDSS proved to be cost-effective relative to routine hospital care (246). 
A recent systematic review investigating the effectiveness and cost-effectiveness of 
interventions aimed at preventing medication error (medicines reconciliation) at 
hospital admission demonstrated that the majority of these interventions are 
pharmacist-led, not physician-led (264) and that the pharmacist-led interventions are 
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generally considered more cost-effective than the respective study comparator 
(265). In addition, two ongoing European multi-centre randomised clinical trials i.e. 
SENATOR and OPERAM (266-268) implement the STOPP/START criteria using a 
computerised CDSS. A recent systematic review concluded that computerised 
interventions are associated with a significant reduction in potentially inappropriate 
prescribing (PIP) in older hospitalised patients (269). Computerised interventions in 
this field appear to reduce cost (270) and be cost-effective (271). It is also envisaged 
that the application of STOPP/START criteria in the SENATOR and OPERAM trials may 
prove less labour-intensive and more cost-effective than its application in the RCT 
analysed in this study (272). Given all this evidence, it is likely that the more clinically 
effective and cost-effective medication screening interventions in older hospitalised 
patients in the future will comprise of pharmacist-led and/or computerised CDSS 
interventions. 
A study conducted in Canada assessed the cost-effectiveness of self-managed versus 
physician-managed oral anticoagulant therapy over a 5-year period using a Bayesian 
Markov model (273). Self-management resulted in fewer adverse drug events than 
physician management with the average discounted incremental cost of self-
management relative to physician management calculated to be $989 per patient 
with incremental QALYs of 0.07 gained (273). Although this study did not assess 
medication screening in the elderly per se, it is yet another example of where a 
physician-implemented medication intervention was not found to be cost-effective. 
Conversely, the literature once again appears to favour medication screening 
programmes involving or implemented by pharmacists. This point is supported by 
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two recently published studies demonstrating cost-effectiveness of pharmacist-
driven medication reviews towards optimisation in older patients (238, 274). 
Notwithstanding the research physician’s absence during medical rounds, the 83.4% 
acceptance rate of STOPP/START recommendations by attending doctors is 
noteworthy (242). However, in a very similar analysis where the research pharmacist 
was absent during medical rounds, a lower acceptance rate of 38.5% by attending 
doctors was notable (275). As the present analysis argues that pharmacist-led 
medication screening interventions are an effective and a cost-effective solution, the 
low rate of acceptance of pharmacist prescribing recommendations by attending 
physicians needs to be further investigated. In relation to pharmacist medication 
reviews, a robust method for economic evaluation of such medication assessments 
has been elucidated (276). Ideally, the evaluation should be conducted with a 1-year 
follow-up period from a healthcare service provider viewpoint. Health-related quality 
of life (HRQoL) is contended as the preferred effectiveness measure utilised, allowing 
correlation with confirmed societal values. The ultimate and most comprehensive 
appraisal would be a cost-benefit evaluation over a 5-year period from a societal 
perspective. Thus, if the standard practice model of medication reviews is to be 
pharmacist-led, the economic evaluation aspect of such reviews should be conducted 
using the proposed methods. 
The cluster randomisation of the RCT that this evaluation is based upon resulted in a 
statistically significant sex imbalance between the control and intervention groups 
(significantly fewer women in the control group (49.7%) than in the intervention 
group (63.9%)). Although sex imbalance in any RCT is not desirable, there is no 
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evidence to indicate that sex had a significant influence on the prevalence rates of 
PIMs, PPOs, or incident ADRs in the trial. The literature has shown that females 
experience higher rates of PIMs and ADRs relative to males (277-279). Given the 
higher proportion of women in the intervention group, one would have expected 
higher rates of ADRs in this arm, yet the results demonstrated the contrary. 
Therefore, it is unlikely that the sex imbalance between groups had a significant 
influence on primary outcome trial results. There were no other significant 
demographic differences between the two treatment arms. As stated, demographic 
analysis is presented in the original RCT paper (242). 
It has been established that conducting economic evaluations based on data from 
RCTs is a suitable methodology (280). This approach has two main advantages i.e. (i) 
internal validity is maintained due to the comprehensive nature of data collection 
during the trial and (ii) there is a modest marginal cost associated with collecting 
required data from a trial which is predominantly clinically orientated (280). While a 
cost-utility analysis with a health-related outcome measure is recommended as the 
reference case in the Republic of Ireland (60), it was not a realistic outcome measure 
for this analysis. The population under consideration had multiple co-morbidities and 
often an initially poor health status (242). Therefore, HRQoL was not appropriate in 
this case (281). Appropriate methods were used to investigate the cost-effectiveness 
analysis of the trial data. Multi-level mixed effect models were chosen as they are an 
acceptable means for estimating the incremental net benefits for a clinical trial of this 
nature. Clustered data can potentially lead to biased results (282). Normal statistical 
analyses are generally inappropriate, however the methods employed for our 
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analysis surmounted this issue (255). These techniques account for both the 
clustering and correlation of cost and effect data. 
4.7.1 Limitations 
There are several limitations to this economic evaluation, principally pertaining to 
extrapolation of the findings to routine clinical practice. Training costs and time 
estimates were not recorded at time of event and were retrospectively informed by 
the primary research team. It is likely that some costs associated with this 
intervention may have been overestimated or underestimated. For example, the 
seven-minute time period allocated for discussion of STOPP/START 
recommendations could vary considerably depending on the number of 
recommendations generated and the subjective prescribing assessment thought 
processes of the attending consultant. In addition, the 30-minute time period 
allocated to compiling the research physician’s printed report could be replaced by a 
five-minute handwritten summary of recommendations into patients’ medical 
records. However, the scenario analysis demonstrated that if HCP time associated 
with intervention implementation was altered by 50% in both directions, this had a 
minimal effect on the original ICER estimate (see Table 4.4). Furthermore, a time and 
motion study, which gathers data on HCP time required to complete the intervention, 
would have reduced uncertainty surrounding this input. As HCPs become more 
familiar with the application of the STOPP/START criteria, they will be able to apply 
them more effectively and arrive at decisions at a faster rate.  
ADRs are often compared to icebergs (283); those that are visible and identified, and 
those that are below the water’s surface where neither patient nor intervening 
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clinician recognise that they are drug effects, and thus unquantifiable. Therefore, it 
is possible that the amount of ADRs identified in both arms of the trial is not the true 
value. Depending on the type and severity of ADR, the cost, patient LOS, and overall 
impact on healthcare utilisation, can vary dramatically (262, 284). This level of detail 
was not reflected in our evaluation. Therefore, it is potentially dangerous to dismiss 
the intervention as not being cost-effective because the outcome at the time was not 
measurable or identifiable. There are also those that may be causing no symptoms 
or signs at the time but represent a real risk in the future. Ideally, a longer duration 
of follow-up for ADR evaluation would have been preferable as it possibly could have 
allowed for further identification of ADRs. 
Moreover, this evaluation is based on the work of one research physician in a single 
centre. Aspects of the intervention that would be variable between sites include the 
clinical experience of the research physician involved and the extent of the uptake of 
STOPP/START criteria recommendations by the receiving medical team. The 
attending physician is solely responsible for deciding whether the application of the 
STOPP/START criteria is clinically important or not. This is a subjective choice, 
irrespective of formal training. There are other examples of medication optimisation 
due to the application of the STOPP/START screening tool (245). This single study site 
increased the possibility of crossover learning between healthcare colleagues within 
the secondary care environment. However, if healthcare decision-makers are 
insistent about supporting and promoting physician-led medication screening 
interventions, this evaluation should be carried out on a larger scale involving 




4.7.2 From evidence to policy 
As stated, the trial was conducted in 2011/2012 and cost-effectiveness was 
calculated using 2012 healthcare costs. When the analysis was re-run using CAHC and 
original trial effectiveness data, the cost of the intervention was marginally lower (see 
Appendix IX); however, there was a slight ICER increase which is attributed to the 
increased 24-hour national Irish hospital stay average cost per patient (see Appendix 
X). It is unlikely that hospital decision-makers would execute the rollout of this 
intervention today as it has become less cost-effective in recent times. However, a 
BIA would have to completed alongside the cost-effectiveness analysis to assess if 
hospital decision-makers and other policymakers were serious about its adoption 
(285). In addition, the results of economic analyses based on RCTs must be 
interpreted with caution especially if there are limitations or flaws inherent in trial 
design. However, the RCT that formed the basis of the present cost-effectiveness 
analysis achieved 80% power to detect a statistically significant difference in ADR 
incidence between the groups at the 95% confidence level (242). It would have been 
interesting to calculate the incremental net benefit statistic to derive the same 
conclusion on cost-effectiveness like that of the ICER. This was not possible since a 
willingness-to-pay threshold for ADRs has not yet been elucidated. 
This is the first study to evaluate the economic impact of a physician-led medication 
review intervention based upon the STOPP/START criteria where recommendations 
from the CHEERS statement were implemented to ensure that this analysis presents 
a transparent high-quality evaluation. Since their development in 2008 (244), the 
STOPP/START criteria have become an extensively used method of identifying and 
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improving instances of PIP (275, 286). This analysis provides further information 
about the adoption of the STOPP/START guidelines as a fundamental part of any 
healthcare review conducted by a HCP in an older population. 
STOPP/START creators Professor Stephen Byrne, Professor Denis O’Mahony, and Dr. 
Paul Gallagher (287) of Schools of Pharmacy and Medicine, University College Cork 
(UCC), Ireland are currently updating the STOPP/START guidelines (version 3.0). This 
revision is scheduled to be released during the summer of 2021. In this study, the 
application of the STOPP/START criteria did not demonstrate cost-effectiveness in the 
secondary care setting. In line with the Sláintecare aim of reorienting health services 
towards integrated primary and community care (23), the formal use of the 
STOPP/START criteria (version 3.0) by pharmacists and GPs in primary care may prove 
cost-effective for the health system and wider society. Further research is required 
on its application in this setting, but research shows that addressing a subset of 
chronic illnesses and related medications, including congestive heart failure, 
diabetes, asthma, angina, epilepsy and hypertension, through clinical leadership in 
primary care settings, results in better outcomes and more appropriate care than if 
provided in hospital (21). When these conditions are effectively managed by primary 
care teams and patients themselves are empowered, exacerbations or 
hospitalisations can be minimised (288). The impact for patients is better health 
when chronic conditions do not deteriorate and for health systems the cost savings 
are significant (289). In addition, the Irish Pharmacy Union (IPU) conducted a new 
medicines service (NMS) pilot in Ireland throughout 2017. This pilot demonstrated 
that the community pharmacist-led NMS intervention had benefits for the vast 
majority of patients, with a positive effect on a total of 85% of all patients in the 
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treatment arm (290). Already, the English NMS has proven to be cost-effective 
compared with normal practice (291). The cost-effectiveness must still be evaluated 
for the IPU NMS. However, if proven, the STOPP/START creators plan to engage in 
talks with the IPU on integrating the STOPP/START criteria into the IPU NMS 
intervention. Thus, the formal transposition of the revised criteria to primary care 
settings is being considered by the STOPP/START actors at present. 
Another avenue the STOPP/START creators are exploring is that the criteria would be 
exclusively applied by pharmacists in association with a computerised CDSS in the 
healthcare setting as opposed to by physicians. As mentioned, a recent cluster RCT 
conducted in the same 810-bed University teaching hospital applied a SPRM which 
was supported by a computerised CDSS. It resulted in significant reductions of ADRs 
(243) and proved cost-effective (246). Reducing the involvement of the physician in 
such interventions would improve the cost-effectiveness from a healthcare payer 
perspective. The STOPP/START creators are involved in both SENATOR and OPERAM 
trials. These trials are currently reporting on similar interventions where the 
STOPP/START criteria are being implemented via a computerised CDSS with 
additional pharmacist involvement. To date, the policy process on how the 
STOPP/START criteria should be optimally delivered (by who, what setting, what type 
of software etc.) is still growing. Figure 4.2 briefly summarises the content, context 
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4.8 Conclusion 
Based on the information extracted from the cluster RCT, the physician-implemented 
medication screening tool based on the STOPP/START criteria is unlikely to be 
considered cost-effective. The healthcare payer would have to pay €20,000 to attain 
a 92.6% probability that this intervention, which prevents ADRs, is cost-effective. 
However, as the authors are unaware of decisions previously made based on the cost 
per ADR prevented, there is uncertainty regarding the cost-effectiveness status of the 
intervention from a policy perspective. Moreover, while the difference in incremental 
effects on an individual basis did demonstrate statistical significance, the difference 
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in overall incremental costs did not. To date, the literature appears to be sparse with 
regard to physician-implemented medication review interventions in the secondary 
care setting in contrast with the multiplicity of studies describing pharmacist-led 
programmes that appear to be clinically effective and budget positive (265). At a 
minimum and as portrayed by the HPT framework, this evaluation further adds to the 
growing body of evidence that a structured form of medication review and 
reconciliation incorporating STOPP/START criteria is superior to usual clinical 
practice. The present data suggests that a pharmacist with/without computerised 
CDSS designed for STOPP/START criteria employed to carry out such medication 
reviews may be a more cost-effective approach than a medication review provided 




5 Chapter 5 Cost minimisation analysis of intravenous 
and subcutaneous trastuzumab treatment in patients 
with HER2-positive breast cancer: evidence for policy 
change at regional level 
5.1 Chapter description 
Similar to chapters 3 and 4, a health-related policy decision was investigated. This 
time the setting grew to include two large acute University teaching hospitals within 
the south/south west hospital group in Ireland. Like in chapter 4, evidence in the form 
of an economic evaluation to inform policy process development was synthesised. 
The policy decision concerned whether trastuzumab subcutaneous treatment should 
replace trastuzumab intravenous treatment for HER2-positive breast cancer patients 
in routine clinical practice. A prospective observational study in the form of a cost 
minimisation analysis constituted study design and was used to generate compelling 
evidence to support policy change. The HPT framework was used to describe the 
various contributing components which show how this contemporary policy is still 
evolving. The study applied the policy triangle model to a health-related policy 
decision made at a provincial/regional level; this has not been observed in the 
literature. The other authors of this chapter and publication reviewed the chapter 
and gave their input and advice during the study. On September 25th, 2018, at the 
request of its Chief Pharmacist, the following published paper was submitted to the 
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HSE-National Cancer Control Programme to inform policymaking and reimbursement 
on this topic. 
5.2 Publication 
The work of this chapter has been modified and published as O’Brien GL, O’Mahony 
C, Cooke K, Kinneally A, Sinnott SJ, Walshe V, Mulcahy M, Byrne S, Cost Minimisation 
Analysis of Intravenous or Subcutaneous Trastuzumab Treatment in Patients with 
HER2-Positive Breast Cancer in Ireland, Clinical Breast Cancer, 2019, 19(3):e440-e451, 






Two large acute Irish University teaching hospitals changed the manner in which they 
treated human epidermal growth factor receptor (HER)2-positive breast cancer 
patients by administering trastuzumab via the subcutaneous (SC) route into their 
clinical practice. 
5.3.2 Objective 
To compare the trastuzumab SC and trastuzumab intravenous (IV) treatment 
pathways in both hospitals and assess which route is more cost-effective and time 
saving in relation to active healthcare professional (HCP) time. 
5.3.3 Methods 
A prospective observational study in the form of cost minimisation analysis 
constituted the study design. Active HCP time for trastuzumab SC and IV-related tasks 
were recorded. Staff costs were calculated using fully loaded salary costs. Loss of 
productivity costs for patients were calculated using the human capital method. 
5.3.4 Results  
On average, the total HCP time saved per trastuzumab SC treatment cycle relative to 
trastuzumab IV treatment cycle was 59.21 minutes. Time savings in favour of 
trastuzumab SC resulted from quicker drug reconstitution, no IV catheter 
installation/removal, and less HCP monitoring. Over a full treatment course of 17 
cycles, average HCP time saved accumulated to 16.78 hours with an estimated direct 
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cost saving of €1,609.99. Loss of productivity for patients receiving trastuzumab SC 
(0.60 days) was less than that of trastuzumab IV (2.15 days) for a full treatment 
course. 
5.3.5 Conclusion 
Trastuzumab SC treatment has proven to be a more cost-effective option than 
trastuzumab IV treatment that also generated greater HCP time savings in both study 
sites. Healthcare policymakers should consider replacing trastuzumab IV with 





Breast cancer is the most common cancer in women (292, 293). The humanised 
monoclonal antibody trastuzumab is indicated for the treatment of both early and 
metastatic human epidermal growth factor receptor (HER)2-positive breast cancer 
(294). In this group of patients, trastuzumab is administered every three weeks for 
one year (either 17 or 18 treatment cycles depending on the decision of the attending 
physician) in early breast cancer or, in the case of metastatic breast cancer until 
disease progression, by intravenous (IV) infusion at a dose calculated according to the 
patient’s weight (294). The duration of administration for trastuzumab IV in this 
condition is 90 minutes in the first administration (loading dose) and 30 minutes for 
consecutive treatment administrations (maintenance dose) (294). In addition to the 
IV formulation, a subcutaneous (SC) formulation exists. It has an administration time 
of less than five minutes and is given by a single-use injection device (SID) or via 
handheld syringe. The dose is independent of the patient’s weight. The SC 
formulation has demonstrated pharmacokinetics, efficacy, and a safety profile 
comparable to the IV formulation in patients with early HER2-positive breast cancer 
in the enHANced treatment with NeoAdjuvant Herceptin (HannaH) trial (295). Both 
the safety and tolerability of Subcutaneous trastuzumab for the adjuvant treatment 
of Human epidermal growth factor receptor 2-positive early breast cancer (SafeHer) 
trial and the Preference for subcutaneous or intravenous administration of 
trastuzumab in patients with HER2-positive early breast cancer (PrefHer) trial have 
also corroborated these findings (296, 297). 
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There are two general approaches to costing healthcare: top-down and bottom-up. 
A top-down approach estimates the cost of an individual service on average, usually 
using routinely available data e.g. average per diem costs. Top-down costing studies 
tend to be relatively quick and straightforward to conduct. However they are also less 
precise and cannot provide information on individual factors driving the costs (54). 
Disease-specific per diem costs (or daily cost) give the average daily cost for 
treatments in each disease category but may still be quite broad (54). Case-mix 
groups yield the costs for each category of ’case’ or hospital patient and take length 
of stay into account. While this approach to costing is more precise than the 
aforementioned approaches, a bottom-up approach (micro-costing) generates a 
more precise estimate but is more onerous to perform. In micro-costing, all resources 
used are identified where the unit costs of the resources are multiplied by the 
quantities used (54). Studies examining the differences between the cost estimates 
produced by both top-down and bottom-up approaches have concluded that 
bottom-up approaches are preferable for estimating cost components which have a 
large impact on total costs (e.g. labour, expensive drugs), for services where there is 
wide variation in costs between patients, and for centres which are integrated within 
a larger hospital compared to independent centres (298-301). 
Trastuzumab IV was first launched in Ireland in December 2000 while trastuzumab SC 
was launched in December 2013 (302). The release of trastuzumab SC came at an 
interesting time when Ireland began to restructure its healthcare funding system 
from one where hospitals are funded based on historical levels of funding adjusted 
for activity and patient mix, to a prospective case based payment system known as 
‘Activity Based Funding’ (ABF) (303). This change is currently being implemented for 
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inpatient and day-case activity and will subsequently include outpatient services 
(303). Within the ABF system, previously referred to as ‘Money Follows the Patient’, 
prices will be set initially with reference to average prices, but with an overall aim to 
implementing best practice prices on an incremental basis (303). Under Ireland’s 
Sláintecare reform policy, work is currently being undertaken to develop the ‘Hospital 
ABF Implementation Plan 2019-2022’ to embed and extend ABF benefits (22). 
Acknowledging the contemporaneous reforms in the Irish healthcare sector, the aim 
of this study was to estimate the total cost of providing trastuzumab treatments to 
HER2-positive breast cancer patients in two large acute Irish University teaching 
hospitals within the south/south west hospital group in the year 2018. The 
perspective of the Irish healthcare service provider was adopted, using a micro-
costing approach, and the loss of productivity was calculated from a societal 
perspective. This is the first economic evaluation examining the impact of switching 
trastuzumab formulations in the Irish healthcare setting.  
 
5.5 Methods 
5.5.1 Hospital 1 – Nurse-led clinic 
Hospital 1, a 431 inpatient and 85 day procedure beds teaching hospital, provides 
general medical, surgical and maternity care to approximately 0.5 million patients of 
southeast Ireland. This hospital is the designated cancer centre for southeast Ireland. 
In 2011, a group of patients in this hospital entered into the SafeHer trial (296). In 
early 2014, this hospital began to switch patients from trastuzumab IV to 
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trastuzumab SC and decided to introduce a dedicated trastuzumab SC clinic for 
patients with HER2-positive breast cancer. The adopted approach of moving this 
cohort of patients out of the day oncology ward was done as an attempt to improve 
the patient journey. The nursing department, upon consultation with a consultant 
oncologist, took the decision to resource the trastuzumab SC clinic with a dedicated 
clinical nurse specialist (CNS), rather than share the resources with the oncology day 
ward. Clinic times run from 09:30-16:00 where each patient receives an allocated 45-
minute treatment slot with a 1:1 patient to nurse ratio. 
5.5.2 Hospital 2 – Infusion clinic 
Hospital 2 is a teaching hospital in the south of Ireland that has a designated bed 
complement of 192 beds and caters for up to 38,400 admissions and 72,500 
outpatient attendances each year. In late 2015, the pharmacy department in this 
hospital, upon consultation with a consultant oncologist, made the decision to switch 
patients from trastuzumab IV to trastuzumab SC. Patients are given either a morning 
or afternoon appointment in the infusion clinic at this hospital where they are 
attended to on a first come, first served basis by a CNS as per entry into the patient 
log.  
5.5.3 Cost minimisation analysis 
A prospective observational study in a subgroup of HCPs and patients with HER2-
positive breast cancer that attended both University hospitals between May and June 
2018 was conducted. All data were collected when both hospitals were each visited 
on four occasions between April and June 2018. Each observation consisted of 
measuring the time required to perform a specific task related to the preparation and 
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administration of trastuzumab. To quantify active HCP time, the time actively 
invested in carrying out the tasks where differences between the routes of 
administration had been predicted, was observed. Figure 5.1 shows the tasks that 
both trastuzumab SC and IV treatment pathways have in common and where the 
related time estimates were recorded. Patients receiving adjuvant pertuzumab 
treatment were excluded. All observations were made using a stopwatch. Patient 
treatment room times (time between entrance and exit from treatment room), were 
inferred from active HCP times. Although not enough sample time estimates were 
recorded for each task to resemble a time and motion study, the estimates gathered 
were verified by the HCPs involved in the study as being a true reflection of average 
times spent on tasks in routine clinical practice. An average time for each task was 
subsequently calculated and used in the cost analysis. This methodology has been 
previously observed in the literature (246, 304). When a sufficient amount of time 
estimates was recorded for a particular HCP activity associated with trastuzumab 
preparation, compounding and administration, Student’s t test was performed for 
the two groups. In all these instances, results were statistically significant (P values < 



















Figure 5.1 Common tasks conducted in the preparation and treatment of 
trastuzumab SC and IV 
 
Direct and indirect costs were calculated. Direct costs included HCP costs for the tasks 
observed (nurses, pharmacists, and pharmacy technicians), costs of consumables, 
and drug costs. Indirect costs included the cost of lost productivity. Although both 
hospitals had been using trastuzumab SC since 2015, contemporaneously available 
healthcare costs, expressed in Euros (€) using 2018 prices (unless otherwise stated), 
were chosen. These updated costs provide a more accurate representation of current 
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compounding 
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spending in the healthcare sector and are more useful in the preparation of a budget 
impact analysis, if required (305). The perspective of the Irish public healthcare 
provider, the HSE, and a societal perspective were adopted. Evidence on resource use 
and patient health outcomes were collected by the research team during the course 
of the study and a retrospective review of patient medical records was conducted. 
However, this was of no major concern in this study given that both trastuzumab 
formulations are clinically equivalent (295). The time horizon for the study was less 
than 2 months thus discounting was not required. Multiple cost components were 
included in the analysis and are described. The mid-point of the HSE healthcare 
professional pay scale was used and adjusted according to guidelines for conducting 
economic evaluation in Ireland (60, 306). Salary was adjusted for employers’ 
insurance cost, pension payments and general overheads (see Table 5.1). While the 
switching process in hospital 1 began in 2014 and in hospital 2 in 2015, the 2018 unit 
cost estimates were deemed appropriate for the analysis as medical inflation in 
Ireland was relatively stable during this period. 
Table 5.1 Costs of healthcare workers 
Job description Gross annual salary (€)(a) Total cost (€)/year(b) Total cost (€)/min 
Pharmacist  48,071 67,179 0.60 
Pharmacy 
technician 
38,447 53,730 0.48 
Clinical nurse 
specialist 
52,393 73,219 0.65 
Staff nurse 37,508 52,417 0.47 
 
(a) April 2018 Revised HSE Consolidated Pay scales (306). 
(b) The mid-point of the HSE pay scale was used and adjusted according to guidelines 




The costs of consumables were determined by retrieving invoices issued from the 
finance department from one of the large acute Irish University teaching hospitals in 
2018 and calculating unit costs (307) (see Table 5.2).  Drug costs were calculated 
according to the 2017 reported ex-factory prices (exclusive of value added tax (VAT)) 
of trastuzumab IV 150 mg (€567.69) and trastuzumab SC 600 mg (€1,645.24) (308). 
The medicinal brand of trastuzumab used in both hospitals was Herceptin® and 
patients were administered the trastuzumab SC formulation via a SID (294). All 
calculations were performed taking an average patient weight of 72.05 kg (average 
weight in Irish women aged 36–64 years (309)) treated with trastuzumab for 17 
triweekly dosing cycles according to the data sheet guidelines where 17 cycles is 
considered one year of treatment i.e. a full treatment cycle. Patient weights were 
retrieved from CliniChemo pharmacy management software. Patients’ date of births 
and sex were retrieved from i.PM (i.Patient Manager). In line with the standard 
clinical practice, all vials were considered used (vial sharing) in patients treated with 
trastuzumab IV resulting in no drug wastage. The effect of possible differences 
between reported and financed prices was assessed in a sensitivity analysis where 
discounts of 15% in the ex-factory price of the vial of trastuzumab IV and between 15 
and 20% in the ex-factory price of trastuzumab SC were applied. These rates are 
believed to mimic national current commercially sensitive transactions offered by 
pharmaceutical manufacturers on biological medicines to Irish hospitals and are 
corroborated by the literature (310, 311). The effect of differences in the weight of 
patients was analysed in another sensitivity analysis in which the costs of treatment 
in patients weighing between 65 and 75 kg were calculated. Vial sharing (no drug 
wastage) and dose banding tables from the NCCP (312) were used in association with 
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the recommended triweekly maintenance dose of 6 mg/kg of body weight for 
trastuzumab IV (294). 
Indirect costs were estimated using the human capital method (313) for inferred 
patient treatment room time. As applied in healthcare evaluation, the human capital 
approach has largely been used to value changes in the amount of time individuals 
are able to allocate to paid work as a result of illness or programmes to alleviate ill-
health (314). According to this approach, the gross wage becomes the unit of value 
for changes in paid working time resulting from healthcare programmes (314). In the 
context of this study, where the healthcare programme (trastuzumab treatment) 
aims to reduce the patient’s overall mortality risk, the change in productivity cost is 
represented by the present value of the stream of additional days in paid work over 
the duration of the patient’s treatment cycle, where each day is valued using the 
gross wage. The average income liable for social insurance in Irish women aged 15-
84 according to the Irish Department of Social Protection and Revenue 
Commissioners data, adjusted according to current (2018) consumer price index 
inflation, (€27,206.40) (315, 316) was used in conjunction with the average recorded 
unemployment rate for Irish women aged 25–74 as of 2017 (5.4%) (317), and the 
average hours worked by women per week in paid employment in 2016 (31.7 hours) 
(318). 
5.5.4 Guidelines and ethical considerations 
This analysis followed the CHEERS guidelines for reporting health economic 
evaluations (259) (see Appendix XIV). Ethical approval for this study was obtained 
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from the clinical research ethics committee (institutional review board) of the local 
teaching hospitals network (see Appendix XV).  
 
5.6 Results  
5.6.1 Direct costs 
5.6.1.1 Cost of consumables 
The cost of consumables per treatment cycle was €56.28 for trastuzumab IV and 
€25.91 for trastuzumab SC, a difference of €30.37 excluding the drug costs. For a 
complete 17-cycle treatment, the cost would be €956.76 for trastuzumab IV and 
€440.47 for trastuzumab SC, resulting in a saving of €516.29 per patient (see Table 
5.2). 
Table 5.2 Costs of consumables in patients treated with trastuzumab IV or 
trastuzumab SC during a treatment cycle 
Different stages of a 
complete treatment cycle 
Cost of preparing 441mg dose 
(3x150mg vials) of trastuzumab 
IV (€) (72.05kg patient(a),(b),(c)) 
Cost of preparing a 600mg 
dose of trastuzumab SC(c) 
(€) 
Equipment needed Number of 
items 
Cost ex-VAT Number of 
items 
Cost ex-VAT 
     
Pre-cleaning of LAF     
70/30 IPA wipes  8 7.04 0 0 
     
Preparation 
    
70% alcoholic wipes  20 1.40 14 0.98 
70/30 IPA wipes  8 7.04 8 7.04 
Sharps bin 1 1.35 1 1.35 
Sterile surface mats 2 2.80 2 2.80 
Chemo protect gowns  1 4.67 1 4.67 
Face masks 1 0.68 1 0.68 
Hand gloves 0 0 2 0.04 
Elbow length sterile gloves 1 2.10 0 0 
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Different stages of a 
complete treatment cycle 
Cost of preparing 441mg dose 
(3x150mg vials) of trastuzumab 
IV (€) (72.05kg patient(a),(b),(c)) 
Cost of preparing a 600mg 
dose of trastuzumab SC(c) 
(€) 
Equipment needed Number of 
items 
Cost ex-VAT Number of 
items 
Cost ex-VAT 
     
Head cap 1 0.02 1 0.02 
Mini grip bags  1 0.08 1 0.08      
Compounding 
    
Trastuzumab 150mg 
vials(b) 
3 1669.01 0 0 
Water for injection 10ml 
cartridges 
3 0.27 0 0 
10ml syringe  1 0.12 0 0 
Pink needle 2 0.04 0 0 
Seal for infusion bag  1 0.05 0 0 
Sodium chloride 0.9% 
250ml bag 
1 0.79 0 0 
30ml syringes  1 0.30 0 0 
70/30 Sterile wipes 4 0.28 1 0.07 
Clinichemo labels 2 0.04 2 0.04 
Flag label 0 0 1 0.04 
Green poly bags  1 0.06 1 0.06 
Trastuzumab 600mg vial 0 0 1 1,645.24 
5ml Syringe compatible 
with the closed system 
device 
0 0 1 1.24 
Vented vial access 
device/adapter 20mm  
0 0 1 1.74 
Cost of running LAF (d) 1 0.05 0 0 
     
Administration 
    
Orange needle  0 0 1 0.02 
Sodium chloride 10ml 0 0 1 0.07 
Sterile swabs 0 0 1 0.06 
Hand gloves 2 0.04 2 0.04 
Fabric plasters  1 0.03 1 0.03 
Alcoholic 2% chlorhexidine 
wipes 
1 0.02 0 0 
Rubber arm band  1 0.45 0 0 
Cannula 1 0.70 0 0 
Rubber bung for cannula  1 0.84 0 0 
Securing tape  1 0.33 0 0 
Opaque infusion giving set  1 5.83 0 0 
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Different stages of a 
complete treatment cycle 
Cost of preparing 441mg dose 
(3x150mg vials) of trastuzumab 
IV (€) (72.05kg patient(a),(b),(c)) 
Cost of preparing a 600mg 
dose of trastuzumab SC(c) 
(€) 
Equipment needed Number of 
items 
Cost ex-VAT Number of 
items 
Cost ex-VAT 
     
Sodium chloride 50ml 2 1.30 0 0      
Post-cleaning of LAF 
    
70/30 IPA wipes  8 7.04 0 0      





VAT on injectables and all 
consumables 23% VAT 










Key: IV: Intravenous; SC: Subcutaneous; VAT: Value Added Tax; LAF: Laminar air flow unit; 
IPA: Isopropyl alcohol 
(a) The National Adult Nutrition Survey, which provides average weights, was used in 
the cost of compounding trastuzumab IV (Women: age 36-50 years = 70.5kg, age 51-
64 years = 73.6kg, thus  the mean weight for these prevalent age categories found 
with HER2-positive breast cancer is 72.05kg) (309). 
(b) Dose banding information on trastuzumab IV provided by the NCCP for a 72.05kg 
patient required 441mg of drug (assume vial sharing/no drug wastage) at a 
maintenance dose of 6mg/kg (312) (initial loading dose was excluded). A 450mg 
dose is prepared in clinical practice to attain 441mg of drug. 
(c) Cost of consumables were retrieved from invoices provided by the finance and 
resource department of the hospital 2 (307). 
(d) Average cost of using a LAF for 900 seconds as per HCP trastuzumab reconstitution 
time where a conversion rate of 1 United States Dollar equals 0.86 Euros as of June 
2018 was applied (321). Trastuzumab IV was compounded by aseptic technique in 
the LAF. Trastuzumab SC was reconstituted safely on the bench using the closed 
system for immediate administration. 
 
5.6.1.2 Healthcare professional costs 
On average, the cost of HCP time invested in the preparation and administration of 
trastuzumab was €44.93 per cycle of trastuzumab IV and €9.83 per cycle of 
trastuzumab SC (see Table 5.3 and Table 5.4). For a complete 17-cycle treatment, this 
would result in a cost of €763.81 for trastuzumab IV and €167.11 for trastuzumab SC, 
with a cost differential of €596.70. Extrapolating these results to a hospital treating 
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25 patients per year with trastuzumab, as per hospitals in this study, the total HCP 
cost would be €19,095.25 if all patients received trastuzumab IV and €4,177.75 if all 
patients received trastuzumab SC, with an average saving of €14,917.50 (-78%) 
favourable to trastuzumab SC. 
Table 5.3 Cost description associated with trastuzumab subcutaneous preparation, 















55 0.55 53 0.53 
Medicine preparation 
by pharmacy technician 
  54 0.43 
Pharmacist double 
check of medicine 
  10 0.10 
ID, blood pressure, 
temperature, pulse, 
blood tests, weight and 
ECHO check by CNS 
342 3.71 331 3.59 
Staff nurse double 
check of medicine  
55 0.43   
Tray preparation for 
drug administration by 
CNS 
15 0.16 10 0.11 
CNS preparation (gloves 
and gowning)  
108 1.17 113 1.22 
Patient preparation 
(legs swabbed with 
alcohol wipe) by CNS 
15 0.16 12 0.13 
Medicine preparation 
by CNS 
45 0.49   
Injection administration 
time by CNS 













Unit cost (€) 
Patient after care (wipe 
and plaster) by CNS 
20 0.22 25 0.27 
Total 965 (16.08 
minutes) 
10.25 888 (14.80 
minutes) 
9.41 
Average HCP time of 
both hospitals 
15.44 minutes  Average HCP 
cost of both 
hospitals 
€9.83 
Key: CNS: Clinical nurse specialist; ID: Identification; ECHO: Echocardiogram; HCP: 
Healthcare professional 
 
Table 5.4 Cost description associated with trastuzumab intravenous preparation, 















119 1.19   
Pre-check of 
prescription and tray 
materials by pharmacist 
  307 3.07 
Preparation of medicine 
tray and alcohol wipe 
down of items by 
pharmacy technician 
243 1.94 122 0.98 
Compounding of 
medicine by pharmacy 
technician in LAF 
998 7.98 882 7.06 
Pharmacist double 
check of medicine  
150 1.50 33 0.33 
ID, blood pressure, 
temperature, pulse, 
blood tests, weight and 
ECHO check by CNS 
351 3.80 372 4.03 
Staff nurse double 
check of medicine 













Unit cost (€) 
Tray preparation for 
drug administration by 
CNS 
182 1.97 200 2.17 
CNS preparation (gloves 
and gowning)  
102 1.11 99 1.07 
Patient preparation 
(cannulation) by CNS 
401 4.34 345 3.74 
Injection administration 
by CNS 
1800 19.50 1800 19.50 
Patient after care (wipe 
and plaster) by CNS 
182 1.97 167 1.81 
Total 4,582 (76.37 
minutes) 
45.72 4,376 (72.93 
minutes) 
44.14 
Average HCP time of 
both hospitals 
74.65 minutes  Average HCP 
cost of both 
hospitals 
€44.93 
Key: CNS: Clinical nurse specialist; LAF: Laminar air flow unit; ID: Identification; ECHO: 
Echocardiogram; HCP: Healthcare professional 
 
5.6.1.3 Drug costs 
In the base case (reported ex-factory price inclusive of a VAT rate of 23% (319)) and 
a national average patient weight of 72.05 kg (309)), the total cost of a 17-cycle 
treatment would be €34,898.97 for trastuzumab IV and €34,401.97 for trastuzumab 
SC, resulting in a difference of €497.00. In the first sensitivity analysis (discount of 
15% for trastuzumab IV and a range of discounts from 15% to 20% for trastuzumab 
SC), the cost differences between treatments ranged from €1,027.84 to €2,747.93 in 
favour of trastuzumab SC. In the subsequent sensitivity analysis (considering patient 
weights between 65 and 75 kg and where banded doses for trastuzumab IV 
recommended by the NCCP, were applied (312)), the cost differences between 
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treatments ranged from €-2,826.71 to €497.00. More extreme weights (i.e. patients 
≥80 kg) could reach savings greater than €3,820.71. 
5.6.2 Indirect costs 
The average patient treatment room time for both study sites was 841 seconds for 
trastuzumab SC and 3,052 seconds for trastuzumab IV (assuming no waiting times for 
patients). Estimated indirect costs according to lost productivity inferred by patient 
treatment room time for a 17-cycle treatment per patient were €243.74 (loss of 2.15 
working days) for trastuzumab IV and €67.15 (loss of 0.60 working days) for 
trastuzumab SC. Trastuzumab SC resulted in lower indirect costs per patient 
compared with trastuzumab IV. 
5.6.3 Total costs 
Direct costs were €36,619.54 for trastuzumab IV and €35,009.55 for trastuzumab SC, 
a net difference of €1,609.99 in favour of trastuzumab SC. When indirect costs were 
added, replacement of trastuzumab IV by trastuzumab SC for a full 17-cycle 
treatment would save €1,786.58 (see Table 5.5). 
Table 5.5 Total costs in patients treated with trastuzumab IV or trastuzumab SC 
Costs IV (€) SC (€) Difference (€) 
    
Direct costs 36,619.54 35,009.55 1,609.99 
    
Healthcare professional 
costs 
763.81 167.11 596.70 
Consumable costs 956.76 440.47 516.29 
Drug costs 34,898.97 34,401.97 497.00 
    
Indirect costs 243.74 67.15 176.59 
    





This study describes active HCP time invested in the preparation and administration 
of trastuzumab. A time saving of 79% was accrued by the replacement of trastuzumab 
IV with trastuzumab SC. In fact, the authors believe this is the highest recorded active 
HCP time saving where other studies report time savings of 51% in Spain, 48% in 
Canada and Russia, 36% in France, 31% in Denmark and 15% in Switzerland (322). 
Greater available HCP time could result in improvements in the quality of care, with 
more time free for monitoring, for other relevant medical duties, or indeed for 
providing patient information or comforting. In addition, by utilising trastuzumab SC 
in the place of trastuzumab IV, a saving of €596.70 per patient in active HCP time for 
a full 17-cycle treatment was gained. This result is consistent with those of 
international studies (323-326). 
The reduction in patient treatment room time resulted in a difference in indirect costs 
of €176.59 per 17-cycle treatment in favour of trastuzumab SC, a conservative 
estimate that only considered lost productivity between entering and leaving the 
patient treatment room. Moreover, this reduction in patient treatment room time 
could allow for the treatment of the same number of patients with fewer resources 
or more patients with the same level of resources. As well as the economic 
implications, quality of life may improve with the time savings associated with 
trastuzumab SC. Indeed, a key finding of the PrefHer study was that patients favoured 
trastuzumab SC as it accumulated more time saved for them relative to trastuzumab 
IV treatment (297). Hence, more than just an estimate of costs from the social 
perspective, according to preferences conveyed, we see that the patient can be the 
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main beneficiary. Quality of life is especially important to those patients with 
metastatic breast cancer as theirs is a chronic illness and so minimising the time spent 
in the hospital setting is an important factor in survivorship. 
Drug cost savings from switching to trastuzumab SC may be underestimated in this 
study. The National Adult Nutrition Survey was used in calculating the cost of 
compounding trastuzumab IV (Women: age 36-50 years = 70.5kg, age 51-64 years = 
73.6kg) where the mean weight for these prevalent age categories found with HER2-
positive breast cancer is 72.05kg. This average weight was an underestimate of the 
true patient weight as Ireland tackles a rising obesity problem (327). In this study, the 
mean patient weight between both centres was 73.44 kg with a range between 
43.5kg-125kg. Therefore, by using the average recommended weight of 72.05kg, the 
trastuzumab IV formulation may appear less costly than it actually is in practice. As 
per sensitivity analyses, drug costs for trastuzumab IV were currently lower than drug 
costs for trastuzumab SC only for patients weighing ≤ 69kg. For patients weighing ≥70 
kg, drug costs for trastuzumab IV began to drastically increase relative to drug costs 
for trastuzumab SC.  
In addition, with respect to the recommended weight of 72.05kg, a maintenance 
trastuzumab IV dose of 6mg/kg (294) would require 432.3mg of drug. This is rounded 
to 441mg according to the national dose banding tables (312) provided by the NCCP. 
This results in 9mg of drug remaining after each trastuzumab 150mg vial 
reconstitution. Over 17 triweekly cycles, this equates to 153mg of drug remaining. In 
this study, we assume vial sharing and no drug wastage. However, in clinical practice, 
it is unlikely this amount of drug would be utilised, as 9mg of drug is a very small 
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quantity to share at each treatment cycle juncture, and vial sharing opportunities do 
not always arise upon reconstitution. Therefore, it is possible that the cost of 17 
triweekly cycles of the trastuzumab IV is appearing €712.22 cheaper per patient than 
it actually is. A loading dose of 8mg/kg is required for patients when starting 
trastuzumab IV therapy, and again if patients miss their scheduled dose of 
trastuzumab IV by more than one week (294). This presents an additional cost for 
trastuzumab IV which was omitted in this analysis. There is no initial loading dose for 
starting treatment or missed treatment with trastuzumab SC (328) resulting in this 
formulation being a more cost-effective option under these circumstances. 
Subcutaneous formats of different oncologic therapies have been available since 
mid-2014, however it is only recently that patient-relevant and hospital benefits are 
being assessed (322, 329). Although open to debate, the literature appears to favour 
subcutaneous oncology treatments over intravenous oncology treatments in terms 
of patient preference, time and cost savings (297, 310, 322, 329-332). A recent ISPOR 
Special Task Force report identified and defined a series of elements that warrant 
consideration in value assessments of medical technologies (333). In the report, 
Lakdawalla et al. discuss that some medical technologies offer advantages over 
existing choices such as simpler dosing schedules, alternative routes of 
administration, or combination treatments. To the extent such factors improve 
patient adherence to treatments and health outcomes, they may impact the 
estimation of the value of the medical technology in the aggregate (334). It is evident 
from this study that the trastuzumab SC formulation offered these advantages when 
compared to the trastuzumab IV formulation. Trastuzumab SC also reduces the need 
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for cannulation of patients whose veins are often compromised due to previous 
therapies and tests. 
5.7.1 Limitations 
The main limitation of the study was that not enough time estimates were recorded 
to conduct a time and motion analysis. Although the estimates gathered were 
verified by the involved HCPs as being a true reflection of average times spent on 
tasks in routine clinical practice, a time and motion study, which gathers data on HCP 
time required to complete the observed tasks, would reduce uncertainty surrounding 
such inputs. As per other time and motion studies investigating this trastuzumab 
formulation switch, it would have been desirable to record hospital time (time 
between entry and exit from the hospital), and patient travel to the hospital, or the 
time lost by accompanying persons, by means of patient interview when calculating 
indirect costs (310). These measurements would capture a broader societal 
perspective. Two recent time and motion studies have demonstrated that a transition 
to both trastuzumab and rituximab SC formulations from their respective IV 
formulations resulted in patient chair and active HCP time savings (322, 330). 
This study was carried out in only two centres where differences in clinical practice 
exist. At times, it was difficult to compare clinical practice procedures for the analysis. 
However, as this study was conducted in routine clinical practice settings yielding real 
world data, as opposed to a study within/alongside a RCT, the results are more 
generalisable. This study’s design and setting may also explain why the active HCP 
time savings value of 79% was numerically higher than those corresponding values 
reported by time and motion studies conducted within open-label randomised 
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crossover studies (322). Nonetheless, as trastuzumab SC gains traction in the Irish 
healthcare setting; further research in more hospital sites should be conducted to 
corroborate these study findings.  
At the time of data collection, one of the 48 patients receiving trastuzumab treatment 
was male. However, as the epidemiology of HER-2 positive breast cancer is much 
greater in females than males (335), indirect costs and loss of productivity were 
calculated using statistics based on data gathered for Irish women. If this method was 
calculated for males, it is likely the indirect costs and loss of productivity would be 
greater based on data gathered for Irish men (315). 
A potential limitation in this study was the issue of ‘dead time’ i.e. the five minute 
time period required for trastuzumab IV to dissolve upon reconstitution (294) and its 
30 minute infusion period. While it was potentially possible that the HCP could 
conduct other medical duties during this dead time, such tasks were impossible to 
cost. The issue of dead time and potential medical opportunity cost is a controversial 
one in the field of costing (336). In addition, as best clinical practices are adopted in 
these two large Irish University teaching hospitals (e.g. vial sharing etc.); it was 
observed that the CNS upheld their duty of care by monitoring patients closely during 
the 30-minute trastuzumab IV infusion period for fear of ADR occurrence. This limited 
the ability of the CNS to perform other activities in parallel. 
Regarding trastuzumab IV treatment, patients should be observed for at least six 
hours after the start of the first infusion and for two hours after the start of the 
subsequent infusions for symptoms like fever and chills or other infusion-related 
symptoms (294). For trastuzumab SC, patients should be observed for six hours after 
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the first injection and for two hours after subsequent injections for signs or symptoms 
of administration-related reactions (328). Follow-up time was excluded from the cost 
minimisation analysis as no cost differential existed. In clinical practice, patients were 
strongly advised to remain in the clinic for the recommended follow-up time, but this 
was seldom adhered to by patients. The resulting variability in follow-up time from 
patients was not measured which means the loss of productivity may be 
underestimated in this study. Paracetamol treatment (by mouth or by IV infusion) 
was recommended for patients receiving both trastuzumab IV and SC treatment. 
Therefore, as no cost differential existed, it too was excluded from the cost analysis. 
In reality, some patients would take paracetamol while others would refuse. 
5.7.2 From evidence to policy 
At present, it can be argued that this study is only of interest to hospital budget 
decision-makers within the south/south west hospital group in Ireland. A similar issue 
arose in a study where the results of an economic evaluation of propofol/fentanyl 
compared with midazolam/fentanyl on recovery in the intensive care unit following 
cardiac surgery was only of interest to the local hospital (337). However, more Irish 
hospitals are beginning to use trastuzumab SC, and following its successful 
implementation in Europe, Oceania and South America (310, 331, 338), it is envisaged 
that this formulation will penetrate the North American oncology landscape next. 
Furthermore, in relation to the current oncology field, biosimilar trastuzumab IV is 
now available (339). It has been approved in Ireland since June 2018, where the 
biosimilar trastuzumab IV 150mg vial Herzuma® yields a drug cost of €401.86 
(exclusive of VAT) (340). This is in comparison to the Herceptin® IV 150 mg vial which 
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yields a drug cost of €567.69 (exclusive of VAT) (308). The individual summary of 
product characteristics documents for both medicinal products appear almost 
identical (294, 339), thus it can be assumed that medicine reconstitution and 
administration tasks are equivalent. This means the only major differential between 
the two products is drug acquisition cost. It is also worth noting that local 
commercially sensitive price reductions are sometimes offered to payers who switch 
to biosimilar medicines (341). It will be interesting to see what impact biosimilar 
trastuzumab will have on the Irish and international markets and indeed how it will 
affect trastuzumab SC market penetration. 
In this study, an attempt to capture the societal perspective was undertaken by 
calculating the loss of productivity via the human capital method as well as presenting 
the more commonly reported healthcare payer perspective. Sanders et al. 
recommended for the sake of consistency and comparability, analysts should report 
‘reference cases’ from two perspectives—the healthcare sector perspective and the 
societal perspective (58). This was also corroborated by an ISPOR Special Task Force 
report (59). In addition, Olsen and Richardson argue that part of productivity effects 
may be included to the extent that it results in increased resources available for 
healthcare (342). In fact, if the trastuzumab SC formulation was taken out of the 
secondary care setting and supplied to patients via their local pharmacy for self-
injection at home, the loss of productivity element would virtually be eliminated as 
patients could avoid going to hospital. In conjunction, this would alleviate some of 
the workload that the exhausted secondary care system already encounters. Ireland 
has devised a ten-year plan for health reform through political consensus called 
Sláintecare which is currently underway (23). Its aim is to establish a universal, single-
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tier health service where patients are treated solely on the basis of health need. 
However, it also plans to re-orient the health system ‘towards integrated primary and 
community care that is consistent with the highest quality of patient safety in as short 
a time-frame as possible’ (21). In line with the overarching aim of Sláintecare, the 
transplantation of trastuzumab SC treatment to the primary care sector would also 
satisfy patient needs who prefer home and community-based medical treatments 
(343). 
This is the first study to evaluate the economic, financial and clinical impact of 
switching patients from trastuzumab IV to trastuzumab SC in Ireland where 
recommendations from the CHEERS statement were implemented to ensure that this 
analysis presents a transparent high-quality evaluation. Accurate cost data are 
essential for ensuring breast cancer services are effective, efficient, and equitable, 
and such costing information should be used to guide policy, planning and 
implementation in this field. This is particularly relevant as the Irish healthcare 
funding system is currently undergoing restructuring (22, 303). As demands on breast 
cancer services increase due to greater numbers of presenting patients (344) with 
more complex care needs, the cost data presented in the analysis will be available for 
cost-effectiveness evaluations of new drugs, technologies, and proposed models of 
care under Sláintecare reform (22, 23). The cost data are of particular interest to the 
NCCP who manages, organises and delivers cancer services on a whole population 
basis in Ireland (345). The policy decision to switch patients to trastuzumab SC at a 
regional level has proven successful to the extent that upon advice from the NCCP, 
other Irish hospitals began to follow by example. Figure 5.2 briefly summarises the 
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Key: HCP: Healthcare Professional; IV: Intravenous; NCCP: National Cancer Control Programme  
 
Figure 5.2 Walt and Gilson policy triangle model describing trastuzumab 
formulation switching policy 
 
5.8 Conclusion 
As portrayed by the HPT framework, the interrelated factors which led to the 
replacement of trastuzumab IV by trastuzumab SC within two large acute Irish 
teaching hospitals has proven to be a more cost-effective approach reducing active 
HCP time, patient treatment room time, and thus improving patients’ quality of life. 
With respect to the Irish healthcare landscape, these reductions in time result in 
economic savings, more efficient resource use, and improved quality of care. 
Trastuzumab SC reduces the cost of consumables. Dependent on the patient’s weight 
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and the hospital’s policy on vial sharing, trastuzumab SC did not always result in drug 
cost savings. A full treatment cycle of trastuzumab SC resulted in total estimated 
direct cost savings of €1,609.99. Every year, between 400 and 500 new cases of HER2-
positive breast cancer present in Ireland (344) where such patients would be 
potentially eligible for treatment with trastuzumab. The widespread use of 
trastuzumab SC for these patients would not only result in direct cost savings but 
would also lead to a reduction in indirect costs due to a decrease in the loss of 
productivity. These clinical and economic aspects demonstrate that trastuzumab SC 




6 Chapter 6 Out of pocket or out of control: a qualitative 
analysis of healthcare professional stakeholder 
involvement in pharmaceutical policy change at 
national level 
6.1 Chapter description 
In this chapter, a public health-related pharmaceutical policy that has affected all 
publicly insured citizens in Ireland since its introduction approximately one decade 
ago was investigated. Evidence was gathered by conducting semi-structured 
interviews with relevant stakeholders to inform future policy process development. 
The pharmaceutical policy concerns the mandatory co-payment fees attached to 
prescription medicines on the Irish public health insurance scheme. It is unknown 
what impact these changes have on relevant stakeholders who work at the coalface 
of this labile policy. A qualitative study using purposive sampling alongside 
snowballing recruitment was used to generate compelling evidence. The HPT 
framework was used to depict the interrelated factors which underpin this national 
pharmaceutical policy. The other authors of this chapter and publication reviewed 
the chapter and gave their input and advice during the study. On June 11th, 2020, the 
following published paper was submitted to the Department of Health, the Irish 
College of General Practitioners, the Irish Medical Organisation, the Irish Pharmacy 





The work of this chapter has been modified and published as O’Brien GL, Sinnott SJ, 
O’Flynn B, Walshe V, Mulcahy M, Byrne S, Out of Pocket or Out of Control: A 
Qualitative Analysis of Healthcare Professional Stakeholder Involvement in 
Pharmaceutical Policy Change in Ireland, Health Policy, 2020, 124(4):411-418, 






Mandatory co-payments attached to prescription medicines on the Irish public health 
insurance [General Medical Services (GMS)] scheme have undergone multiple 
iterations since their introduction in October 2010. To date, whilst patients’ opinions 
on said co-payments have been evaluated, the perspectives of community 
pharmacists and general practitioners (GPs) have not. 
6.3.2 Objective 
To explore the involvement and perceptions of community pharmacists and GPs on 
this pharmaceutical policy change. 
6.3.3 Methods 
A qualitative study using purposive sampling alongside snowballing recruitment was 
used. Nineteen interviews were conducted in a southern region of Ireland. Data were 
analysed using the Framework Approach. 
6.3.4 Results  
Three major themes emerged: 1) the withered tax-collecting pharmacist; 2) concerns 
and prescribing patterns of physicians; and 3) the co-payment system – impact and 
sustainability. Both community pharmacists and GPs accepted the theoretical 
concept of a co-payment attached to the GMS scheme as it prevents moral hazard. 
However, there were multiple references to the burden that the current method of 
co-payment collection places on community pharmacists in terms of direct financial 
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loss and reductions in workplace productivity. GPs independently suggested that a 
co-payment system may inhibit moral hazard by GMS patients in the utilisation of GP 
services. It was unclear to participants what evidence is guiding the GMS co-payment 
fee changes. 
6.3.5 Conclusion 






According to the WHO, a co-payment (user charge or user fee) is defined as ‘money 
people are required to pay at the point of using health services covered by a third 
party such as the Government, a health insurance fund or a private insurance 
company’ (346).  These out-of-pocket fees are paid by the insured patient on many 
health services such as outpatient visits, dental care, inpatient care and prescription 
medicines. There are many documented advantages to having a co-payment 
attached to prescription medicines; cost containment, moral hazard prevention and 
revenue generation (347). Disadvantages include lower rates of drug treatment, 
worse adherence among existing users, more frequent discontinuation of therapy, 
and increased patient financial responsibility (348, 349). Co-payments are a common 
feature of western health care systems (346). 
The GMS scheme in Ireland is a tax-funded, means-tested, public health insurance 
scheme (3). It provides many health benefits including inpatient and outpatient care, 
GP services and prescription medicines to those who meet the eligibility criteria 
(350), all free at the point of access. Currently, 32% (1,565,049) of the Irish population 
receive healthcare on this scheme (5). Patients who avail of health coverage on the 
GMS scheme are known as medical card holders. In October 2010, in an attempt to 
counteract rising Government expenditure amid a severe economic downturn post 
2008, and to reduce medicine wastage, the DoH introduced a €0.50 co-payment per 
prescription item, capped at €10 monthly, for the first time, for publicly insured GMS 
patients (351). Since then, the GMS prescription medicine co-payment, also known 
as the GMS levy, has undergone numerous iterations in both monetary value per 
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prescription medicine and in monthly cap fee (capped after the first 10 prescription 
medicines per month for each of the GMS co-payment iterations). Indeed, this levy 
acts like a form of taxation. Figure 6.1 below reveals a timeline of all recent GMS co-
payment changes and includes the introduction of different co-payments for 
separate age groups which was first introduced in March 2017. 
In the Irish context, patients were mostly accepting of the initial €0.50 co-payment 
with some reservations concerning an increased price and the way in which 
generated revenue would be used by Government (351). This aligns with 
international patient perspective where most patients accept paying toward 
medication in principle (352-354). Contemporary quantitative analysis on the GMS 
co-payment increases has demonstrated that the €0.50 co-payment was associated 
with reductions in adherence ranging from −2.1% to −8.3% for essential medicines 
and reductions in adherence of −2% to −9.5% for less essential medicines (355). The 
€1.50 co-payment generally resulted in smaller reductions in adherence to essential 
medicines with anti‐depressant medications being the exception with a decrease of 
−10.0% after the co-payment increase (355). For publicly insured families with 
children, a detrimental effect on health was not found from small co-payments 
(€0.50, €1.50 and €2.50) on prescription items (6). 
The objective of the study was to retrieve insight into the engagement and opinions 
of experienced HCPs on the GMS co-payment policy changes. Using the qualitative 
data collected from interviews, this analysis aims to inform healthcare policymakers 
on this specific pharmaceutical policy as Ireland is currently in the process of 
attempting to deliver whole system reform and universal healthcare known as 
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Sláintecare for all its citizens (23). This study adds to the literature by investigating 
the stakeholder involvement of HCPs in co-payments attached exclusively to 
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Figure 6.1 Timeline review of recent GMS co-payment introductions and changes 2010-2018 
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6.5.1 Study design, setting and sampling 
The sampling frame for this study included registered community pharmacists and 
GPs who had been consistently practising for at least six months prior to the first GMS 
co-payment introduction in October 2010 to April 2019 (data collection cessation). 
Nineteen semi-structured interviews (13 community pharmacists, 6 GPs) were 
conducted between January 2018 and April 2019 where HCPs working in five 
different socioeconomic areas were interviewed in the province of Munster, Ireland 
(see Table 6.1). Both community pharmacies and medical surgeries were classified 
by their respective socioeconomic classes via the Trutz Haase Deprivation Index 2016 
by electoral division (356). HCPs from both independent and franchise pharmacies 
were included. Franchise pharmacies were defined as those that consist of several 
similar businesses which are corporately owned. All medical surgeries in this study 
were independently owned. Most interviews were conducted in an urban practice 
save for two marginally above average medical surgeries and one marginally above 
average community pharmacy which were considered to be rural practices (357). 
Varying socioeconomic and workplace structures and locations were included to 
ensure that a broad range of thoughts and attitudes could be obtained from a range 
of social circumstances, age, gender, and work place practices. All interviewees 
declared they had no obvious bias to declare on this topic. This was asked to ensure 




Interviewing was chosen as the preferred data collection method for many reasons. 
First, given that some of the interviewees owned their own pharmacy/medical 
surgery, the topic of work place practices, medicines, and money/financial loss could 
be considered a sensitive subject. Secondly, focus group dynamics can be 
unpredictable where more in depth coverage, with a lower risk of social desirability 
bias, is possible when interviewing an individual (64). Participant information letters 
(see Appendix XVII) and consent forms (see Appendix XVIII) were made available. 
Participants were sampled using purposive and snowball-sampling methods (64, 
358). An initial ‘core set’ of potential participants were identified by the research 
team through personal contact. These participants were then asked to suggest other 
individuals they believed could assist with the study. Participants were free to decline 
the invitation to partake but did this not happen. Once HCPs agreed to be 
interviewed, the interviewer explained who they were, clarified the aims and 
objectives of the study, and assured participants of anonymity and data 
confidentiality. Participants were asked for verbal and written consent. The 









Table 6.1 Distribution of practices by location and ownership status 
Practice location  Independent Franchise Total 
Affluent 2 1 3 
Marginally above 
average 
7 2 9 
Marginally below 
average 
2 0 2 
Disadvantaged 2 2 4 
Very 
disadvantaged 
1 0 1 
Total 14 5 19 
 
6.5.2 Data collection 
Two very similar topic guides were developed in order to achieve structured feedback 
from participants (see Appendix XIX). One topic guide was targeted at community 
pharmacists whilst the other was used when interviewing GPs. Given that both topic 
guides were designed to have a strong resemblance, data from both community 
pharmacists and GPs were analysed together as one combined HCP data pool. Both 
topic guides drew on existing related literature (351, 355, 359-364), and the 
professional experience of the research team. The topic guides were initially piloted 
with two pharmacists and one GP and were amended as the interviews progressed 
to obtain current and topical feedback from participants. The decision was made to 
exclude the pilot interviews from the analysis. The pharmacist topic guide underwent 
four iterations whereas the GP topic guide underwent two iterations. Many issues 
were discussed with both pharmacist and GP participants and some of these are 
highlighted in Table 6.2. All interviews consisted of one interviewer and one 
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interviewee and were recorded and transcribed verbatim using two methods of audio 
recording: a Dictaphone (Sony IC Recorder ICD-PX240) and a mobile phone device 
(Samsung Galaxy S6 SM-G920F). Interviews took place in the workplace office of the 
HCP being interviewed allowing for a quiet and confidential space. Interviews ranged 
in time from approximately 7 minutes to 30 minutes. A field diary was brought to 
each interview to record noteworthy observations. 
The study did not have a target sample size; rather it aimed to recruit participants 
until data saturation of key themes emerged. During data collection, before 
considering further participation recruitment, preliminary data analysis was 
conducted to highlight when researchers were approaching data saturation (165). In 
addition, the Francis et al. method was intended to be used as a supplementary 
means to determine data saturation (365). This method involves identifying an initial 
analysis sample size and then defining a stopping criterion. The stopping criterion is 
a defined number of interviews that will take place in which no new themes will 
emerge. It was agreed that data saturation had been reached after 16 interviews with 









Table 6.2 Issues discussed in interviews 
Topic Question 
Positive/negative aspects of co-
payment? 
What are your thoughts on the co-payment 
attached to prescription medicines? 
Influence of co-payments on your 
practices and procedures? 
Has the co-payment influenced your practice or 
procedures in the work place? 
Co-payment retrieval? 
How easy or difficult is it to retrieve the co-
payment? 
Patients’ perception of co-
payment? 
How do you think patients perceive paying the co-
payment? 
Financial loss? 
Have you suffered financial loss from patients not 
paying? 
Medicine utilisation? 
Do you think the co-payment has influenced 
patients’ utilisation of medicines? 
Impact of co-payments on GPs 
prescribing habits? 
Has the co-payment changed the way you prescribe 
or influence the amount of prescriptions you issue? 
Future status of co-payment/policy 
suggestions? 
What do you think the future holds for the co-
payment? Should it be 
increased/decreased/abolished? 
 
6.5.3 Analysis  
The Framework Approach was used to identify themes emerging from the data 
obtained and was chosen because of its relevance in policy change and detailed 
format in comparison to regular thematic analysis (64, 366). The framework method 
contained seven key stages that allowed for the categorisation and organisation of 
the large amounts of data to help develop underlying themes and emerging 
phenomena. These seven stages consisted of i) transcription ii) familiarisation with 
the interview iii) coding iv) developing a working analytical framework v) applying the 
analytical framework vi) charting data into the framework matrix and vii) data 
interpretation and mapping (55, 367). The framework constructed throughout this 
process was continually amended and ‘tested for fit’. Language was seldom altered 
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in an attempt to retain original meaning and context. The analysis was interpretative 
recognising the interaction between the researcher and the data.  
The data were managed through NVivo12 Plus, QSR International software (368). 
Data analysis was conducted by GOB, a research pharmacist undertaking a clinical 
pharmacy PhD. Intercoder reliability was used at early stages of the project to ensure 
a high rate of intracoder reliability on subsequent transcript data analysis. A sample 
of four random transcripts were coded and indexed by BOF. At the time of data 
collection, BOF was an undergraduate pharmacy student. Both GOB and BOF 
discussed arising differences in this process to ameliorate the accuracy of the 
thematic framework and the application of the framework to subsequent transcripts. 
Some disagreements in coding arose. The most common reason for disagreement 
was the generation of redundant labels/codes that described the same phenomenon 
e.g., dissatisfaction with Government and anger towards the Irish HSE. Through  
discussion,  these  indexing  discrepancies  were resolved (369). Both GOB and BOF 
had undertaken qualitative data analysis training courses prior to data collection. 
6.5.4 Guidelines and ethical considerations 
The Consolidated Criteria for Reporting Qualitative Research (COREQ) statement 
guided study reporting (370) (see Appendix XX). Ethical approval was sought from 
and granted by the Clinical Research Committee of the Cork Teaching Hospitals prior 





6.6 Results  
Nineteen HCPs were interviewed in total each with varying experience (see Table 
6.3). The Framework Approach produced three main themes as elaborated on below. 
In the reported analysis, participant pseudonyms were created to provide 
information about: practice ownership [Independent (‘Indep’) or Franchise (‘Fran’); 




Table 6.3 Characteristics of interviewees 
Sex Male 13 
Female 6 















Employment status Full-time 14 
Part-time 5 







6.6.1 The withered tax-collecting pharmacist  
It was unanimously accepted that although the current co-payment system has 
advantages pertaining to cost containment and waste reduction, the pharmacist is 
just one party who suffers from its consequences:  
“I didn’t study for five years in order to become an organ of revenue collection 
for the Government, it is outside the terms and conditions of my role and it’s 
certainly outside the terms and conditions of my contract with the HSE to raise 
money for the revenue commissioners” IndepCP11.  
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Pharmacists can occasionally find themselves in “dangerous situations” FranCP12 
upon co-payment retrieval, and in scenarios whereby they must supply the medicine 
without retrieving the co-payment: 
“you’re spending your time trying to look after the best interests of the patient 
and sometimes the best interests of the patient is I need you to take these 
medications so I'm going to have to sacrifice. My duty of care to you as a 
patient trumps my duty of care to the state to collect a tax for them. So 
therefore the net loser in that transaction is the pharmacist who essentially is 
now working for free” IndepCP11. 
Pharmacists also expressed a loss in workplace productivity by collecting the co-
payment: 
“if it’s simply that they're paying by credit card it’s taking up a minute, two 
minutes but you add that 100 times a day, your efficiency is gone down 
dramatically and that's time that’s taken from something” IndepCP05.  
Pharmacists too experience patient disgruntlement at the point of transaction:  
“I think there is still a lack of understanding that it’s a Government levy as 
opposed to a personal, pharmacist into-the-pocket levy. That is something 
that is still an area of confusion, even now” IndepCP02.  
There was an emergent consensus that pharmacists should not bear the financial loss 
if a patient cannot/will not pay. When a pharmacist supplies a medicine to a patient 
who cannot/will not pay, the primary care reimbursement services (PCRS) still deduct 
this co-payment tax/levy from the pharmacist. In addition, as there is a maximum 
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monthly co-payment cap for households, if family members are not recognised as 
one household unit on the electronic PCRS system, the pharmacists bear the resulting 
financial deficit. As a result, pharmacists have reported large financial losses:  
“Tens of thousands of euro for reasons of non-payment, but also for reasons 
of families weren’t linked properly on the PCRS database. Those are probably 
the two most common causes of a deficit in what I should have taken in, what 
the State deducted from me and what I was able to take in” IndepCP11.  
Pharmacists note that a proportion of GMS patients acknowledge the value of having 
the co-payment attached to their medicines: 
“…….. they think they’re getting good value for money and that it’s a good 
thing for the country…” FranCP13.  
However, the risk to patient safety which arises from having a co-payment system 
was recognised by community pharmacists:  
“From the pharmacy perspective it has introduced extra administrative issues, 
…… therefore has caused a danger, in my view, to patient safety because if 
you are having to talk to Mrs. Murphy about a blasted prescription charge, 
when you really should be concentrating on the prescription and the dose and 
the interactions and all of this…….” IndepCP05. 
6.6.2 The co-payment system – impact and sustainability 
Before the introduction of the co-payment on the GMS, medication stockpiling and 
wastage was noted as a prominent feature by both pharmacists and GPs: 
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“I did a house call and I asked the lady, ‘Oh, where do you keep your tablets?’  
In under the stairs I removed at least 10 Tesco® plastic shopping bags full of 
unused medication. They were stockpiled in the thing.…..There was bags of 
them…..going back like 10 years…….There was like tens of thousands of tablets 
that she wasn’t taking” IndepGP02.  
Medication waste seems to be ongoing but not at the level that it once straddled: 
“unfortunately, we see it particularly again when patients pass away, the big 
black bag of unused medication, I don’t believe the black bags have got any 
smaller since the October 2010, ‘til January 2018” FranCP08. 
The consensus from interviewees is that the co-payment system influences medicine 
utilisation and adherence rates:  
“The PRN stuff would be the first to go, so if there are items they genuinely 
don’t need, they would be the ones that would first go” IndepCP04.  
However, some pharmacists advocate:  
“the co-payment certainly has disimproved compliance for certain groups of 
people. So I think in terms of benefits to how people take their medicine, the 
people that come back regularly for medication, when there was no 2.50 levy 
or no 50 cent levy, would generally be compliant.  There are people that now 
choose to come back regularly for certain items and not for others or they will 
take items, run them up and not take them the next month, so they’ll alternate 
items, you know.  So that certainly isn’t beneficial when a patient has to make 
a decision as to whether their blood pressure is more important than their 
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cholesterol. You don’t feel your blood pressure being high. You don’t feel your 
cholesterol level being high. They would be always the easier ones to drop” 
FranCP13.  
This is worrying as it means patients must choose between which essential 
medications to take; this poses a big threat to patient safety. This feature is also 
observed amongst patients without medical cards and how much more they pay for 
medication:  
“….... It’s the poor private paying patient…..They’ll come to you and they’ll say, 
‘Look, ok, that blood pressure tablet’ and it might be for example an ACE 
inhibitor, ‘what’s the cheapest one I can get of that?” IndepGP02.  
Most HCPs agree that the co-payment system is a good tool to deter moral hazard 
but not to generate revenue:  
“If it was 50 cents like it had been initially, then there’s an understanding of 
why it’s there. Going to 2.50 in 2013 was the one that impacted most…… So, 
2.50 would probably be the straw that breaks the camel’s back in terms of the 
amount that patients are going to pay. Being at the 50 cent charge was the 
one to leave it at.  We understood the policy behind it, you know.  Trying to 
increase it up to generate revenue just doesn’t make sense from a health point 
of view” FranCP13.  
In fact, HCPs recommend eligible patients with a long-term illness (LTI), as classified 
by the HSE, to switch to the LTI scheme where there is no co-payment on prescription 
medicines i.e. GMS co-payment (tax) avoidance:  
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“we’ve been migrating them (eligible medical card patients) over to the LTI 
scheme” IndepCP02 and “if you go online to the Diabetes Ireland website, 
they’ll tell you, ‘If you’ve a medical card, make sure you get a long-term 
illness‘. So, they’re actually telling people to avoid the levy” IndepCP11.  
 However, some participants described the unfairness of this scheme which is not 
means-tested: 
“Why should a long term illness patient, you can have a retired High Court 
judge, a retired Taoiseach [Irish Prime Minister] who might have Type 2 
diabetes availing of all those levies for their cardiovascular medicines, their 
statins, their aspirin all free of charge, not even a levy paid and somebody with 
mental health difficulties who could be in very poor social circumstances, on 
social welfare, having to pay €2.  That is grossly unfair” IndepCP11.  
Both pharmacists and GPs want the system to remain in place: 
“if Sinn Féin [A left-leaning Irish political party] get into Government, they 
might promise to abolish it (the GMS co-payment) as a great stroke to the 
people, but I firmly believe that the people in the medical card system get an 
excellent service for nothing and that the co-payment is a very small little 
contribution to the exchequer and it’s tiny in the overall scheme of things” 
IndepGP03.  
Notwithstanding this perspective, it was interesting to note that some interviewees 
suggest that the co-payment system “should be means-tested” in order to reduce 
health inequalities IndepGP05. As well as GPs who believe that: “GP unions should be 
involved in co-payment policy because it does affect the workload” IndepGP01, 
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pharmacists too want to be heavily involved in the co-payment policy. They have 
many suggestions for co-payment policy improvement: 
“The fee should certainly be decreased down back to 50 cent, but with a 
greater emphasis then on exemptions so that there could be specific patients 
who shouldn’t have to pay, a greater cohort of patients that shouldn’t have to 
pay.  So, say for example, if a patient is diagnosed with cancer and is entitled 
to a medical card, then they should be getting the medical card and have it 
free of charge” FranCP13. 
6.6.3 Concerns and prescribing patterns of physicians 
GPs report that the co-payment has fine-tuned their prescribing habits: 
 “has made me a little bit more conscious of what I prescribe for patients in 
that are they going to take it?  Are they going to pay 2.50?  Ok, it doesn’t 
sound like a lot, but do you know, whatever it is, it’s nearly €30 a year, 
whatever, per item and patients on a social welfare budget, that’s an awful 
lot of money. So it makes me a little bit more conscious of it” IndepGP06. 
 In addition, the co-payment seems to create additional dialogue in the medical 
surgery “Maybe I get into the conversation of what they need this month more so 
than I would have in the past” IndepGP05. It appears that having a co-payment 
system on medicines may result in a more customised prescription for the patient. 
An unforeseen concept that arose from the GP interviews was the suggestion of the 
potential introduction of a co-payment system attached to GP surgery visits for 
medical card holders. Medical card holders currently avail of unlimited GP surgery 
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visits free at the point of access. This was first alluded to by a pharmacist in the early 
stages of the data collection phase:  
“…if the patient had a medical card and had to pay €5 to see the doctor or €10 
to see the doctor, they’d see something then….” FranCP09.  
When interviewing subsequently commenced with GPs, this idea was something that 
materialised through many indirect quotations where eventually one GP concisely 
summarised the issue:  
“I think we are heading towards free GP care and free medication which I don’t 
necessarily agree with……GPs would be in favour of advocating for co-
payment both for medication and attendance of surgery visits” IndepGP06.  
As there is an ongoing general practice crisis with over 26 communities in Ireland 
without a GP (371), the potential introduction of a co-payment system attached to 
GP surgery visits for medical card holders could prevent unnecessary consultations 
and thus would alleviate current GP capacity strains. 
 
6.7 Discussion 
This exploratory study provides a range of insights into HCP views on GMS 
pharmaceutical policy change over the last decade. What was evident from this 
analysis is that all participants, in some manner, think the GMS prescription medicine 
co-payment system is a good idea. However, the pharmacist cohort state they do not 
want to be an “organ of revenue collection” for the GMS co-payment. This tends to 
result in various losses of productivity that are not remunerated. Indeed, this financial 
182 
 
loss is much more than not being able to retrieve the levy. It is felt in the form of loss 
of staff productivity where administration workload and procedures have 
dramatically increased. In addition, it appears that the current information 
technology (IT) systems are not fit for purpose with respect to GMS co-payment 
retrieval. Financial losses suffered by pharmacists are also brought about by the 
absence of family unit linking on IT software systems in the pharmacy setting. For 
example, one family might pay the GMS co-payment cap of €20 for medicines per 
calendar month. However, because of poor IT systems communication, it not is 
recognised that the individuals in the family, who form a family unit, all fall under the 
same GMS co-payment cap, therefore the PCRS will deduct the €20 co-payment cap 
for each individual instead of for the family unit each calendar month. This results in 
financial loss for the pharmacist. This is something which needs to be rectified 
between the PCRS and primary care IT system providers. From the data, pharmacists 
would be happy to be removed from their current role in the co-payment retrieval 
transaction. As the GMS co-payment essentially is a tax, it could be argued that 
patients should deal directly with the tax collector/revenue commissioner regarding 
the payment of this levy as is done with other forms of taxation. Alternatively, 
pharmacists may be remunerated for co-payment collection, or at the very least, not 
financially penalised when they are unsuccessful at co-payment retrieval as is 
currently the case. The literature is sparse on this topic and further research is 
required. 
Like in some western European countries (105, 372), publicly insured patients in 
Ireland including those aged over 70, those under 6 years, and carers avail of GP visits, 
free at the point of access (6). An unexpected finding from this study was that GPs 
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have suggested that a co-payment policy be attached to GMS patient-physician 
consultations that occur in their medical surgeries to prevent unnecessary overuse of 
this free saturated service (371). This finding indicates that overburdened GPs are 
aware of the concept of moral hazard and are proposing potential solutions on how 
to handle increasing demand on healthcare services. More European countries are 
attempting to or already have put policies like this in place for publicly insured 
patients (105). For instance, patients aged 20 years or older on the public health 
insurance scheme in Sweden must provide a mandatory co-payment of 
approximately €10 to a front desk receptionist per primary care physician visit (373). 
Although subtleties exist across different Swedish regions, in general, the co-payment 
is seen as an income to the primary care centre, and this will be considered when 
funds are distributed from the regional government to each local care centre. In the 
Czech Republic, the evidence reveals that doctor visit co-payments do not impact the 
number of children's doctor visits (374). However, before such a policy could be 
implemented in Ireland, the fee for this co-payment would have to be carefully 
selected. Some research has found that prescription medicine co-payments could 
potentially affect the number of doctor visits (375) especially higher co‐payment fees 
which may reduce healthcare service utilisation mainly because of a demand 
reduction by poorer patients (376). Thus, more in-depth investigation is required to 
determine the optimal co-payment fee per patient-physician consultation in primary 
care; how best this fee could be retrieved in practice; and if the introduction of this 
co-payment would adhere to Sláintecare policy.  
It appears that GMS co-payment policy has a ripple effect on the LTI scheme 
pharmaceutical policy. HCPs and others have recommended that GMS patients with 
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an eligible LTI, as classified by the HSE, avoid paying the co-payment by switching to 
the non-means-tested LTI scheme. Although the dispensing fees paid to community 
pharmacies for both GMS and LTI reimbursement schemes are equivalent (5), this 
switching of schemes creates extra administrative burden elsewhere in the health 
system. It results in patients straddling two medication schemes at pharmacy level. 
Patients get their LTI-related medicines free of charge while concomitantly using the 
GMS scheme to retrieve their non LTI-related medicines. This led to discussion from 
interviewees on the complexity of the whole medicine reimbursement system in 
Ireland and the associated co-payments where over 20 such schemes exist in the 
primary, secondary and tertiary care settings (5, 377). One HCP summarised the 
medicine reimbursement system and the GMS scheme co-payment quite nicely 
“Even saying this out loud sounds absolutely ridiculous, you know, because if you 
landed from Mars and you said, ‘I've got an idea for a tax (co-payment fee)’, nobody 
would think that this was credible” IndepCP11.  
6.7.1 Limitations 
This study was not without its limitations. Access to the total number of patients that 
each medical practice serves, and which proportion of those patients were medical 
card holders, was unattainable. Such information could have been useful in drawing 
conclusions between the socioeconomic differences of different patient groups. 
Recruitment of participants was conducted between January 2018 and April 2019. 
Arguably, the data collection could process could have been quicker but the primary 
researcher (GOB) was involved in multiple ongoing research projects at the time. 
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As mentioned in the methods section, an initial core set ‘convenience sample’ was 
used for data collection. Concerns regarding selection bias in recruitment were 
reconciled by the fact that the sample obtained was representative of the practising 
HCP population. Pilot interviews were excluded from the data analysis. Although valid 
interviews, the interviewers felt their interviewing techniques at this early stage may 
have influenced participants’ responses. Securing interviews with GPs proved more 
difficult than with pharmacists which resulted in disproportionate numbers between 
the groups. However, an approximately equal amount of pharmacist quotations and 
GP quotations are reported in the results section of this paper in an attempt to 
further minimise selection bias.  
At the time of data collection, the main interviewer was a research pharmacist and 
the second interviewer was a final year pharmacy student, thus there was a 
possibility that participants gave socially desirable responses.  This bias was difficult 
to eliminate as the research team felt that by disclosing their backgrounds to 
interviewees, an element of professionalism could be introduced into the interviews. 
However, given that participants were also HCPs, and practising much longer than 
both interviewers, it was believed that the interviewers established a solid rapport 
with participants where socially desirable answers did not feature dominantly in the 
results. 
From 1st April 2019, around the same time data collection had ceased, the 
prescription charge decreased to €1.50 per GMS prescription item for people aged 
70 years and over, up to a maximum of €15 per month per person or family unit (378). 
For people aged under 70 years, the prescription charge remained at €2, up to a 
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maximum of €20 per month per person or family unit. Therefore, it is believed that 
this co-payment change did not affect the study results. Furthermore, in October 
2019, the Department of Finance announced that a €0.50 reduction per GMS 
prescription item for all medical card holders will come into effect in July 2020 (379). 
This research was originally intended to be part of a mixed methods study where the 
overall aim was to determine the impact of altering prescription charges on patient 
adherence to medicines on the GMS scheme in Ireland. The quantitative study 
planned to measure changes in adherence in essential and less-essential medicines 
(341, 380) pre- and post-GMS co-payment changes. However, access to national PCRS 
data (381) required for said analysis is only available to select research institutions. 
6.7.2 From evidence to policy 
This is the first study to investigate HCP stakeholder involvement in co-payments 
attached exclusively to prescription medicines, where recommendations from the 
COREQ statement were implemented to ensure that this analysis presents a 
transparent high-quality evaluation. It was unclear to the HCP interviewees what 
evidence is guiding these GMS co-payment fee changes. GMS co-payment changes 
are usually announced around general election time by contesting politicians or on 
national budget day by Government officials, unaccompanied by any solid evidence 
of what impact such increases or decreases can have. Previous iterations have yielded 
reductions in adherence to essential medicines, including anti‐depressant 
medications with a large decrease of −10.0% (355). Reduction in the use of essential 
medicines results in worsening patient adherence, leading to poorer health outcomes 
and increased usage of health services (382-384). Given the recent flippant GMS co-
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payment increases, this pharmaceutical policy appears to be more about generating 
revenue rather than preventing moral hazard and positively influencing prescribing 
patterns. If Ireland’s ten-year Sláintecare plan for whole health system reform 
through political consensus is going to be implemented successfully, then healthcare 
policymakers need stakeholder buy-in to ameliorate existing pharmaceutical polices 
like this. In this study, both community pharmacists and GPs have suggested that 
their respective representative bodies should be more involved in the policy 
formation stages, not the post-implementation stages. Sláintecare represents a 
unique opportunity for all key stakeholders including policymakers, HCPs and 
patients to collaborate and provide input into a healthcare system that works for all. 
Figure 6.2 briefly summarises the content, context and process underpinning this 














Key: DoH: Department of Health; GMS: General Medical Services; GP: General Practitioner; HSE: Health 
Service Executive; PCRS: Primary Care Reimbursement Services 
Figure 6.2 Walt and Gilson policy triangle model depicting the related factors 
pertaining to the pharmaceutical policy 
 
6.8 Conclusion 
The GMS co-payment has undergone various iterations in recent times. Previous 
studies have examined its impact and sought to retrieve ‘the optimal co-payment’ 
which concomitantly prevents medicine wastage and acts as a revenue stream (351, 
355). This study too implies that there is no optimal co-payment fee as far as patients 
and HCPs are concerned; GPs and pharmacists did seem to favour a lower amount. 
Perhaps healthcare policymakers should formally evaluate the fee value every few 
years to see if a change is warranted. However, given all the interrelated components, 
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as portrayed by the HPT framework, that influence the pharmaceutical policy, this 
would not be a straightforward task.  Indeed, this study comes at an important time 
as the Irish healthcare system undergoes major political, economic and health policy 
reform under the Sláintecare policy (23). Through political concord, the Irish 
Government are aiming to reorient the health system ‘towards integrated primary 
and community care, consistent with the highest quality of patient safety in as short 
a time-frame as possible’ (21, 385). This study has provided a platform for 
experienced primary care HCPs to express their views and accounts of the Irish GMS 
co-payment system. For the most part, HCPs agree that there is merit to having a 
nominal charge attached to prescription medicines on the GMS scheme. However, 
participants have highlighted outstanding issues that need to be optimised in order 
to ameliorate primary healthcare practices and procedures (304, 386). With respect 
to Lewin's basic change theory model of unfreezing, changing, and refreezing (387), 
healthcare policymakers responsible for implementing the ten-year Sláintecare 
reform can bypass the unfreezing stage of this contemporary pharmaceutical policy. 
Both community pharmacists and GPs want to see their representative bodies more 
involved in supporting evidence-based policy decisions.
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7 Chapter 7 Discussion 
7.1 Chapter description 
The research in this thesis analysed local, regional and national healthcare policy 
change within different Irish healthcare settings over the last decade with regard to 
(i) development processes, (ii) evidence generation, (iii) implementation, and (iv) 
outcomes using the HPT framework. This chapter is an interpretation and discussion 
of the key findings presented in the individual study chapters presented within the 
thesis. Initially, key findings of each individual study chapter were summarised and 
followed by a description of the implications of the research for policy decision-
making. Subsequently, strengths and limitations of the research were identified. 




7.2 Summary of findings 
An objective of this thesis was to formally review the recent international literature 
in relation to the HPT framework. The narrative literature review (Chapter 2) sought 
to explore and summarise the application of the HPT framework to health-related 
(public) policy decisions from January 2015 to January 2020. The review identified 
that most health policies were positioned at national or international level mostly in 
lower to upper-middle-income countries and primarily concerned public health 
issues. It emerged that the HPT framework was commonly applied to health-related 
policy decisions which concerned: 
i. health human resources, services and systems  
ii. communicable and non-communicable diseases  
iii. physical and mental health  
iv. antenatal and postnatal care 
While it was found that that the HPT framework was used ubiquitously in the 
literature to analyse a large number of health-related issues mostly positioned at 
national or international level, further research was required to seek an in-depth 
understanding of the application of the HPT framework to health-related policy 
decisions at a local/regional level, and to discern any potential benefits in doing this. 
Thus, the overarching aim of this thesis was to analyse local, regional and national 
health policy change within different Irish healthcare settings over the last decade 
using the HPT framework. Based on this, several research objectives were developed 
and addressed. See Figure 1.2 repeated below for a diagrammatic depiction of how 
these questions sit under one overarching aim and how they relate to one another.  
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Background and Hypothesis (Chapter 1): 
The HPT framework is widely used to analyse health-related issues commonly positioned at (inter)national level. Further research was required to seek a greater 
understanding of the application of the HPT framework to health-related issues to inform its use in smaller scale health policy decisions at local and regional levels 
 
Discussion (Chapter 7): 
Synthesise the findings from each chapter to show the generalisable nature and novel application of the HPT framework to local, regional and national 
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To analyse local, regional and national health policy change within different Irish healthcare settings over the last decade using the HPT framework 
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The chapter concluded that given the generalisable nature of the HPT framework, 
future research which uses this framework in smaller scale health policy decisions at 
local and regional levels, could be beneficial. This conclusion fueled the thought 
process behind subsequent research chapters. 
Following on from Chapter 2, another literature review (Chapter 3) successfully 
applied the policy triangle model, as a scaffolding framework, to help describe how 
emerging evidence was used by a large acute Irish teaching hospital to permit the 
introduction of biosimilar infliximab CT-P13, for the treatment of IBD, into routine 
care in a safe and timely manner (341). The application of the policy triangle model 
to similar medicine-related policies is common in the literature; the framework has 
been used in studies that explore medication safety concerns (94), herbal medicine 
regulation (96), and HPV vaccination (99, 129). The review of this local policy decision 
(Chapter 3) concluded that there was a significant time lag between regulatory 
approval and clinical acceptance given that the EMA had granted market 
authorisation for biosimilar infliximab CT-P13 three years prior to the initiation of this 
hospital’s switching process (341). Another finding from Chapter 3 was the actors 
remarked that with the existential concern and uncertainty still surrounding the 
clinical use of biosimilar medicines, a distinct and individualised approach for 
biosimilar medicine implementation is required. However, while the MMP biosimilars 
initiative are doing pioneering work in this field by publishing prescribing and cost 
guidance to support clinicians in the prescribing of these medicines (206), the 
national biosimilar medicines policy referred to in Chapter 3 has yet to be published 
by the DoH (at time of writing – August 2020). Across European countries, differences 
exist in biosimilar policies, leading to variations in uptake of biosimilars and 
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divergences in savings all over Europe (388). Internationally, the Nordic countries, as 
well as some health districts in the UK, have attained victory when it comes to the 
switching and substitution of biosimilars. Success of the use of biosimilar infliximab 
CT-P13 at University Hospital Southampton (220, 221) and in Norway and Denmark 
has been observed, where after two years since its introduction, biosimilar infliximab 
reached market penetration levels in excess of 90% relative to the originator 
medicinal product (as of April 2016) (222). Such uptake resulted in substantial drug 
acquisition cost savings and subsequently increased patient access to the biosimilar 
medicine (188, 220). A recent study involving IBD patients in Finland showed that 
switching to biosimilar infliximab has no significant impact on health-related quality 
of life or disease activity, while reducing costs by two thirds (389). 
In Chapter 4, the cost-effectiveness of physicians applying the STOPP/START (version 
1.0) screening tool to older hospitalised patients with multimorbidity and 
polypharmacy compared with standard of care in a large acute Irish teaching hospital 
was evaluated by conducting a secondary analysis of RCT data (390). This study 
demonstrated that on average, the intervention arm was more costly but was also 
more effective. Compared with usual care (control), the intervention was associated 
with a non-statistically significant increase of €877 (95% CI −€1,807, €3,561) in mean 
healthcare cost, and a statistically significant decrease of −0.164 (95% CI −0.257, 
−0.070) in the mean number of ADR events per patient. The associated ICER per ADR 
averted was €5,358. The probability of the intervention being cost-effective at 
threshold values of €0, €5,000 and €10,000 was 0.236, 0.455 and 0.680 respectively. 
The physician-led intervention was deemed not likely to be cost-effective compared 
with usual hospital care (390). In contrast, other studies have shown that when a 
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pharmacist replaces the role of the physician, the outcome is more likely to be cost-
effective (246). In addition, a recent systematic review concluded that computerised 
interventions are associated with a significant reduction in PIP in older hospitalised 
patients (269). Computerised interventions in this setting appear to reduce cost (270) 
and prove cost-effective (271). Indeed, the literature appears to suggest that 
pharmacists, in association with computerised CDSS, employed to carry out such 
medication reviews may be a more cost-effective approach (265). Within the context 
of this thesis, the HPT framework was used to describe how this local level policy 
decision concerning the physician-led STOPP/START intervention was not 
implemented but that the generated economic evidence contributes to the evolving 
STOPP/START criteria policy formation, growth and future evaluation. The policy 
triangle model has been cited in similar health-related interventions like a maternal 
health intervention (75) and a skilled birth attendance intervention (124). 
In Chapter 5, two large acute University teaching hospitals at regional/provincial level 
comprised the study population. Similar to Chapter 4, evidence was synthesised in 
the form of an economic evaluation to inform policy process development. The 
regional policy decision concerned whether trastuzumab SC treatment should 
replace trastuzumab IV treatment for HER2-positive breast cancer patients in routine 
clinical practice (385). A prospective observational study in the form of cost 
minimisation analysis constituted study design and was used to assess which route 
was more cost-effective and time saving in relation to active HCP time. On average, 
the total HCP time saved per trastuzumab SC treatment cycle relative to trastuzumab 
IV treatment cycle was 59.21 minutes. Time savings in favour of trastuzumab SC 
resulted from quicker drug reconstitution, no IV catheter installation/removal, and 
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less HCP monitoring. Over a full treatment course of 17 cycles, average HCP time 
saved accumulated to 16.78 hours. In fact, this time saving of 79% is believed to be 
the highest recorded active HCP time saving where other studies report time savings 
of 51% in Spain, 48% in Canada and Russia, 36% in France, 31% in Denmark and 15% 
in Switzerland (322). Greater available HCP time could result in improvements in the 
quality of care, with more time free for monitoring, for other relevant medical duties, 
or indeed for providing patient information or comforting. In addition, by utilising 
trastuzumab SC in the place of trastuzumab IV, a saving of €596.70 per patient in 
active HCP time for a full 17-cycle treatment was gained. This result is consistent with 
those from international studies (323-326). Loss of productivity for patients receiving 
trastuzumab IV (2.15 days) was greater than that of trastuzumab SC (0.60 days) for a 
full treatment course (385). The HPT framework was used to describe the various 
contributing components which led to the replacement of trastuzumab IV by 
trastuzumab SC in clinical practice and how this contemporary policy is still evolving 
especially since the introduction of biosimilar trastuzumab IV to the market. The use 
of the policy triangle model in similar medicine-related policies is frequently observed 
in the literature (94, 96, 99, 129). More Irish hospitals are beginning to use 
trastuzumab SC, and following its successful implementation in Europe, Oceania and 
South America (310, 331, 338), it is envisaged that this formulation will penetrate the 
North American oncology landscape next.  It has yet to be seen what impact 
biosimilar trastuzumab IV will have on the Irish and international markets and indeed 
how it will affect trastuzumab SC market penetration. 
In Chapter 6, a qualitative interview study of Irish HCPs was conducted. The study 
explored the involvement and perceptions of community pharmacists and GPs on a 
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national pharmaceutical policy change concerning mandatory co-payments attached 
to prescription medicines on the Irish public health insurance scheme (391). Chapter 
6 showed that both community pharmacists and GPs accepted the theoretical 
concept of a co-payment attached to the GMS scheme as they felt it prevents moral 
hazard. However, there were multiple references to the burden that the current 
method of co-payment collection places on community pharmacists in terms of direct 
financial loss and reductions in workplace productivity. GPs independently suggested 
that a co-payment system introduced in their field of practice may inhibit moral 
hazard by GMS patients in the utilisation of GP services. More European countries 
are attempting to or already have put policies like this in place for publicly insured 
patients (105). For instance, patients aged 20 years or older on the public health 
insurance scheme in Sweden must provide a mandatory co-payment of 
approximately €10 to a front desk receptionist per primary care physician visit (373). 
Although subtleties exist across different Swedish regions, in general, the co-payment 
is seen as an income to the primary care centre, and this will be considered when 
funds are distributed from the regional government to each local care centre. In 
addition, it was unclear to both community pharmacists and GPs in this research 
chapter what evidence is guiding the GMS co-payment fee, or changes to the policy 
over time (391). However, such iterations have yielded reductions in adherence to 
essential medicines, including anti‐depressant medications with a large decrease of 
−10.0% (355). Reduction in the use of essential medicines results in worsening patient 
adherence, leading to poorer health outcomes and increased usage of health services 
(382-384). The HPT framework was used to depict the interrelated factors which 
underpin this national pharmaceutical policy. Going forward, both community 
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pharmacists and GPs have suggested that their respective representative bodies 
should be more involved in the policy formation stages, not the post-implementation 
stages (391). Similarly, a recent study that examines the implementation of out-of-
pocket payments to GPs in Denmark applied both the HPT framework and Kingdon’s 
multiple streams theory in its policy analysis (105). It found that the potential 
introduction of out-of-pocket payments in Denmark may lead to decreased health 
expenditure, but also increased inequalities.  
 
7.3 From evidence to policy 
The principal contribution of this thesis has been the novel and successful application 
of the HPT framework to diverse local, regional and national healthcare decisions in 
the Irish context which exemplifies the generalisable nature of the policy triangle 
model. This demonstration bears significant relevance for the Irish healthcare system 
at present given that Sláintecare is officially underway (21). The Sláintecare 
Programme Implementation Office refined the implementation strategy (which 
contained 106 sub-actions) into a programmatic action plan in 2019 (22). This is the 
first of many action plans and will be updated annually during the ten-year 
implementation period. The author of this thesis proposes that the HPT framework 
should be used in the analysis of/for policy in the myriad of upcoming health policies 
to be made and reviewed under Sláintecare reform in its future action plans. This 
framework can have a notable impact on local, regional and national health policy 
analysis reform if implemented in Sláintecare decision-making. Other countries like 
Iran and Ghana have already used the HPT framework when exploring potential 
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issues and policies surrounding the similar aim of UHC facilitation in their primary 
healthcare settings (79, 98). In addition, the robust economic and qualitative 
evidence generated over the course of this thesis will assist other local and regional 
healthcare payers and interested parties to objectively determine whether it is worth 
pursuing and examining a respective health policy relevant to them. 
Evidence produced and reviewed in the thesis has and will influence healthcare policy 
decisions, through conference publication nationally and internationally and through 
peer reviewed publications. Fortunately, implementation of the some of the 
proposed health policy decisions investigated throughout Chapters (3 - 6) will not 
require a substantial investment. However, the reallocation of funds for additional 
employment or additional payment of services, in addition to agreement of all 
stakeholders involved in the provision of care to the relevant patient group, may be 
challenging. 
While dissemination of research through the medium of academic journals and 
conferences is an important aspect of any research thesis, communication through 
these channels may not be reaching the correct audience if one wants to see research 
influencing policy at local, regional and national levels. It is vital that if this research 
is to make an impact, it is brought to the attention of key decision-makers within the 
healthcare system. The author of this thesis has ensured that throughout the course 
of the research, engagement with the wider health policymaker community was 
made. This thesis resulted in collaboration with four major teaching hospitals, 




In addition, on October 18th, 2018, the published paper which underpinned Chapter 
3 was submitted to the HSE-Medicines Management Programme in response to their 
national ‘best-value biological medicines’ consultation (206); parts of the published 
paper helped inform version 2.0 of the ‘MMP roadmap for the prescribing of best-
value biological medicines in the Irish healthcare setting’ document published from 
the consultation process (392). On July 13th, 2018, at their request, the published 
paper derived from Chapter 4 was submitted to the creators of the STOPP/START 
criteria; the developers are currently updating the STOPP/START guidelines (version 
3.0) to help inform future policymaking regarding the most appropriate means of 
application and delivery for this screening tool. On September 25th, 2018, at the 
request of its Chief Pharmacist, the published paper which stemmed from Chapter 5 
was submitted to the HSE-National Cancer Control Programme to inform 
policymaking and reimbursement on this topic. On June 11th, 2020, the published 
paper that comprised Chapter 6 was submitted to the DoH, the Irish College of 
General Practitioners, the Irish Medical Organisation, the IPU, and the 
Pharmaceutical Society of Ireland to inform future policymaking on the subject area. 
Moreover, once this thesis is published by the Cork Open Research Archive (based in 
UCC), relevant segments that demonstrated the generalisable nature and novel 
application of the HPT framework to diverse local, regional and national healthcare 
decisions in the Irish context will be forwarded to the Committee on the Future of 
Healthcare. This will be in the guise of a policy briefing document (see Appendix XXII) 
and will highlight the framework’s potential utility in future Sláintecare reform and 
implementation action plans. 
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7.4 Strengths and limitations 
All research Chapters (2 - 6) outlined have generated full publications in peer 
reviewed academic journals (341, 385, 390, 391, 393). Additionally, research has 
been presented at multiple conferences in both poster and oral format (see Appendix 
III). While publication is not the definitive goal for investigating a problem, it is one 
metric that reflects the impact of this thesis overall and the interest in the topics from 
the wider academic community. The author adopted a proactive approach to 
ensuring that a wider and lay audience was made aware of any work undertaken by 
publishing blogs (see Appendix I) and a policy brief (see Appendix XXII). 
The research findings presented in this thesis use the HPT framework to help 
describe, examine and understand various health-related policy decisions. 
Frameworks like the policy triangle model are systematically used to organise inquiry 
for theory generation through identifying elements and relationships among these 
elements (96, 105, 127). Other frameworks for examining policy (394) and theories 
of the policy process (40) were considered to be more narrow in scope, focusing on 
either the contents of policy or the actors/processes and requiring specific 
information beyond that which would be commonly provided/available.  
As mentioned, analysis of policy is the most accurate way to describe the use of the 
HPT framework throughout research Chapters (3 - 6). It is generally retrospective and 
explanatory; it looks back to explore the determination of the policy capturing how 
the policy got on the agenda, what the policy consisted of, who was involved and did 
it achieve its goals (30). In contrast, prospective policy analysis hypothesises potential 
opportunities for influencing the policy environment; there are few accounts in the 
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overall policy literature of prospective policy analysis (395). By applying the 
descriptive HPT framework to health-related policy decisions, it assists interested 
parties and invested decision-makers in interpreting the policy in question. It allows 
for comparison between policies that stem from different sectors of healthcare using 
four components (actors, content, context, process). This demonstrates the broadly 
applicable nature of the policy triangle model. The narrative review (Chapter 2) has 
already identified how the HPT framework can be applied to a wide variety of health-
related (public) policy decisions such as communicable and non-communicable 
diseases (102, 109, 113, 128), mental health (103, 121, 132) and the provision of 
primary healthcare (118, 122). In addition, a recent literature review has shown that 
the HPT framework is widely used to understand diverse policy experiences in 
multiple LMIC settings, with applications that encompass both quite simple and 
descriptive narratives and less frequently, fuller more explanatory analysis (47). 
These reviews exemplify the generalisable nature of the HPT framework. 
In this thesis for example, the policy triangle model provides a platform that allows 
policymakers to consider health policy decisions concerning biosimilar medicines 
(Chapter 3), medication screening interventions (Chapter 4), pharmaceutical 
formulation switching (Chapter 5), and co-payment charges (Chapter 6) using a 
common descriptive framework. If for example, a Sláintecare decision-maker had 
funding to invest in only one of the four policies explored throughout Chapters (3 - 
6), they could quickly examine the different contributing components of each policy 
by comparing and contrasting the respective actors, content, context and process 
(see Table 7.1); this could help inform their decision. This action bears resemblance 
to cross-country comparative policy analysis studies discussed in Chapter 2 (70, 104, 
203 
 
141). However, the difference being that instead of examining one policy among 








Table 7.1 Components of HPT framework from Chapters (3 - 6) 




Independent systematic evidence trail 
outlined in Figure 3.1 in Chapter 3 
Irish biosimilar landscape influenced 
by national biosimilar policy; DoH; 
EMA; HPRA; IPHA; MMP; Sláintecare 
reform 
Three-year procedure; new patients 
initiated; all patients subsequently 
switched; continuous post-switch 
monitoring by actors 





SENATOR & OPERAM clinical trials; 
cost-effectiveness results of the 
Chapter 4 trial and of the SPRM with 
CDSS trial in same hospital 
Increasing life expectancy of and 
healthcare expenditure on elderly as 
reported by OECD; NMS intervention; 
Sláintecare reform 
Ongoing; STOPP/START criteria 
application being evaluated in a variety of 
healthcare settings involving different 
HCPs & CDSS 
5 Consultant 
Oncologists & Nursing 
& Pharmacy 
Departments 
HannaH, SafeHer & PrefHer clinical 
trials; cost savings, reduced active HCP 
time & decreased loss of productivity 
results from the economic evaluation 
in Chapter 5 
Irish biosimilar & oncology landscape 
(biosimilar trastuzumab IV launch); 
NCCP; Sláintecare reform 
Hospital 1 (Chapter 5) involvement in 
SafeHer trial in 2011; switching period 
commencement in early 2014 and late 
2015; continual positive emerging clinical 
and economic evidence 
6 Government health 
officials (DoH); 
(incoming) politicians 
Previous Irish literature published on 
this topic; financial and workplace 
productivity losses, patient safety risks 
& system reform proposals reported 
from Chapter 6 
Annual national budget; DoH; GMS 
scheme; GP & Pharmacy unions; HSE; 
Irish general election; PCRS; 
Sláintecare reform 
Implemented mandatory collection by 
community pharmacists without 
negotiation; ambiguity concerning what 
evidence is currently guiding co-payment 
fee changes (no evaluation of policy) 
Key: CDSS: Clinical Decision Support Software; DoH: Department of Health; EMA: European Medicines Agency; GMS: General Medical Services; GP: General 
Practitioner; HCP: Healthcare Professional; HPRA: Health Products Regulatory Authority; HSE: Health Service Executive; IPHA: Irish Pharmaceutical Healthcare 
Association; IV: Intravenous; MMP; Medicines Management Programme; NCCP: National Cancer Control Programme; NMS: New Medicines Service; OECD: 
Organisation for Economic Co-operation and Development; PCRS: Primary Care Reimbursement Services; SPRM: Structured Pharmacist Review of Medication 
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The chapters within this body of work used a variety of rich data sources to inform 
the overall analyses and subsequent conclusions drawn from the thesis. The findings 
from the qualitative analysis (Chapter 6) are based on a sample that was broadly 
representative of the practising HCP population. This mediates concerns regarding 
selection bias in recruitment. The cost-minimisation analysis (Chapter 5) was based 
on primary data collected for a prospective observational study. Data collection was 
spread over two centres which provided a larger data pool. The cost-effectiveness 
analysis (Chapter 4) was based on primary data collected for a RCT. This enabled the 
accurate identification of resource use associated with both intervention and control 
arms. Chapter 3, a review into how emerging evidence was used by a large acute Irish 
teaching hospital to permit the introduction of biosimilar infliximab CT-P13 for the 
treatment of IBD into routine care, was informed by a literature review consisting of 
published studies, reviews, reports, position statements, articles, clinical guidelines 
and recommendations from national bodies, regulatory authorities and professional 
organisations (341). By including both formal and informal literature in the Chapter 3 
review, this facilitated a thorough appraisal of how this biosimilar policy change came 
to fruition in a large acute Irish teaching hospital at local level. 
Each research chapter was subject to extensive methodological rigour. The trial-
based economic evaluation (Chapter 4) adopted the CHEERS guidelines as guidance 
for reporting the research in the paper write-up (259). In addition, the methodologies 
used are highly suitable for use alongside cluster RCTs (255); the use of multi-level 
mixed effect models is an appropriate method of evaluating clustered data. The 
manuscript published from Chapter 5 also adopted the CHEERS guidelines for 
reporting (259). The research published from Chapter 6 abided by the COREQ 
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guidelines (370). The qualitative data in Chapter 6 was analysed using the Framework 
Approach (55). This method originated in large-scale social policy research but is 
becoming an increasingly popular approach in medical and health research (64) 
making it highly suitable for analysis of qualitative data like that gathered for use in 
Chapter 6 and for use in health policy analysis.  
Individual chapters elaborate on the specific limitations of each study in the 
‘Discussion’ sections. However, it can be argued that Chapter 4 underwent more 
analysis than the others and thus some additional limitations are noteworthy. For 
example, while trial-based economic evaluations (Chapter 4) are an established and 
relevant form of assessment, they do give rise to their own methodological 
challenges including choice of comparison therapy; measurement in trials versus 
routine practice; intermediate versus final health outcome; inadequate patient 
follow-up; protocol driven costs and outcomes (54). In addition, while the datasets 
used were considered trustworthy and generally complete, all datasets where data 
are manually collected and compiled tend to have some degree of missing data. 
Depending on the degree of missingness and significance of the missing variable(s), 
such omissions could potentially systematically bias the analysis. However, 
missing/censored data were not an issue in the evaluation, as follow-up was 
facilitated by a unique hospital number identifier and confined to a single centre over 
a short time period. Moreover, in the case of the medication review research 
(Chapter 4), the trial follow-up period was shorter than the period during which 
differences in health effects and use of healthcare resources between interventions 
persist; increasing the uncertainty surrounding whether investing in this intervention 
would be a good use of healthcare resources over a longer period of time. 
207 
 
Furthermore, the research (Chapter 4) was predominantly incorporated around 
retrospective evaluation of data sources or as an add-on to previously completed 
clinical trials; reductions in uncertainty surrounding some of the input such as HCP 
time estimates data could have been reduced through earlier engagement with 
primary researchers. However, scenario analyses were conducted to account for this 
uncertainty (390). 
Although the research that uses the HPT framework presented within this thesis does 
have some exploratory or investigative aspects, it is largely descriptive in nature, thus 
lacking an analytical focus. The main question the model often asks is ‘what 
happened’ and not ‘what explains what happened’. So, while the HPT framework is 
useful to think systematically about all the different factors that might affect policy, 
it is a highly simplified representation of a complex set of interrelationships which 
gives the impression that its four components can be considered separately (30); they 
cannot. Indeed some research has suggested that the triangle model pays too little 
attention to other factors that explain why and how policies change (396, 397).  
The research within this thesis focuses on experience around separate respective 
policies in one country (Ireland) at one time point, rather than comparing and 
contrasting experience across countries or over time, between health policies or 
across sectors within a country, or between implementing units and people/patient 
groups. While it is reported that the consistent application of the HPT framework 
across polices from different health systems can enhance the reliability of cross-
country comparisons (70, 104, 398); it is a possibility that the substantive findings 
from this thesis may not be generalisable to other international health settings. This 
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is potentially owing to Ireland’s distinctive ethnicity and political situation which 
underpins the content and context components of the HPT framework used to 
describe the health-related policy decisions outlined in Chapters (3 - 6). This 
distinctive political situation was described in Chapter 1 where, for example, Ireland 
is the only country in western Europe that does not offer universal access to primary 
care (4). However, the methodology of applying the HPT framework to health-related 
policy decisions at local and regional level is not restricted by geography or health 
system infrastructure. 
For the purposes of this research, distinct health-related policies made in various 
health sectors at local, regional and national levels in Ireland were deliberately 
chosen for the application of the policy triangle model; this helped address the 
overarching aim and sub-objectives of the thesis. But in practice, more explicit use of 
formal case study analysis approaches is observed. For example, appropriate case 
selection criteria must be established, each case must be adequately contextualised, 
and efforts must be made to deliberately identify and explain unusual experiences 
and findings (399). 
Political context was considered through the medium of Sláintecare. However in 
reality, the political contexts described in Chapters (3 - 6) for each health-related 
policy decision may be much more complex than illustrated. There could be power 
play and politics involving actors at local, regional and national level where such a 
milieu may not be captured in the presented research. The influence of power and 
actor relations is commonly cited in the literature (400, 401). Stakeholder analysis 
can be used to help understand about relevant actors, their intentions, interrelations, 
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agendas, interests, and the influence or resources they have brought or could bring 
on decision-making processes during policy development (52). The use of stakeholder 
analysis could have been used in this thesis to complement the HPT framework policy 
analysis approach as is sometimes seen in the literature (92, 107, 139, 141). However, 
given that most health-related policies explored throughout this thesis were 
positioned at local and regional level, it is believed that a stakeholder analysis would 
contribute no additional benefit to the description of the policies in question. 
The process of policymaking refers to the way in which policies are initiated, 
developed or formulated, negotiated, communicated, implemented and evaluated 
(30). The most common approach to understanding policy process is to use the stages 
heuristic model (37). The process component for each health-related policy decision 
in Chapters (3 - 6) was largely descriptive in nature thus not explored extensively. 
However, given that these policy decisions were looked at a local and regional level, 
the formal steps of development through to implementation can often be bypassed 
quite quickly. By generating an understanding of the factors influencing the 
experience and results of policy change, such analysis can inform action to strengthen 
future policy development and implementation. However, as mentioned in specific 
chapters, some policy decisions are still in development and the nature of their 
respective process will evolve over time. Further research may formally document 
their process journey and should investigate the use of explanatory policy process 
theoretical frameworks such as the Kingdon’s multiple streams theory or ACF (44). 




7.5 Future research 
There are many interpretations from the research findings presented in this thesis. 
Chapter 2 identified that the types of health policies analysed using the HPT 
framework were almost all positioned at national or international level mostly in 
lower to upper-middle-income countries and primarily concerned public health 
issues. Following this finding, Chapters (3 - 6) successfully investigated different 
health-related policy decisions at local, regional and national level in a high-income 
country (Ireland) using the policy triangle model. Its successful application to smaller 
scale health policy decisions represents one of the novel aspects of this thesis. It is 
evident that the HPT framework is not confined to any one setting or to a particular 
type of health-related policy decision. Although not investigated in this thesis, further 
applications using the policy triangle model as a descriptive framework in policy 
arenas outside health could be explored. 
The current interest in health policy and systems research provides exciting 
opportunities for the field, but also brings the threat of disciplinary capture by the 
clinical, biomedical, and epidemiological disciplinary perspectives dominant in wider 
health research (402). Health policies are complex social and political phenomena, 
constructed by human action rather than naturally occurring (402). As the health 
policy field continues to grow, it is crucial that all perspectives on health policy issues, 
from social science to epidemiology, are respected; this will ensure that an 
interdisciplinary understanding is built into all health policy analysis approaches. 
The use of the Walt and Gilson policy triangle model in this thesis provided a rich 
descriptive analysis and narrative of the development of various health-related policy 
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decisions in Ireland. This was useful in highlighting how policy issues emerged, how 
they were developed and what current status they hold. To enhance understanding 
of the policy dynamics, future research would comprise of an explanatory analysis 
using one or more policy process theoretical frameworks such as the ACF (38), the 
Kingdon’s multiple streams theory (39), the punctuated equilibrium framework (40) 
and the institutional analysis and development framework (40).  
A myriad of policy frameworks and theories exists (31). The burgeoning literature of 
health policy analysis sees novel policy frameworks being developed quite frequently 
with the ‘policy cube’ approach being the latest addition (36). While it is great to 
observe such advancements in the field, having too many choices of frameworks can 
potentially complicate the selection process. The research from this thesis has 
illustrated how generalisable and adaptable the application of the HPT framework is 
to health-related policy decisions of almost any nature in various settings. Given this 
advantage, the author of this thesis would like to see the policy triangle model used 
by the Committee on the Future of Healthcare who steer Sláintecare 
implementation. By standardising the approach to health policy analysis during this 
ten-year reform period by using a common framework, health-related policy 
decisions have the potential to be made more easily and readily thus ensuring 
successful fruition of Sláintecare goals (see Appendix XXII). 
 
7.6 Conclusion 
Overall, many beneficial health-related policy decisions are being made at local, 
regional and national levels that add/remove substantial value to/from the Irish 
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healthcare system. These policy decisions, driven by actors, often result in economic 
and clinical benefits for health service providers and patients alike. This thesis has 
contributed to the overall evidence base surrounding the various health-related 
policy decisions explored throughout. It also has successfully demonstrated that, 
notwithstanding the setting or nature relating to a particular health policy, it is 
possible to compare and contrast wide-ranging health policies using the HPT 
framework thus fulfilling the overarching thesis aim. In the past, much of the valuable 
health policy research produced was regularly considered within the scope of its own 
field without the ability to easily make comparisons with other health policy research 
stemming from different subject areas.  Using assorted health policies from different 
healthcare settings in Ireland over the last decade, this thesis has overcome a large 
element of the knowledge deficit by demonstrating that the generalisable nature of 
the policy triangle model allows for comparing and contrasting of health policies that 
come from almost any health-related field. 
However, this finding will prove ineffectual unless acted upon and alerted to relevant 
health policy actors. Sláintecare reform proposes the establishment of a universal, 
single-tier health service where patients are treated solely on the basis of health 
need; the reorientation of the health system ‘towards integrated primary and 
community care, consistent with the highest quality of patient safety in as short a 
time-frame as possible’. To promise the delivery of such major policy change to a 
national health system over a ten-year period requires that consideration be given to 
the application of a common framework that can be used by all decision-makers 
when conducting the relevant required health policy analysis.  
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Research and evidence presented throughout this thesis has shown that despite 
limitations, the generalisable and adaptable nature of the policy triangle model 
demonstrates that it could be used as a common descriptive framework to assist with 
health policy analysis under Sláintecare reform plans. By each relevant decision-
maker applying the same model to all health-related policy decisions, the Sláintecare 
implementation process could proceed more quickly and effectively to the benefit of 
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Biosimilar Infliximab in the Irish Secondary Care Setting” 
Gary L O’Brien, Donal Carroll, Valerie Walshe, Mark 
Mulcahy, Garry Courtney, Cian O’Mahony, Stephen 
Byrne (2018) Value in Health, 
DOI:10.1016/j.jval.2018.09.876 - ISPOR Europe, 
Barcelona, Spain, November 2018 
Value in Health 1st 
“Cost Minimisation Analysis of Intravenous or 
Subcutaneous Trastuzumab Treatment in Patients with 
HER2-Positive Breast Cancer in Ireland” Gary L O’Brien, 
Cian O’Mahony, Katie Cooke, Ada Kinneally, Sarah-Jo 
Sinnott, Valerie Walshe, Mark Mulcahy, Stephen Byrne 
(2019) Journal of Oncology Pharmacy Practice, 
DOI:10.1177/1078155219871150 - ISOPP International 






“Computerised Medication Analysis Designed to 
Minimise Inappropriate Prescribing in Older 
Hospitalised Patients: A Systematic Review” Kieran 
Dalton, Gary L O’Brien, Denis O’Mahony, Stephen Byrne 
(2017) Age and Ageing, DOI:10.1093/ageing/afx144.236 
- The 65th Jubilee Annual & Scientific Meeting of the 
Irish Gerontological Society, Wexford, Ireland, 
September 2017 
Age and Ageing 2nd 
“Investigating Patient Safety Culture using the Open 
Comments Section of the Safety Attitudes 
Questionnaire (SAQ)” Laura L Gleeson, Gary L O'Brien, 
Leanne Tobin, Erin K Crowley, Aoife Delaney, Denis O' 
Mahony, Stephen Byrne (2019) International Journal of 
Pharmacy Practice, DOI:10.1111/ijpp.12533 - Health 
Services Research & Pharmacy Practice Conference, 






“Measurement Health Outcomes Associated with 
Medicines at a National Level” James Gallagher, 
Muireann McAlister, Stephen Byrne, Gary L O’Brien 
(2019) Value in Health, DOI:10.1016/j.jval.2019.04.1164 
- ISPOR New Orleans, LA, USA, May 2019 
Value in Health  Senior 
Author 
Position 
Other publications:   
“Biosimilar Adoption and Acceptance in Ireland – Still 
More To Be Done” Gary L O’Brien, Donal Carroll, Valerie 










Adamason, Stephen Byrne (2018) Value & Outcomes 







“Biosimilars Infographic – VOS By the Numbers” Gary L 
O’Brien, Koen Degeling, Jayeshkumar Patel, Simrun K 
Grewal, Blythe Adamason (2018) Value & Outcomes 








“Medication Screening of Older Hospitalised Patients: 





SPHeRE Blog 1st 
“A European Cancer Plan; Make it Disruptive!” Gary L 
O’Brien (2019) EHFG Blog, 
https://blog.ehfg.org/2019/10/10/a-european-cancer-
plan-make-it-disruptive-f12/ 
EHFG Blog 1st 
“Can People Afford to Pay for Healthcare; New 
Evidence on Financial Protection in Europe” Gary L 




EHFG Blog 1st 
“Can People Afford to Pay for Healthcare? An Interview 
with Tamás Evetovits” Gary L O’Brien, Stefano 
Guicciardi (2020) EHFG Blog, 
https://blog.ehfg.org/2020/08/17/can-people-afford-
to-pay-for-healthcare/ 
EHFG Blog 1st 
“How Prescription Charges for Medical Cardholders 








“Overcoming Hurdles; Measurement of Health-Related 
Outcomes Associated with National Level Medicines 
Usage in Ireland” Gary L O’Brien, Muireann McAlister, 
Stephen Byrne, James Gallagher (2020) Drugs in 
Context, DOI:10.7573/dic.2020-4-2 






8.2 Appendix II – Postgraduate taught modules completed 
Module 
code 
Module name (completed as part of UCC structured PhD - 
compulsory requirements) 
ECTS 
PG6003  Teaching and Learning for Graduate Studies  5 
PG6008  Qualitative Data Analysis and Computer Assisted Qualitative Data 
Analysis Software for the Social Sciences and Humanities  
5 
PG6009 Graduate Information Literacy Skills  5 
PG7016 Systemic Reviews for the Health Sciences  5 
PG7200 External Module 10 




Module name (completed as part of PGCert in Innovation, 
Commercialisation and Entrepreneurship) 
ECTS 
AC6301 Innovation Finance 5 
IS6306 Technology Business Planning 5 
IS6307  Creativity and Opportunity Recognition 5 
LW6104 Intellectual Property Law for High-tech Entrepreneurs 5 
MG6305 People and Organisations 5 





8.3 Appendix III – Training courses and conferences attended 
Training course name Location Date 
attended 
(mm/yyyy) 
HRB-TMRN Workshop on Economic Evaluations alongside 




Introduction to SPSS (2 days) UCC 12/2016 
STATA Software Training (1 day) UCC 05/2017 
Foundations of Economic Evaluation in Health Care (5 days) University of 
York 
06/2017 
ICH Good Clinical Practice (GCP) Training (1 day) HRB CRF‐C 
UCC 
09/2017 
NVivo Software Training (2 days) UCC 01/2018 
Qualitative Research Methods of Analysis (2 days) University of 
Oxford 
05/2018 
Advanced Methods for Cost-Effectiveness Analysis: Meeting 




Outcomes Measurement and Valuation for Health Technology 





Conference name Presentation Location Date 
attended 
(mm/yyyy) 
National Centre for Pharmacoeconomics (NCPE) None Dublin 03/2017 
All-Ireland Schools of Pharmacy Conference None UCC 04/2017 
Irish Gerontological Society (IGS) Oral Wexford 09/2017 
Irish Institute of Pharmacy (IIOP) Poster Louth 10/2017 
European Drug Utilisation Research Group 
(EuroDURG) 
Poster* Glasgow 11/2017 
International Society for Pharmacoeconomics 
and Outcomes Research (ISPOR) 
Poster Glasgow 11/2017 
The Irish Network of Medical Educators (INMED) Poster UCC 02/2018 
NCPE None Dublin 03/2018 
School of Pharmacy (SOP) PhD Seminar Oral UCC 03/2018 
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Conference name Presentation Location Date 
attended 
(mm/yyyy) 
International Conference on 
Pharmacoepidemiology & Therapeutic Risk 
Management 
None Prague 08/2018 
Hospital Pharmacists Association of Ireland 
(HPAI) Aseptics Special Interest Group (ASSIG) 
meeting 
Guest Speaker Dublin 10/2018 
ISPOR Poster x 2 Barcelona 11/2018 
New Horizons Research Conference Poster x 2 UCC 12/2018 
College of Business and Law, and Institute for 
Social Science Irish Healthcare System 
Conference on Patient Payment 
None UCC 03/2019 
SOP PhD Seminar Oral UCC 04/2019 
Novartis Centre for Health Economics Research 
Seminar 
Guest Speaker Dublin 05/2019 
NCPE None Dublin 05/2019 
Cork University Business School (CUBS) 
Postgraduate Research Symposium 
Oral UCC 05/2019 
SOP Athena Swan Research Day Posters x 3 
Oral x 1* 
UCC 05/2019 
International Symposium on Oncology Pharmacy 
Practice (ISOPP) 
Poster London 10/2019 
European Health Forum Gastein (EHFG) None Bad 
Hofgastein 
10/2019 
EuroDURG Posters x 2 Szeged 03/2020 
* Awarded best poster/oral presentation prize at conference  
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8.5 Appendix V - Chapter 2 Framework descriptions  
Brief Description of Policy Frameworks 
Name Description 
Advocacy Coalition Framework The advocacy coalition framework was 
designed as an alternative to the stages 
heuristic; it intentionally avoids a linear 
description of the policy process (38). It 
addresses highly challenging issues in which 
there are substantial goal conflicts, 
important technical disputes and multiple 
actors from several levels of Government 
(40). The advocacy coalition framework 
examines the interaction within a policy 
subsystem of a small number of advocacy 
coalitions composed of actors from 
different institutions sharing similar policy 
beliefs (40). The advocacy coalition 
framework describes three tiers of beliefs: 
(i) deep core beliefs, (ii) policy core beliefs, 
(iii) secondary beliefs.  
Institutional Analysis and Development 
Framework 
The institutional analysis and development 
framework provides a language, and way of 
thinking about the means in which 
different institutions foster collective action. 
It highlights key insights on institutional, 
technical, and participatory aspects of 
collective interventions, or the commons 
problem, and their resulting effects (43). At 
the framework’s core is the ‘action arena’. 
The action arena is composed of an action 
situation and actors and is used as the unit 
of analysis and investigation (44). The action 
situation refers to a social space where the 
actors interact, solve the commons 
problem, and exchange goods and services; 
the actors are those who participate in the 
situation (40). A major advantage of the 
framework is bringing an institutional 
perspective to policy analysis, which doesn’t 
appear to be as present in other 
frameworks. 
Kingdon’s Multiple Streams Theory Kingdon’s multiple streams theory within 
the policy process focuses on the role of 
policy ‘entrepreneurs’ inside and outside 
Government who take advantage of agenda 
setting opportunities ‘policy windows’ and 
move items onto the Government’s formal 
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Brief Description of Policy Frameworks 
Name Description 
agenda (30). The model postulates that 
policy choices are made when the three 
streams (problem stream, policy stream and 
politics stream) intersect at pivotal time 
points ‘policy windows’ where opportunities 
can occur spontaneously (39). When a 
policy window opens, the policy 
entrepreneur must immediately seize the 
opportunity to initiate action. 
Policy Cube The non-communicable disease policy 
cube, developed as part of the PA4NCDs 
project, brings together three axes to assess 
the strength of a policy framework to 
combat diet-related non-communicable 
diseases: comprehensiveness, effectiveness 
and equity. The fuller the cube, the more 
robust the policy framework for the 
prevention and control of non-
communicable diseases (36). 
Punctuated Equilibrium Model  Punctuated equilibrium model theorises 
that the policymaking process is 
characterised by periods of stability with 
minimal or incremental policy change, 
disrupted by bursts of rapid transformation 
(31). The concept was initially developed in 
paleontology to explain sudden bursts of 
change in the fossil record scattered among 
longer-term minor changes (41). Central to 
the theory are the concepts of the ‘policy 
image’ and the ‘policy venue’. The model 
has been used to explain the tendency for 
policy inactivity and sudden change in 
health policy issues like drug abuse and 
pesticide control in the USA (42). 
Stages Heuristic The stages heuristic is the ‘idealistic’ to the 
policy process (37). It divides the policy 
process into a series of five stages: (i) 
agenda setting, (ii) policy formulation, (iii) 
policy adoption, (iv) policy implementation, 
and (v) policy assessment. This model has 
been widely criticised given that its linear, 
systematic approach to solving policy 
problems is rarely found. Nonetheless, it is 
helpful to think of policymaking occurring in 




8.6 Appendix VI - Chapter 2 Search strategy 
Search Terms and Strategy Devised upon Consultation with Medical Librarian: 
Search Terms: 
Health Policy Triangle  
OR 
Policy Triangle Framework 
OR 
Policy Triangle Model 
i.e. 
(Health AND Policy AND Triangle) 
OR 
(Policy AND Triangle AND (Model or Framework)) 
 
Search Strategy Conducted in early February 2020 (Search Restrictions: English Language 
only, Time period 1st January 2015 – 31st January 2020) 
 
(A) The following is the search strategy used for Medline, CINAHL Plus with Full Text, 
APA PsycInfo in the EBSCO database: 
 
1 (Health.tw AND Policy.tw AND Triangle.tw) 
OR 
2  (Policy.tw AND Triangle.tw AND (Model or Framework).tw) 
154 for APA PsycINFO, 947 for CINAHL, 762 for Medline 
 
(B) The following is the search strategy used for Pubmed: 
 
1 (Health AND Policy AND Triangle) All Fields 
OR 
2  (Policy AND Triangle AND (Model or Framework)) All Fields 
 
599 for Pubmed 
(((((Health) AND Policy) AND Triangle AND ("2015/01/01"[PDat] : "2020/01/31"[PDat]))) OR 
(((Policy) AND Triangle) AND Framework AND ("2015/01/01"[PDat] : "2020/01/31"[PDat]))) 




(C) The following is the search strategy used for EMBASE: 
 
1 (Health AND Policy AND Triangle) All Fields 
OR 
2  (Policy AND Triangle AND (Model or Framework)) All Fields 
 
559 for EMBASE 
 
#1 OR #2 OR #3 
#3 
('policy'/exp OR policy) AND triangle AND ('model'/exp OR model) AND [english]/lim AND 
[embase]/lim AND [1-1-2015]/sd NOT [1-2-2020]/sd 
162* 
#2 
('policy'/exp OR policy) AND triangle AND ('framework'/exp OR framework) AND 
[english]/lim AND [embase]/lim AND [1-1-2015]/sd NOT [1-2-2020]/sd 
63* 
#1 
('health'/exp OR health) AND ('policy'/exp OR policy) AND triangle AND [english]/lim AND 
[embase]/lim AND [1-1-2015]/sd NOT [1-2-2020]/sd 
 
(D) The following is the search strategy used for Web of Science: 
 
1 ALL=(Health AND Policy AND Triangle) ALL = All Fields 
OR 
2  ALL=(Policy AND Triangle AND Model) 
OR 
3 ALL=(Policy AND Triangle AND Framework) 





#5 OR #4 OR #3 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-
EXPANDED, IC Timespan=2015-2020 
# 5 
515 
(ALL=(Policy AND Triangle AND Model)) AND LANGUAGE: (English) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-
EXPANDED, IC Timespan=2015-2020 
# 4 
231 
(ALL=(Policy AND Triangle AND Framework)) AND LANGUAGE: (English) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-
EXPANDED, IC Timespan=2015-2020 
# 3 
873 
(ALL=(Health AND Policy AND Triangle)) AND LANGUAGE: (English) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-
EXPANDED, IC Timespan=2015-2020manual  
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8.9 Appendix IX - Chapter 4 Supplementary cost description 
Costs associated with care of patients in intervention arm in 2015 (CAHC) 
Cost Component  Unit 
Cost (€) 
Description   Reference  




0.56  circa 240 minutes of training 
required costing approximately 
€200.00 
Experience-based opinion from 




2.50 Median time of three minutes 
to apply intervention (252) 








5.83 Approximated time of seven 
minutes (Experience-based 
opinion from original research 
team) 
HSE salary scales (403) 
Specialist 
consultant being 







Approximated time of seven 
minutes (Experience-based 
opinion from original research 
team) 
 






25.00 Approximated time of 30 
minutes (Experience-based 
opinion from original research 
team) 
HSE salary scales (403) 
Hospitalisation 
Costs 
839.00 24-hour national Irish hospital 
stay average cost per patient  
Healthcare Pricing Office (404) 





8.10  Appendix X - Chapter 4 Supplementary incremental cost-
effectiveness analysis 
Incremental cost-effectiveness analysis using CAHC and original trial effectiveness data 
  Intervention group (n = 360)  Control group (n = 372)  
Cost analysis   
Total cost (€)      
    Mean (SD)  12,380 (13,802)  11,419 (12,795)  
Effectiveness analysis   
Participants experiencing ≥ 1 
ADRs [n (%)]  
42 (11.67)  78 (20.97)  
ADRs experienced per 
patient [n (%)]  
    
    0  318 (88.33)  294 (79.03)  
    1  39 (10.83)  67 (18.01)  
    2  3 (0.83)  11 (2.96)  
ADRs per patient [mean  
(SD)]  
0.125 (0.356)  0.239 (0.492)  
  
Incremental cost-
effectiveness analysis  
Intervention vs Control  
Incremental cost  
Difference in mean 
healthcare cost (€) (a,b) 
895 (95% CI −1851, 3642) 
Incremental effect  
 Difference in odds ratio for 
ADR events (a,c) 
0.391 (95% CI 0.233, 0.657)  
Difference in mean ADR 
events (a,c)    
−0.164 (95% CI −0.257, −0.070)  
ICER per ADR averted (€) 5,469 
Threshold value (λ) per  
ADR averted (€) 
Probability that intervention is cost-effective (d) 
             0  0.236 
         500  0.255 
      1,000  0.274 
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Threshold value (λ) per  
ADR averted (€) 
Probability that intervention is cost-effective (d) 
      5,000  0.450 
    10,000  0.672 
    20,000  0.921 
Key: SD: standard deviation; ADR: adverse drug reaction; CI: confidence interval; ICER: 
incremental cost-effectiveness ratio 
(a)  Reported estimates for incremental differences in costs and effects adjusted to 
account for baseline differences between arms  
(b) Regression for total costs estimated using multilevel mixed-effects linear 
regression models and controlling for treatment arm, age, sex, number of 
medications at admission and clustering 
(c) Regression for ADR event estimated using mixed effect logistic regression models 
and controlling for treatment arm, age, sex, number of medications at admission 
and clustering 
(d) Probabilities for cost-effectiveness estimated parametrically using net benefit 





8.11  Appendix XI - Chapter 4 Supplementary scenario analysis 
Scenario analysis using CAHC and original trial effectiveness data  
 50% increase in healthcare professional 
time 
Incremental Analysis - Intervention vs Control 
Incremental Cost: Total Cost (€) 
Difference in Mean  
 918 (95% CI −1828, 3664) 
  
Incremental Effect: No. of ADR Events (n)      
Difference in Mean  
 −0.164 (95% CI −0.257, −0.070) 
Incremental cost-effectiveness ratio (€) 5,608  
50% decrease in healthcare professional 
time 
Incremental Analysis - Intervention vs Control 
Incremental Cost: Total Cost (€) 
Difference in Mean 
  872 (95% CI −1875, 3620) 
Incremental Effect: No. of ADR Events (n)     
Difference in Mean 
−0.164 (95% CI −0.257, −0.070) 
Incremental cost-effectiveness ratio (€) 5,330 
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8.17  Appendix XVII - Chapter 6 Participant information letter  
A qualitative analysis of the healthcare professional stakeholder involvement in 
pharmaceutical policy change in Ireland 
You are being invited to take part in a research project that is being conducted at the 
University College X.  
Before you decide whether or not you wish to participate you should read the information 
provided below carefully, and you are free to discuss it with your family, friends or colleagues. 
You should clearly understand the risks and benefits of participating in this study so that you 
can make a decision that is right for you. Take time to ask questions – do not feel rushed or 
under any obligation to make a hasty judgment.  
You have the right to withdraw your participation at any time (before, during and after the 
study) for whatever reason without having to justify your decision and with no negative 
impact for you. Your data will then be excluded from the study results. 
Why is this study conducted? 
Co-payment policies on the General Medical Services (GMS) scheme have existed since 2010 
and have gone through multiple iterations, starting at €0.50 in October 2010 and reduced to 
€2 in January 2018. The involvement of the Healthcare Professionals (HCPs) such as General 
Practitioners (GPs) and Pharmacists in such pharmaceutical policy changes on the GMS 
scheme has not been evaluated. As part of his PhD, X wants to gather feedback on the 
perceptions and challenges experienced by HCPs resulting from the GMS co-payment 
changes. For example, are co-payment changes creating additional administrative burden for 
HCPs? Have altering co-payments influenced GPs’ prescribing patterns? How have 
pharmacists handled the implementation of this policy? What happens if patients cannot 
afford these prescription medicine co-payments? This study seeks to retrieve qualitative data 
on HCP stakeholder involvement for all existing co-payment alterations in the Irish context. 
Why have you been asked to participate? 
You have been asked because you are a Healthcare Professional currently working in a GP 
practice or a community pharmacy in the Republic of Ireland.  
What will your participation involve? 
Your participation will involve a 30-minute (maximum) interview about matters relating to 
your experiences of the effects of the altering GMS prescription co-payments on patients. X, 
who is a pharmacist, will ask questions as the session progress. A small amount of extra time 
will be allowed for explaining the aims of the study and your questions about the study.  
Will your participation be kept confidential? 
Yes, all information will be treated in a confidential manner and your participation is 
anonymous. The interview will be audio recorded so that it can be transcribed afterwards. 
Your name will not be recorded on any information which is collected about you. Instead you 
will be provided with a unique code. The only person with access to the code will be X. The 
results of the study will be included in X’s PhD thesis but there will be no way of identifying 
you from these results. The results will be seen by X’s supervisors, a second marker and an 
external examiner, again these will be anonymous. The thesis may be read by future 
students. The study may be presented at scientific conferences and/or published in an 
academic journal.  
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The audio recording will be erased once the interview has been transcribed. Transcripts will 
be stored in a protected manner for 5 years, after which they will be destroyed in line with 
University College X confidential waste destruction guidelines. 
What are the possible benefits of participating? 
Your contribution to this study will be used to reveal how HCPs have previously dealt and are 
currently dealing with these GMS co-payment policy changes since its inception in 2010. X 
hopes to publish such findings that may influence future healthcare policymaking decisions 
to the benefit of the HCP and patient. 
Are there any risks of participation? 
We do not think that participation in this study will have any negative effect on you.  
Further information 
Approval has been granted to do this study by the Clinical Research Ethics Committee of the 
Cork Teaching Hospitals.  
If you would like a copy of the results, please let X know. 
If you need any further information, do not hesitate to contact the primary researcher, X, by 
telephone X or by email to X or email the supervisor of the project, Professor Y by Y 
(Telephone:Y). 
Thank you for taking the time to read this information sheet. If you agree to take part in the 
study, please sign the consent form overleaf.  
 
Kind regards,  
X 




8.18  Appendix XVIII - Chapter 6 Participant consent form 
A qualitative analysis of the healthcare professional stakeholder involvement in 
pharmaceutical policy change in Ireland 
 
I                                                    declare that information about this 
research project has been given to me and that I understand the purpose, methods, risk and 
benefits of participating in this study.  
I am aware that participating is voluntary and that I can withdraw my participation at any 
time with no negative impact on my professional status.  
I give permission for my responses in the interview to be audio-recorded and that anonymity 
will be ensured by disguising my identity.  
I understand that disguised extracts from what I say may be quoted in the thesis and any 
subsequent publications.  
I agree that I have received a copy of this Consent Form and a copy of the Information Letter. 
I hereby give my informed consent to participate in the research study. 
 
 
Participant Signature                                                Date 
 
Would you like a copy of the Interview Transcript?                  YES               NO    
 
Would you like a copy of the findings after the study is completed?  YES               NO    
 
Email address:       
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Pharmacist Topic Guide 
Interviewing practising Irish primary healthcare professionals about their opinions, 
perceptions, challenges and experience of the GMS co-payment from inception to current 
day. 
Before we start, I just want to check that you are still happy for this interview to be recorded 
and that you know we can stop at any time.  
 
I would like to thank you for agreeing to participate in this interview and stress that 
everything said here today is completely confidential. Your name will not appear on any 
documents or recording discs and I personally will anonymise the transcript from this 
interview and will ensure that no one else will be identifiable either.  
 
These interviews are part of a study I am conducting for my PhD. The aim of the study is to 
gain an understanding of the perceptions and challenges experienced by healthcare 
professionals from the various GMS co-payment iterations since 2010. 
 
There are no right or no wrong answers to these questions. 
The interview will probably last between 10-30 minutes.  




• Address of Pharmacy? Independent or Franchise Pharmacy? 
• Gender? 
• Number of years practising in community Pharmacy? 
• Full-time/Part-time? 
• Year received pharmaceutical society of Ireland (PSI) number? 
• Do you have any obvious biases to declare on this topic? 
In Supplementary Material Figure 1 presented to you in the information leaflet, you can see 
the GMS co-payment has undergone various iterations since its initial introduction in 2010. 
As you have been practising throughout these changes, I am interested to learn about your 
experiences in considering these policy changes in your routine clinical practice.  
Version 4  
 
1) What are your own thoughts on the GMS co-payment attached to 
prescription medicines? 
 
• Positive aspects/negative aspects? 
• Do you know why it was initially brought in and its impact to date? 
• Are you aware of the GMS co-payment exemptions for specific patient groups? 
2) How have co-payments influenced your practice and procedures in the Pharmacy, if at all? 
• Have they changed the way you and the Pharmacy staff work, if so, how? 
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3) How easy or difficult is it to retrieve co-payments from patients?  
• What happens if a patient cannot pay? Do you supply the medicine anyway? 
• Have you a procedure in place for patients who cannot pay? 
• Have you encountered awkward situations when a patient cannot pay? 
• Have you suffered financial loss because of patients not paying? 
4) In your opinion, have co-payments presented an administrative burden to you/your 
practice?  
• Have you noticed/recommended eligible patients to switch to the long-term illness 
(LTI) scheme to avoid paying the co-payment?  
5) How do you think GMS patients perceive paying the co-payment attached to their 
prescription medicines? 
• Do you think the co-payments are reasonably or unfairly priced for GMS patients?  
6) Do you think co-payments have influenced patients’ utilisation of medicines?  
• Increase/decrease in patients picking up their medicines?  
• Are there particular types of medicines affected more by the GMS co-payment 
changes? 
7) Looking at Figure 1, would you have regarded any one of these GMS co-payment changes 
to be more influential or impactful than the others? 
• Effect on patient picking up medication 
• More difficult to retrieve the co-payment from the patient upon being increased? 
8) Have you noticed any changes to the prescribing patterns of physicians since the 
introduction and changes in the GMS co-payment?  
• Any issues/concerns arising from GPs concerning GMS co-payments?  
• An increase in generic prescribing since the beginning of the co-payment? 
9) What do you think the future holds for the GMS co-payment?  
• Should the co-payment be increased, decreased or abolished? 
• Do you think the previous GMS co-payment changes were evidence-based? 
• How should Pharmacists/representative bodies be involved in this policy, if it all?  
 
   Have you anything else to say/add on this topic? Thank you for your time 
 
General Practitioner (GP) Topic Guide 
Interviewing practising Irish primary healthcare professionals about their opinions, 
perceptions and experience of the GMS co-payment from inception to current day 
Before we start, I just want to check that you are still happy for this interview to be recorded 
and that you know we can stop at any time.  
 
I would like to thank you for agreeing to participate in this interview and stress that 
everything said here today is completely confidential. Your name will not appear on any 
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documents or recording discs and I personally will anonymise the transcript from this 
interview and will ensure that no one else will be identifiable either.  
 
There will not be any consequences to what you tell me and there will be no blame attributed 
to you or anyone else.  
 
These interviews are part of my PhD There are no right or no wrong answers to these 
questions, just give as much detail as you can. It will probably last between 10-30 minutes.  




• Address of GP practice? Independent or medical centre practice? 
• Gender? 
• Number of years practising as a GP? 
• Full-time/Part-time? 
• Year received Irish medical council (IMC) number? 
• Do you have any obvious biases to declare on this topic? 
 
In Supplementary Material Figure 1 presented to you in the information leaflet, you can see 
the GMS co-payment has undergone various iterations since its initial introduction in 2010. 
As you have been practising throughout these changes, please answer the following 
questions with respect to this. 
Version 2  
1) What are your own thoughts on the GMS prescription medicine co-payments? 
• Positive aspects/negative aspects? 
• Do you know why it was initially brought in and its impact to date? 
• Are you aware of the GMS co-payment exemptions for specific patient groups? 
Which ones? 
 
2) How have co-payments influenced your practice and procedures as a GP, if it all? 
• Have they changed the way you prescribe, if so, how? 
• Have they influenced the amount of prescriptions you issue, if so, how? 
• What happens if you know a patient cannot pay? Do you still prescribe the medicine? 
• Have you noticed/recommended eligible patients to switch to the long-term illness 
(LTI) scheme to avoid paying the GMS co-payment? 
 
3) How do you think GMS patients perceive paying the co-payment attached to their 
prescription medicines? 
• Do you think the co-payments are reasonably or unfairly priced for GMS patients?  
4) In your opinion, are GMS co-payments effective at preventing patients from collecting 
medicines they actually do not require? 
• Yes/no – Why? 




• An increase in patients asking you to prescribe/deprescribe certain medicines 
• A decrease in patients asking you to prescribe/deprescribe certain medicines 
 
6) In your opinion, are there particular types of medicines affected more by the GMS co-
payment changes? 
7) Looking at Figure 1, would you have regarded any one of these GMS co-payment changes 
to be more influential or impactful than the others? 
• Effect of patient asking you to prescribe/deprescribe certain medicines 
• Patient expressing concern to you on co-payment changes 
 
8) Have you encountered any issues or concerns from patients concerning GMS co-payments 
that they may have experienced when collecting prescription medicines at their pharmacy?  
9) Have you encountered any issues or concerns from pharmacists concerning GMS co-
payments that they may have experienced when serving patients in the pharmacy? 
10) What do you think the future holds for the GMS co-payment?  
• Should it be increased, decreased or abolished?  
• Do you think the previous GMS co-payment changes were evidence-based? 
• What advice have you for policymakers on it? Should GP representative bodies be 
involved?          
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8.20  Appendix XX - Chapter 6 COREQ checklist  
Consolidated criteria for reporting qualitative studies (COREQ): 32-item checklist (370) 
 
Developed from: Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative 
research (COREQ): a 32-item checklist for interviews and focus groups. International Journal 
for Quality in Health Care. 2007. Volume 19, Number 6: pp. 349 – 357  
 
YOU MUST PROVIDE A RESPONSE FOR ALL ITEMS. ENTER N/A IF NOT APPLICABLE 
No.  Item  
 
Guide questions/description Response 
Domain 1: Research team 
and reflexivity  
  
Personal Characteristics    
1. Interviewer/facilitator Which author/s conducted the interview or 
focus group?  
GOB and BOF  
2. Credentials What were the researcher’s credentials? E.g. 









4. Gender Was the researcher male or female?  Male 
5. Experience and training What experience or training did the researcher 
have?  




Group, May 2018, 
University of Oxford 
Relationship with participants    
6. Relationship established Was a relationship established prior to study 
commencement?  
No 
7. Participant knowledge of 
the interviewer  
What did the participants know about the 
researcher? e.g. personal goals, reasons for 
doing the research  
Based on participant 
information letter 
provided 
8. Interviewer characteristics What characteristics were reported about the 
interviewer/facilitator? e.g. Bias, assumptions, 







Domain 2: study design    
Theoretical framework    
9. Methodological orientation 
and Theory  
What methodological orientation was stated 
to underpin the study? e.g. grounded theory, 
discourse analysis, ethnography, 




Participant selection    
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No.  Item  
 
Guide questions/description Response 
10. Sampling How were participants selected? e.g. 




11. Method of approach How were participants approached? e.g. face-
to-face, telephone, mail, email  
Email, phone, face-
to-face 
12. Sample size How many participants were in the study?  19 
13. Non-participation How many people refused to participate or 
dropped out? Reasons?  
0 
Setting   
14. Setting of data collection Where was the data collected? e.g. home, 




15. Presence of non-
participants 
Was anyone else present besides the 
participants and researchers?  
No 
16. Description of sample What are the important characteristics of the 




the introduction of 
the co-payment in 
2010 to end of study 
date 
Data collection    
17. Interview guide Were questions, prompts, guides provided by 
the authors? Was it pilot tested?  
Questions were 
based on the topic 
guides used 
18. Repeat interviews Were repeat interviews carried out? If yes, 
how many?  
N/A 
19. Audio/visual recording Did the research use audio or visual recording 
to collect the data?  
Two methods of 
audio recording 




20. Field notes Were field notes made during and/or after the 
interview or focus group? 
Notes were added 
to a field diary 
immediately after 
the interview 
21. Duration What was the duration of the interviews or 
focus group?  
7 - 30 minutes 
22. Data saturation Was data saturation discussed?  Yes  (Francis 
method(365)) 
23. Transcripts returned Were transcripts returned to participants for 
comment and/or correction?  
Optional if 
participants 
required – choice 
presented on the 
consent form 
Domain 3: analysis and 
findings  
  
Data analysis    
340 
 
No.  Item  
 
Guide questions/description Response 
24. Number of data coders How many data coders coded the data?  One primary coder 






25. Description of the coding 
tree 
Did authors provide a description of the coding 
tree?  
Yes 
26. Derivation of themes Were themes identified in advance or derived 
from the data?  
Both deductive and 
inductive themes 
are presented 
27. Software What software, if applicable, was used to 
manage the data?  
NVivo 12 Plus - QSR 
International 
28. Participant checking Did participants provide feedback on the 
findings?  
No 
Reporting    
29. Quotations presented Were participant quotations presented to 
illustrate the themes/findings? Was each 
quotation identified? e.g. participant number  
Yes 
30. Data and findings 
consistent 
Was there consistency between the data 
presented and the findings?  
Yes 
31. Clarity of major themes Were major themes clearly presented in the 
findings?  
Yes 
32. Clarity of minor themes Is there a description of diverse cases or 



























8.22  Appendix XXII - Chapter 7 Policy brief 
The Health Policy Triangle Framework - Health Policy Analysis and Sláintecare 
Reform 
Author: Gary L O’Brien 
Affiliation: School of Pharmacy, University College Cork, Cork, Ireland 
Contact: gary_obrien@umail.ucc.ie 
Date of issue: September 2020 
Issue 
The burgeoning literature of health policy analysis sees novel policy frameworks and theories 
being developed quite frequently. While it is great to observe such advancements in the field, 
having too many choices of frameworks and theories can potentially complicate the selection 
process and hinder their application.  
Policy implications 
In May 2017, an Irish cross-party parliamentary committee published the ‘Houses of the 
Oireachtas Committee on the Future of Healthcare Sláintecare report’. Sláintecare sets out a 
high-level policy road map roadmap to deliver whole system reform and universal 
healthcare, phased over a ten-year period. Sláintecare details reform proposals which, if 
delivered, will establish; a universal, single-tier health service where patients are treated 
solely on the basis of health need; the reorientation of the health system ‘towards integrated 
primary and community care, consistent with the highest quality of patient safety in as short 
a time-frame as possible’. Given that Sláintecare implementation is in its early stages, it is 
argued that incorporation and use of a common descriptive health policy framework should 
be used in the analysis of all upcoming Sláintecare-related health policy decisions. 
Key findings 
Using diverse healthcare settings within the Irish context, researchers from the Irish Health 
Service Executive, London School of Hygiene & Tropical Medicine, and University College 
Cork have recently analysed local, regional and national healthcare policy change over the 
last decade with regard to (1) development processes, (2) evidence generation, (3) 
implementation, and (4) outcomes using the health policy triangle (HPT) framework. The 
research trialled the generalisable nature of the HPT framework when applied to various 
health-related policy decisions at different stages in their life cycle and subsequently proved 
it can be used at local, regional and national level. The HPT framework helped describe:   
• A policy decision concerning the initiation and switching of patients to biosimilar 
infliximab CT-P13 from the originator medicinal product at local level. It was decided 
to conduct a literature review on the supporting evidence behind this policy decision. 
The HPT framework was applied as a scaffolding framework to describe the various 
contributing components which ultimately led to the successful implementation of 
the biosimilar policy.  
• A policy decision concerning whether a physician would be the most cost-effective 
healthcare professional to implement a medication screening tool based upon the 
STOPP/START criteria from the perspective of the Irish health service at local level. A 
cost-effectiveness analysis alongside conventional outcome analysis in a cluster RCT 
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was used to generate compelling evidence. The HPT framework was used to describe 
the different relevant components which show how this contemporary policy is still 
evolving.  
• A policy decision concerning whether trastuzumab subcutaneous treatment should 
replace trastuzumab intravenous treatment for HER2-positive breast cancer patients 
in routine clinical practice at regional level. A prospective observational study in the 
form of cost minimisation analysis constituted study design and was used to produce 
credible evidence to support policy change. The HPT framework was used to describe 
the various contributing components which show how this topical policy is still 
maturing.  
• A pharmaceutical policy concerning the mandatory co-payment fees attached to 
prescription medicines on the national Irish public health insurance scheme. It was 
unknown what impact these changes have on relevant stakeholders who work at the 
coalface of this labile policy. A qualitative study using purposive sampling alongside 
snowballing recruitment was used to generate compelling evidence. The HPT 





This research has illustrated how generalisable and adaptable the HPT framework is when 
applied to health-related policy decisions in various Irish healthcare settings. Given this 
advantage, it is proposed that the HPT framework should be used in Sláintecare reform 
policy. Using a common descriptive framework and standardising the approach to health 
policy analysis during this ten-year reform has the potential to increase the successful fruition 
of Sláintecare policy goals. 
Further reading  
O’Brien GL., Using the Health Policy Triangle Framework to Describe Local, Regional and 
National Healthcare Policy Changes within Ireland's Diverse Healthcare Settings, PhD Thesis. 
https://cora.ucc.ie/handle/xxxxxx (in press) 
